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Abstract 
 
Cattle are a very important part of the human food chain. Administration of 
veterinary drugs and other xenobiotic compounds to cattle can often result in the 
accumulation of metabolic residues in edible tissues that can potentially affect 
humans through the food chain. An understanding of drug metabolism in this 
species is vital to ensure safe use of drugs in cattle and eventually the provision of 
safer animal derived food products to man. Sulfation catalysed by 
sulfotransferases (SULTs) is an important phase 2 drug metabolising reaction. It is 
not only involved in the detoxification of drugs and xenobiotics but also in the 
bioactivation of procarcinogens. It is also important in the metabolism of several 
drugs used routinely in cattle. However, very little work has been carried out on 
SULTs in cattle. A variety of in vitro tools are available to study drug metabolising 
enzymes (DMEs) like SULTs. These include tissue microsomes, cytosol, 
recombinant enzymes and isolated cells such as the hepatocytes.  Recombinant 
SULTs are important tools that can be used for the study of isoform specific drug 
biotransformation, drug-drug interactions and the effect of genetic 
polymorphisms on the activity of specific isoforms. As the liver is the major drug 
metabolising organ in the body, it is essential to study expression and activity of 
cytosolic liver sulfotransferases. Hepatocytes contain DMEs and drug transporters 
along with all the necessary cofactors that represent in vivo conditions. This makes 
hepatocytes a better representative of in vivo conditions as compared to 
microsomes, cytosol or recombinant enzymes. In this study we have characterised 
sulfotransferases in cytosol, recombinant enzymes and hepatocytes.  
 
 
Antibodies previously raised against human sulfotransferase isoforms were used 
in the detection of cytosolic bovine sulfotransferases. Probe substrates established 
for activity with human SULTs were used for assessing the activity of recombinant 
and cytosolic bovine sulfotransferases. Cytosol was prepared from 8 male livers 
and 12 female livers (8 untreated and 4 treated with an exogenous progestin).  
SULT1B1, SULT1E1 and SULT2A1 were detected in bovine liver cytosol.  
Expression of SULT2A1 in the bovine liver was sex specific with males expressing 
almost twice as much SULT2A1 compared to the females. However, no activity 
was detected with dehydroepiandrosterone (DHEA) which is used as a probe 
substrate for SULT2A1 in humans. Pregnenolone is metabolised by SULT2A1 and 
SULT2B1 in humans. Activity towards this substrate was detected in the bovine 
liver, however no sex related differences in activity were observed. 4-nitrophenol 
is metabolised by several members of the SULT1 family in humans such as 
SULT1A1, SULT1B1 and SULT1C. 17β-estradiol is a probe substrate for human 
SULT1E1. Activity was detected with 4-nitrophenol in male and female bovine 
livers. Male liver cytosol followed Michaelis-Menten kinetics whereas the female 
liver cytosol displayed partial substrate inhibition. This suggests that different 
enzymes have been involved in the biotransformation of 4-nitrophenol in the male 
and female liver. Activity towards 17β-estradiol in the female liver was almost 4 
times higher than in the male liver.  
Recombinant bovine sulfotransferases (SULT1A1, SULT1B1, SULT1E1 and 
SULT2A1) were expressed in E. coli. All bovine SULTs except SULT2A1 were 
expressed in the soluble fraction. Like human SULT1A1, bovine SULT1A1 also 
displayed partial substrate inhibition, however the extent of inhibition (as seen 
with the Ki values) was lower compared to human SULT1A1. Bovine SULT1B1 
 
 
followed Michaelis-Menten kinetics with 4-nitrophenol. Substrate specificity 
profiling carried out with equal amounts of bovine SULT1A1 and SULT1B1 
revealed that SULT1B1 was better at sulfating phenolic compounds as compared 
to bovine SULT1A1. SULT1A1 is highly expressed in the human liver and is the 
major enzyme involved in drug metabolism in the human liver. This might not be 
the case in cattle given that SULT1B1 was found to be better at sulfation than 
SULT1A1 and expression of SULT1A1 was not detected in the bovine liver using 
antibodies. Human SULT1E1 is known to metabolise 17β-estradiol with a very 
high affinity and with a Km in the low nanomolar range. Comparatively, bovine 
SULT1E1 metabolised 17β-estradiol with a lower affinity, in the micromolar 
range. 
Expression and activity of bovine sulfotransferases differed from human 
sulfotransferases and some of the differences could be attributed to key amino 
acid residue substitutions in the active site of the bovine SULTs. For example, 
substitution of Phe141 in human SULT1E1 to Leu141 in bovine SULT1E1 restricts 
the ability of bovine SULT1E1 to form strong van der Waals interactions with the 
substrate due to loss of an aromatic hydrocarbon ring. This could explain the 
reduced affinity of bovine SULT1E1 for 17β-estradiol. Substitutions of small 
uncharged residues with large charged ones in the active site of bovine SULT2A1 
could have unforeseeable effects that could result in the formation of an insoluble 
protein. Substitutions in the active site of bovine SULT1A1 that bind the second 
molecule of 4-nitrophenol could be responsible for the reduced partial substrate 
inhibition effects observed in comparison to human SULT1A1. In order to further 
validate some of these findings it would be necessary to perform additional 
experiments that involve mutating the substituted residue to the original one as 
 
 
found in the human/mouse counterpart and looking for restoration of original 
properties.  
The work was extended to investigate conjugative metabolism of the steroid 
hormone 17β-estradiol and its stereoisomer 17α-estradiol in microsomes, cytosol 
and cryopreserved hepatocytes all prepared from bovine liver. It was found that 
glucuronidation was the main route for estradiol metabolism in cattle since large 
amount of glucuronide metabolites were detected in microsomes and 
cryopreserved hepatocytes. In comparison no sulfate metabolites were detected in 
cytosol and hepatocytes.  
We now have a better understanding of some of the important phase 2 drug 
metabolism pathways in cattle.  
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1.1 Animal pharmaceutical market and regulation  
The worldwide animal health market was estimated at $11 billion in sales in 2001 
with Northern America and Western Europe accounting for 60% of the market 
(Evans and Chapple, 2002). Livestock products dominated the market as they 
accounted for 70 % of the sales with cattle health products accounting for 31.1% 
followed by companion animals at 29.3%, pigs (19%), poultry (14%) and sheep 
(7%)  (See figure 1). Since 1991, the companion animal market has grown at 6.6% 
per annum. This matches the growth seen for the human healthcare market 
(Ahmed and Kasraian, 2002). The prime reasons for this are the economic growth 
in the developed world in the 1990s and pet owners’ willingness to invest in the 
health of their animals. This coupled to lower costs, risk and improved time to 
market makes it more profitable compared to food producing animal products. 
However, the companion animal industry as opposed to the livestock industry is 
more vulnerable to changes in the economic situation and hence the 
pharmaceutical industry still continues to invest in food producing animals 
(Ahmed and Kasraian, 2002). Since 1991, the animal health industry has grown by 
1.9% per annum as opposed to the human health industry which is touching a 
double digit growth. In contrast to the ‘blockbuster drug’ oriented human 
healthcare industry, the animal health industry consists of a large number of drugs 
with small revenues. Indeed only 17 animal health products have sales that exceed 
$100million in the US and only 6 products in the UK have annual sales exceeding 
£5million. Infact, 93% of all licensed animal healthcare products in the UK have 
annual sales of less than £1million (Evans and Chapple, 2002).  Developing human 
health care products is a longer and a more stringent process as compared to the 
development of animal healthcare products. The former requires preclinical 
3 
 
testing in animal models followed by phase 1 trials to evaluate safety and phase 2 
and 3 to confirm safety and efficacy. In contrast, animal healthcare products 
require establishment of safety and efficacy in the target species eliminating the 
need to carry out preclinical and phase 1 study. The time to reach the market is 2-
3 years shorter compared to human healthcare products. In addition to this there 
is little or no post-marketing surveillance (phase IV) for animal healthcare 
products (Ahmed and Kasraian, 2002).  
 
 
 
 
 
 
 
Figure 1: The animal pharmaceutical market 
Market shares of cattle, pets, pigs, poultry and sheep in the animal pharmaceutical 
market. (Evans and Chapple, 2002) 
 
1.2 Concern over drug residues in animal derived food products 
Contamination of animal derived food products is a major cause of concern to the 
animal health industry. Chemical safety of animal derived food products is 
required to ensure consumer health and to maintain consumer confidence and 
satisfaction. Contamination of animal food products can occur by the presence of 
inorganic residues such as mercury, arsenic, lead and cadmium or organic 
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residues such as dioxins (Andree et al., 2010). However, exceedingly relevant and 
of great concern to the animal pharmaceutical industry and regulatory bodies is 
the presence of metabolic residues of veterinary drugs and growth promoters in 
animal derived food products (O'Keeffe, 1998; Reig, 2008; Stolker, 2007). 
 Clenbuterol is a β2-adrenergic agonist that has been traditionally used as a 
bronchodilator in people with breathing disorders. It can also cause an increase in 
aerobic capacity, central nervous system stimulation and increase in blood 
pressure and oxygen transportation. It is also used illegally as a performance 
enhancing drug by athletes.  In animals, it was used as a treatment for respiratory 
disorders. It was also used as a muscle relaxant in cattle. Its ability to increase 
muscle-to-fat ratio makes it a popular option to use to obtain leaner meats illegally 
in cattle. In addition to this it was also used a non-steroidal anabolic growth 
promoter.  Recent incidences of clenbuterol poisoning in Portugal, and China have 
been reported by consumption of lamb and bovine meat containing metabolic 
residues of clenbuterol. Intoxicated people developed symptoms such as nausea, 
headache, tachycardia and myocardial infarctions (Barbosa, 2005). Use of 
clenbuterol is now banned in the US and Europe (Mitchell and Dunnavan, 1998). 
The presence of residual antibiotics in edible tissues can cause allergies in humans 
or the transfer of resistant bacteria through the food chain (Butaye et al., 2001). 
Ingestion of trace levels of antimicrobials can disturb the composition of human 
intestinal gut flora which acts as a barrier to colonization from pathogenic 
bacteria and hence aids digestion (Cerniglia and Kotarski, 1999). Furazolidone, 
nitrofurazone and nitrofurantoin are nitrofuran antibacterial agents which have 
been used widely as feed additives for the treatment of gastrointestinal infections 
in cattle, pigs and poultry. Use of nitrofurans in the EU was prohibited in 1997 
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after research showed that furazolidone was a mutagenic and genotoxic drug. In 
addition to this, natural hormones such as 17β-estradiol, testosterone and 
synthetic steroids such as estradiol benzoate, trenbolone acetate that are 
administered to improve growth rate in animals are also known to produce 
metabolites of a carcinogenic potential. Their usage in food producing animals is 
strictly regulated (Andree et al., 2010). Synthetic derivatives of natural steroid 
hormones such as melengestrol acetate (progesterone) are used for oestrus 
synchronisation in cattle.  
In the United Kingdom alone, adverse drug reactions (ADRs) in humans account 
for 7% of hospital admissions of which approximately 0.15% result in death. This 
costs the national health services (NHS) in excess of £400 million per year 
(Pirmohamed et al., 2004). In order to minimize ADRs in humans as a result of 
consuming contaminated animal food products, it is important to understand the 
process of drug and xenobiotic compound metabolism in food producing animals.  
In the past, research has mainly focussed on understanding drug metabolism in 
laboratory animals such as rat, mouse and guinea pig and extrapolation of 
metabolism data from laboratory animals to livestock species (Friess, 1983; 
Rumsey, 1983; Watkins and Klaassen, 1986). Marked differences exist in the 
extent of metabolism and nature of metabolites formed across species (Dalvi et al., 
1987; Nebbia et al., 2003; Short, 1994). Studies relating hepatic biotransformation 
of xenobiotics reported 100-fold to 1000-fold differences in enzyme activities 
towards certain substrates measured under identical conditions in laboratory 
animals (Gregus et al., 1983) and livestock species (Smith et al., 1984).  In light of 
these differences observed, it is essential to have drug metabolism data on animals 
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of the livestock species, especially cattle which is one of the major food producing 
animals.  
1.3 Drug Metabolism 
Drug metabolism can be defined as the biochemical modification of xenobiotic 
compounds by a specialised group of enzyme system present in the liver, kidney, 
lung and the GI tract (Meyer, 1996). The endoplasmic reticulum in the liver is the 
major site of drug metabolism. Drug metabolism can result in either the 
production of toxic (activation) or nontoxic metabolites (deactivation) although 
majority of the final drug metabolite is water soluble detoxified product that is 
rapidly excreted through urine and bile (See figure 2). Drug metabolism usually 
proceeds through phase 1 and phase 2 reactions. Phase 1 reactions generally 
precede phase 2 reactions although they can also occur independently of each 
other. Phase 1 reactions are involved in the functionalization of drugs and 
xenobiotic compounds which often increases their biological activity. Phase I 
reactions may occur by oxidation, reduction, hydrolysis, cyclization or 
decyclization reactions (Meyer, 1996). The majority of the phase 1 reactions are 
carried out by a group of enzymes called the cytochrome P450s (CYPs). Oxidation 
reactions brought about by the CYP enzyme family discovered in the 1950s are the 
most extensively studied Phase I reactions. CYPs are membrane bound enzymes 
found in the endoplasmic reticulum or the surface of mitochondria. CYPs are a 
large family of phase 1 drug metabolising enzymes with 18 families and 48 
subfamilies. If  the drug molecule is sufficiently polar past the phase 1 stage it can 
be excreted, however this is generally not the case. In phase 2, polar functional 
groups of phase 1 metabolites are conjugated with endogenous substrates to form 
highly polar conjugates which are readily excreted. Metabolites of phase 2 
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reactions are usually too hydrophilic to diffuse out of the cell on their own and 
need to be actively pumped out. This job is done by some members of the ATP-
binding cassette (ABC) transporter family such as multi drug resistant associated 
proteins (MRP2), breast cancer resistant protein (BCRP) and P-glycoprotein (pgp). 
These transporters are referred to as phase 3 metabolism.    
 
 
 
 
 
 
 
 
 
Figure 2: Schematic representation of xenobiotic/drug metabolism in liver.  
Benzene is oxidised to phenol in phase 1 and subsequently conjugated to a sulfate 
group in phase 2. Metabolism can give rise to toxic and active as well as nontoxic and 
inactive metabolites although the latter is more often the case. 
Xenobiotics Metabolism Inactive Excretion 
Products
Urine Bile
Liver
Benzene Phenol Phenyl Sulfate
OH OSO3HPhase 1 Phase 2
Toxic Metabolites
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Figure 3: The percentage of phase I and phase II metabolism of drugs 
contributed by each enzyme in the human liver. 
 It is estimated by the relative size of each section of the corresponding chart. ADH, 
alcohol dehydrogenase; ALDH, aldehyde dehydrogenase; CYP, cytochrome P450; 
DPD, dihydropyrimidine dehydrogenase; NQO1, NADPH:quinone oxidoreductase or 
DT diaphorase; COMT, catechol O-methyltransferase; GST, glutathioneS-transferase; 
HMT, histamine methyltransferase; NAT,N-acetyltransferase; STs, sulfotransferases; 
TPMT, thiopurine methyltransferase; UGTs, uridine 5′-triphosphate 
glucuronosyltransferases.  (Evans and Relling 1999). 
 
1.4 Drug Metabolism in Cattle  
Most of the research carried out on drug and xenobiotic metabolism in cattle has 
involved cytochrome P450s. Very little research has been done on phase 2 drug 
metabolism in cattle. In the following section I present current knowledge on drug 
metabolism in cattle. Cytochrome P450 (CYP) enzymes represent a superfamily of 
membrane bound haem containing mono-oxygenases that catalyse the 
incorporation of an atom of oxygen into the substrate from molecular oxygen 
using the co-factor NADPH. These enzymes are present in almost all living 
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organisms from bacteria to mammals and are involved in the 
activation/detoxification of xenobiotics, endogenous steroids and pharmaceutical 
drugs (Fink-Gremmels, 2008). They have been extensively studied in humans and 
laboratory species such as the rat. Relatively less research has been carried out on 
food producing species including cattle. Most of the studies have used rat and 
human as a reference species i.e. using rat/human antibodies for the detection of 
CYPs and rat/human probe substrates for expression and activity studies 
respectively in livestock animals (Darwish, 2010; Machala et al., 2003; 
Sivapathasundaram et al., 2001; Szotakova et al., 2004). In veterinary species, 
CYPs are most abundant in liver followed by the lung, kidney and intestine. 
Members of the CYP1A, 2B, 2C, 2D,2E, 3A and 4A have been detected in the liver of 
cattle (Grasso et al., 2005). CYP1A1 expression in mostly hepatic in humans and 
rats (Ioannides and Parke, 1990) but in the bovine it is predominantly 
extrahepatic and was found to have higher activity than ovine, porcine and 
caprine liver microsomes for ethoxyresorufin O-deethylation  (EROD)(Darwish, 
2010), the classic CYP1A1 probe substrate (Szotakova et al., 2004). CYP1A1 
catalyses the biotransformation of a variety of environmental pollutants and 
veterinary drugs (Ioannides and Parke, 1990). Unlike CYP1 family, the 
contribution of CYP2 family members to drug metabolism is modest unless 
induced by appropriate compounds. For example benzphetamine and 16α- 
testosterone are CYP2B6 substrates in man and rat (Ioannides, 2006). In cattle, a 3 
fold increase in 16β-OH testosterone production was observed in liver 
microsomes treated with phenobarbital (Cantiello M, 2006). CYP2B enzymes 
metabolise small molecule drugs such as barbiturates, benzodiazepines or 
pesticides such as aldrin and parathion (Nebbia et al., 2003). In the bovine, 
CYP2B6 is highly expressed in the lung as compared to other tissues (Darwish, 
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2010). However other members of the CYP2 family like CYP2C9 and CYP2E1 have 
a strong hepatic expression (Darwish, 2010). CYP2E1 is also induced by 
xenobiotics like acetone and alcohol. The CYP3 family is the most active 
contributor to drug metabolism and is responsible for the metabolism of a wide 
range of xenobiotics, steroids and medicinal drugs like chlorpheniramine, 
chlorpromazine, erythromycin and bromhexine. The N-demethylation of the 
antibiotic erythromycin is used as a probe for studying the activity of CYP3A4 in 
humans and rats (Wrighton et al., 1985). High expression of CYP3A4 was recorded 
in cattle liver as compared to other drug metabolising organs (Darwish, 2010). In 
contrast to CYP1, 2 and 3 families which are mainly involved in the metabolism of 
xenobiotics and pharmaceutical drugs, CYP4 family members are involved in the 
oxidation of fatty acids. CYP4A activity in humans and rats is measured using ω-
hydroxylation of lauric acid (Tamburini et al., 1984). It was found that bovine liver 
microsomes poorly catalysed this substrate in comparison to rat, sheep pig and 
goat. The amount of immunoreactive protein detected was also lower in 
comparison to rats (Szotakova et al., 2004). 
Glutathione S-transferase (GSTs) is a phase 2 enzyme multigene family involved in 
the detoxification of various exo and endogenous compounds such as plant 
phenols, mycotoxins and carcinogens. They are also involved in steroid 
metabolism and prostaglandin synthesis (Sheehan et al., 2001). GSTs catalyse the 
nucleophillic attack of GSH on electrophilic substrates (Gusson et al., 2006). To 
date 7 classes of GSTs have been identified in mammals (Frova, 2006). GSTα 
contributes significantly to the biotransformation of promutagens and 
procarcinogens. 1-chloro-2,4-dinitrobenzene  (CDNB) is a substrate widely used 
for assessing GSTα activity (Gusson et al., 2006). Activity of cattle towards this 
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substrate was lower when compared to that of rats and other species such as 
rabbits, horses and pigs (Gusson et al., 2006; Sivapathasundaram et al., 2003). 
GST-CDNB activity in rat hepatocytes was found to be 6 fold higher than bovine 
hepatocytes and this has been inversely related to different hepatic cytotoxic 
potency of aflotoxin B1 from either species (Kuilman et al., 2000). Moreover cattle 
were also found to be supposedly deficient in other classes of GST enzymes 
(Gusson et al., 2006). Expression of GSTα like mRNA has been detected in liver, 
lung, kidney and muscle tissue of cows with the kidney having the highest 
expression levels of all the tissues examined (Darwish, 2010).  
Several factors such as breed, sex and age affect the expression profile and activity 
of drug metabolising enzymes in the above animals including cattle (Giantin et al., 
2008) and these factors must be taken into account when comparing drug 
metabolism data between animals.  
1.5 Sulfation 
Sulfation has been known to be involved in the modification of several compounds 
that carry out diverse physiological processes. These include endogenous 
molecules such as steroid hormones (Luu-The et al., 1996), cholesterol, low 
molecular weight compounds such as iodothyronies (Visser, 1994; Visser et al., 
1998) and vitamin C (Baker et al., 1971) as well as large macromolecules such as 
proteoglycans found in connective tissue (Bernfield et al., 1999; Kolset and 
Salmivirta, 1999). Posttranslational modification of secreted and membrane 
bound proteins by sulfation has generated a lot of interest in sulfation being  
implicated in protein-protein interaction mediating various biological process 
such as leucocyte adhesion, chemokine signalling and homeostasis (Kehoe and 
Bertozzi, 2000).  It is also involved in the biotransformation of various 
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endogenous and xenobiotic compounds. Some very commonly used human drugs 
metabolised by sulfation include paracetamol, minoxidil and salbutamol 
(Anderson et al., 1998; Clements et al., 1984; Zhang et al., 2007). Sulfation was 
first discovered by Eugen Baumann in 1876 when he isolated and characterized 
the sulfate conjugate of phenol from urine of a patient treated with carbolic acid as 
an antiseptic. However, it was not until 1953 when the mechanism of 
biotransformation by sulfation was elucidated. In 1953, Lipmann et al discovered 
3’-phosphoadenosine 5’-phosphosulfate  (PAPS), the obligatory co-factor / sulfate 
donor of sulfation reactions (Robbins and Lipmann, 1957). Sulfation is defined as 
the transfer of sulfate radical  (SO3-) from a donor molecule 3’-phosphoadenosine 
5’-phosphosulfate  (PAPS) to an acceptor site on the substrate (Klaassen and 
Boles, 1997). Given below is an illustration of the sulfation reaction. PAPS is 
synthesised from an inorganic sulfate and two molecules of ATP and hence is an 
expensive molecule for the cells to make.  It is present in low concentration in the 
cell (<20-30µM).  Sulfation is limited by the bioavailability of PAPS (Falany, 1997). 
The synthesis of PAPS from inorganic sulfate results from the concerted action of 
two enzyme systems namely, ATP sulfurylase and APS kinase.  The first step in 
PAPS synthesis is catalysed by ATP sulfurylase and it involves the reaction of ATP 
and inorganic sulfate (SO42-) to form adenosine 5’-phosphosulfate (APS) and 
pyrophosphate (PPi) in the presence of Mg2+. In the second step, APS reacts with 
another molecule of ATP to form PAPS and ADP. This reaction too takes place in 
the presence of Mg2+ but is catalysed by APS kinase (Lyle et al., 1994a; Lyle et al., 
1994b) (See figure 4). In most species however, these 2 enzyme systems are 
incorporated in a single bifunctional protein called the PAPS synthetase. The 
catalytic domain of APS kinase is located at the N terminal region whereas the ATP 
sulfurylase domain is located at the C terminal end of this bifunctional protein 
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(Venkatachalam et al., 1998). In humans and mice, 2 isoforms of this enzyme exist 
that are products of genes PAPSS1 and PAPSS2. Mutations in PAPSS2 are 
responsible for a rare inherited connective tissue disorder in humans called 
spondyloepimetaphyseal dysplasia (Faiyaz ul Haque et al., 1998).  
 
 
 
  
 
 
Figure 4:  Sulfotransferase catalysed sulfation of the drug paracetamol.  
The reaction depends on the availability of the obligate co-factor PAPS. PAPS is 
synthesized in a two stage reaction  (1 and 2) and involves the use of an inorganic 
sulfate and 2 molecules of ATP (Coughtrie, 2002) 
 
1.6 The Sulfotransferase enzyme superfamily  
Sulfation is carried out by two broad classes of enzyme families termed as 
sulfotransferases (SULT). Membrane bound SULTs are located in the golgi 
apparatus of the cell and sulfate large macromolecules such as proteins, lipids and 
glycosaminoglycans. On the other hand, cytosolic SULTs sulfate xenobiotics and 
small endogenous compounds such as steroids, bile acids and neurotransmitters 
(Falany, 1997; Negishi et al., 2001). The focus of this research is limited to 
studying cytosolic sulfotransferases only.  Like many other drug metabolising 
enzymes sulfotransferases belong to a large family of enzymes. Attendees at the 
third international sulfation workshop held in Drymen, UK (1996) and the fourth 
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international ISSX meeting in Seattle (1995) agreed that ‘SULT ‘should be adopted 
as the abbreviation for cytosolic sulfotransferases and that ‘SULT ‘would be the 
gene symbol. Nomenclature published by Blanchard et al, puts SULTs sharing 45% 
sequence identity into the same family and members within the same family 
sharing more than 60% identity are put in the same sub family. cDNAs that 
encoded amino acids with more than 97% sequence identity were assigned 
identical isoform names. SULT families were  designated by an Arabic numeral 
following the name (e.g. SULT1) and sub families recognized by alphabetical 
letters  (e.g. SULT1A) (Blanchard et al., 2004). Isoforms within a subfamily were 
recognized by an Arabic numeral following the subfamily alphabet. (e.g. 
SULT1A1). It was decided that the first published sequence in a subfamily would 
be recognized as isoform 1 and any other isoforms discovered subsequently 
would be assigned Arabic numbers based on their percentage amino acid identity 
relative to isoform 1.  
1.6.1 SULT1A family  
The SULT1 family is subdivided into 5 subfamilies. Members of the SULT1A family 
are also known as phenol sulfotransferases due to their ability to primarily sulfate 
small phenolic compounds (Brix et al., 1999; Wilborn et al., 1993). However, their 
sulfation capacity is not limited to small phenolic compounds as they can also 
sulfate endogenous compounds such as 17β-estradiol, 17α-ethinylestradiol 
(Falany, 1997) and iodothyronines (Li et al., 2001) and carcinogens such as N-
hydroxy-PhIP (Ozawa et al., 1995). SULT1A1 has been identified in a large number 
of species including humans (Wilborn et al., 1993), rat (Ozawa et al., 1990), mouse 
(Kong et al., 1993), cow (Schauss et al., 1995) and rabbit (Riley et al., 2002). In 
most of the species only a single SULT1A member, SULT1A1 has been identified.  
15 
 
In humans, 4 SULT1A genes namely SULT1A1, SULT1A2, SULT1A3 and SULT1A4 
have been identified (Blanchard et al., 2004; Hildebrandt et al., 2004). Genes 
encoding these proteins are clustered around the short arm of chromosome 16 
and seem to have arisen due to gene duplication or recombination events (Dooley, 
1998). Human SULT1A1 was first characterized following isolation from liver 
cDNA library. The protein exists as a dimer in solution,  is made up of 295 amino 
acid and has a subunit molecular mass of 32KDa (Wilborn et al., 1993). It is widely 
distributed throughout the body with the highest expression in liver and 
expression to a lesser degree in lung, brain (Richard et al., 2001), skin, breast 
(Falany and Falany, 1996a), intestine (Teubner et al., 2007) kidney, placenta and 
platelets (Gamage et al., 2006). Human SULT1A1 is also the most extensively 
studied isoform with respect to biotransformation of several drugs such as 
paracetamol, and minoxidil (Gamage et al., 2006; Meisheri et al., 1993). Studies 
carried out at the mRNA level show that SULT1A1 is widely expressed in human 
drug metabolising tissues. Protein quantification studies have shown that 
SULT1A1 is the most abundant enzyme present in human liver (Riches et al., 
2009). Because of its broad tissue distribution, broad substrate specificity and 
high expression in major drug metabolising tissues such as the liver and GI tract, 
SULT1A1 is considered the major drug/xenobiotic metabolising SULT.    
Ozawa et al first cloned the SULT1A2 cDNA from a human liver library. It has 
approximately 95% sequence identity to SULT1A1 (Ozawa et al., 1995). This 
isoform has only been identified in humans. It sulfates phenolic substrates such as 
4-nitrophenol, 2-naphthol and minoxidil with a much lower affinity than SULT1A1 
(Ozawa et al., 1995).  Although SULT1A2 cDNA has been isolated from human liver 
(Zhu et al., 1996), to date protein expression of SULT1A2 has not been detected in 
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any human tissue. Due to low levels of activity and no expression relative to 
SULT1A1, this isoform is not considered important with respect to 
drug/xenobiotic metabolism.   
SULT1A3 was initially isolated from a human brain cDNA library (Zhu et al., 1993). 
It encoded a 295 amino acid peptide that resulted in the formation of a 34kDa 
protein that was 93% similar to SULT1A1 (Zhu et al., 1993). Although the 
sequence identity of the whole gene was 60%, the coding region of SULT1A3 had > 
90% sequence identity to SULT1A1 (Blanchard et al., 2004). SULT1A3 is not 
typically a phenol sulfotransferase like SULT1A1; instead it specifically sulfates 
catecholamines and neurotransmitters such as dopamine (Dajani et al., 1999b). 
SULT1A3 and SULT1A4 produce identical proteins that can be referred to as 
SULT1A3 or SULT1A4. It will be referred to as SULT1A3 throughout this 
manuscript. It is believed that SULT1A3 and SULT1A4 must have arisen from 
sequential gene duplication on chromosome 16 (Hildebrandt et al., 2004). Gene (s) 
encoding SULT1A3 has thus far been identified only in primates. SULT1A3 is 
expressed in human brain, intestine, placenta and lungs (Richard et al., 2001; 
Windmill et al., 1998). It is majorly expressed in the fetal liver; however no 
expression has been detected in the adult liver.  
1.6.2 SULT1B 
The first member of this family was cloned from a rat liver cDNA library and was 
shown to have activity towards tyrosine substrates and L-dopa (Sakakibara et al., 
1995). The first human form of SULT1B1 was isolated and characterized from a 
liver cDNA library (Fujita et al., 1997; Wang et al., 1998). The human form of 
SULT1B1 was shown to be 74% identical to rat SULT1B1. The structural gene for 
SULT1B1 is located on 4q13.1 (Meinl and Glatt, 2001) and encodes a protein that 
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is 296 amino acids long and has a subunit molecular mass of approximately 
35KDa. SULT1B1 was initially termed as the thyroid sulfating enzyme because of 
its high affinity to thyroid hormone substrates and its ability to sulfate a range of 
thyroid hormones (Wang et al., 1998). Indeed human SULT1B1 may be the 
principal hepatic iodothyronine sulfating enzyme. Expressed SULT1B1 has also 
been shown to conjugate phenolic substrates such as 1-naphthol, 4-
isopropylcatechol and 4-nitrophenol. Overlapping substrate specificities with 
SULT1A1 make the identification of a probe substrate that is exclusively 
metabolised by SULT1B1 very difficult. Most steroids are not readily sulfated by 
SULT1B1 (Fujita et al., 1999). Expression of human SULT1B1 has been detected in 
liver, colon, small intestine and leukocytes. No expression in thyroid tissue has yet 
been determined. In addition to rats and humans, the SULT1B1 enzyme has been 
isolated and characterized from mouse, chicken (Wilson et al., 2004) and dog 
(Blanchard et al., 2004)  
1.6.3 SULT1C 
Members of the SULT1C family have been identified in a variety of species such as 
Sult1C1, 1C2 and 1C3 from rat, Sult1C1 from mouse and Sult1C2 from rabbit 
(Blanchard et al., 2004) and chicken SULT1C1 (Wilson et al., 2004). In humans, 
SULT1C1, 1C2 and 1C3 members of the family have been identified. Human 
SULT1C2 was first isolated from a fetal liver spleen library (Freimuth et al., 2000) . 
SULT1C2 is located at chromosomal position 2q11.2 (Her et al., 1997) and encodes 
a protein that is 302 amino acids long. SULT1C1 is also located at position 2q11.1-
11.2 and encodes a 296 amino acid long protein that is 63% identical in sequence 
to SULT1C2 (Nagata et al., 1993). Expression of human SULT1C1 and 1C2 was 
detected in fetal liver and kidney (Her et al., 1997). In addition to this, 1C2 was 
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also found to be expressed in adult human stomach and  kidney (Her et al., 1997). 
Human SULT1C2 has been shown to catalyse the sulfation of high concentration of 
4-nitrophenol as well as metabolically activating procarcinogens such as N-
hydroxy-2-acetylaminofluorene (Freimuth et al., 2000). Chicken SULT1C1 had 
activity towards 4-nitrophenol, 2-bromophenol, dopamine, tyrosine and 
apomorphine (Wilson et al., 2004).  
1.6.4 SULT1E 
SULT1E1 is most widely studied for its role in estrogen biotransformation. Human 
SULT1E1 has a very high affinity (in the nanomolar range) towards natural 
hormones such as 17β-estradiol and estrone. It also sulfates a variety of synthetic 
estrogens such as 17α-ethinylestradiol, diethylstilbesterol and 4-
hydroxytamoxifen (Falany and Falany, 1997). Although other sulfotransferases 
such as SULT1A1 and SULT2A1 also metabolise 17β-estradiol, they do so at non-
physiological conditions i.e. in the micromolar range (Falany and Falany, 1997). 
Bovine SULT1E1 was the first cDNA cloned as a known sulfotransferase (Nash et 
al., 1988). Since then members of the SULT1E subfamily have been identified in 
guinea pig, rat, mouse, pig and humans (Aksoy et al., 1994; Blanchard et al., 2004). 
Human SULT1E1 is expressed in fetal and adult liver, jejunum, lung, kidney and 
hormone responsive tissues such as the endometrium, breast, testis and placenta 
(Coughtrie, 2002). The enzyme is expressed in the endometrium and is tightly 
regulated during the menstrual cycle under the influence of progesterone 
(Buirchell and Hahnel, 1975; Falany and Falany, 1996b; Rubin et al., 1999). In 
addition to estrogenic compounds, SULT1E1 is also known to be a principal SULT 
involved in thyroxine metabolism (Kester et al., 1999a).  
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1.6.5 SULT2A family 
Members of the SULT2 family are commonly referred to as hydroxysteroid 
sulfotransferases due to their ability to sulfate a wide range of steroids. The SULT2 
family has been divided into 2 subfamilies termed SULT2A and SULT2B based on 
their amino acid sequence identities (Blanchard et al., 2004). SULT2A1 is 
commonly referred to as dehydroepiandrosterone (DHEA) SULT due to DHEA 
being its preferred substrate. However in addition to DHEA, the enzyme also 
metabolises other steroids such as pregnenolone, testosterone, estradiol, estrone 
and androsterone (Comer et al., 1993; Forbes et al., 1995). SULT2A2 was first 
identified in rats who are known to have 3 different isoforms of SULT2A namely 
SULT2A1 (Ogura et al., 1989), SULT2A2 (Chatterjee et al., 1987) and SULT2A3 
(Ogura et al., 1990). SULT2A1 has also been identified in various other species 
such as the mouse, rabbit, humans and monkey (Blanchard et al., 2004). As 
opposed to the 3 SULT2A isoforms discovered in rats, only a single SULT2A1 
isoform has thus far been identified in humans. In humans, SULT2A1 is primarily 
expressed in liver, GI tract, steroidogenic organs such as adrenal and ovary and 
androgen dependent tissues such as prostrate (Javitt et al., 2001). SULT2A1 is 
known to be an important bile acid sulfating enzyme in the human liver where it 
functions to protect the liver against the hepatotoxic effects of bile acids 
(Radominska et al., 1990). In rats it has emerged that SULT2A1 might play an 
important role in androgen responsiveness of the liver during development by 
controlling the sulfoconjugation of testosterone (Roy, 1992b).  SULT2A1 
expression and presence of DHEA and pregnenolone sulfate has been detected in 
the rat brain (Corpechot et al., 1981; Corpechot et al., 1983) where it is postulated 
they act as excitatory neurosteroids by being potent antagonists of the GABAA 
receptor (Paul and Purdy, 1992). DHEA sulfate is the most abundant steroid in the 
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human circulation and is known to play an important role in pregnancy and fetal 
development. During the third trimester of gestation, high levels of estrogen are 
reached (Katz and Kappas, 1967). This is derived from DHEA sulfate produced in 
the fetal adrenal gland due to the high level of SULT2A1 expression (Siiteri, 1966). 
Postnatally, the levels of DHEA sulfate drop only to rise again just before puberty. 
Thus SULT2A1 is expressed in an age dependent manner in the human adrenal 
(Hornsby, 1995; Suzuki et al., 2000). DHEA sulfate is also an important precursor 
for estrogen synthesis in postmenopausal women.  
1.6.6 SULT2B 
 SULT2B1 localizes to chromosome 19q13.3, contains alternative exon and 
encodes two mRNAs. cDNAs for SULT2B1a and SULT2B1b encode proteins that 
are 350 and 365 amino acid respectively (Her et al., 1998). Both the enzymes have 
very narrow substrate preferences in comparison to SULT2A1. SULT2B1a 
extensively metabolises pregnenolone followed by DHEA and cholesterol that it 
weakly metabolises. Hence it is also known as pregnenolone sulfotransferase. 
SULT2B1b on the other hand strongly metabolises cholesterol and is thus known 
as cholesterol sulfotransferase. It metabolises pregnenolone also but with 1/10th 
efficiency with which it sulfates cholesterol. Both SULT2B1a and SULT2B1b 
metabolise DHEA; however their affinity for the compound is several orders of 
magnitude lower than SULT2A1 (Javitt et al., 2001). Unlike SULT2A1, SULT2B1 
does not sulfate bile acids, androsterone or estradiol. SULT2B1b is more widely 
expressed than SULT2B1a. SULT2B1a is expressed in the placenta, prostate and 
skin. Expression of SULT2B1b is not only predominant in the placenta, prostate 
and the skin but also extends to colon, lung, kidney, stomach, GI tract and thyroid 
(Geese and Raftogianis, 2001). Cholesterol sulfate aids keratinocyte differentiation 
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and is known to play a role in skin development and creation of the epidermal 
barrier (Kawabe et al., 1998; Shimizu et al., 2003).  
1.6.7 SULT4 family 
SULT4A1 was first identified in rat and human brain (Blanchard et al., 2004). 
SULT4A1 is located on chromosome 22 (22q13.2-q13.31 and encodes a 33KDa 
protein (Falany et al., 2000). It is expressed only in the brain and no natural or 
xenobiotic substrates for this enzyme have yet been identified (Falany et al., 
2000). The PAPS binding pocket of this enzyme is predicted to be smaller than 
other SULTs and hence might not accommodate the sulfuryl donor, PAPS. Allali-
Hassani et al were also unable to demonstrate the binding of this enzyme to PAP. 
This could therefore mean that SULT4A1 is an atypical sulfotransferase that lacks 
the ability to use PAPS as a sulfuryl donor to carry out sulfation. (Allali-Hassani et 
al., 2007) However, predominant brain expression, and high degree of sequence 
identity across species are suggestive of an important physiological function 
which might take application of knock out or transgenic technologies to 
completely understand.  
1.6.8 SULT6 family 
SULT6A1 has been reported to be cloned from chicken liver and differentially 
down regulated in GH receptor deficient dwarf chickens. Recombinant Chicken 
SULT6A1 catalysed the sulfation of estradiol and corticosterone. SULT6B1 was 
discovered in human testis (Cao et al., 1999). However no substrates for human 
SULT6B1 have been found yet.  
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Bovine SULT  
(gene/cDNA) 
identified 
Expression in 
bovine tissues 
Commonly known 
endogenous 
substrates in human 
Commonly known 
xenobiotic substrates in 
humans 
References for 
expression in bovine 
tissue 
SULT1A1 
Lung and 
intestine 
Iodothyronines, 
estrogens 
Paracetamol, minoxidil, 
small phenolic compounds  
(4-nitrophenol) 
  (Baranczyk-Kuzma 
and Szymczyk 1987)  
SULT1B1 Not known Iodothyronines 
Simple phenols  
 (1-naphthol) 
NA 
SULT1C Not known Not known 
4-nitrophenol, N-hydroxy-
2-AAF 
NA 
SULT1E1 
Placenta, 
epididymis, 
adrenal gland, 
fetal liver, skin, 
testis 
Estrogens 
Various estrogens: 2-
hydroxyestrone, 2-
hydroxyestradiol 
  (Nash, Glenn et al. 
1988; Frenette, Leclerc 
et al. 2009; Lopparelli, 
Zancanella et al. 2010; 
Khatri, Frenette et al. 
2011) 
SULT2A1 Not known Steroids: DHEA 
Carcinogens: 1-
hydroxymethylpyrene, 
hycanthone 
NA 
SULT2B1 Not known 
DHEA, pregnenolone, 
cholesterol 
Not known NA 
SULT4A1 Not known Not known Not known NA 
 
Table 1: Summary of major SULT genes identified in cattle (Zimin et al., 2009) 
The expression of SULT genes in bovine tissues  (see references column) and the commonly known substrates for assessing the enzyme 
activity in vitro (Gamage et al., 2006). NA stands for not applicable 
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1.7 Structure and function of sulfotransferases 
Despite having broad and overlapping substrate specificities, individual SULT 
enzymes display high selectivity towards certain substrates. Generation of crystal 
structures of SULTs has helped understand the structural basis behind the 
substrate specificity which is crucial to elucidate the catalytic mechanism and 
function of SULTs. The majority of the structures solved to date are those bound 
with the co-factor PAP. Very few structures have been solved complexed with both 
cofactor PAP, or indeed PAPS, and substrate. This has hindered the elucidation of 
structural principles underlying the recognition and utilization of a given 
substrate (Gamage et al., 2006). 
Mouse SULT1E1 was the first cytosolic sulfotransferase to be structurally 
characterised in the presence of PAP and the substrate 17β-estradiol (Kakuta et 
al., 1997). This was followed by structural characterisation of the first human 
sulfotransferase, SULT1A3 (Dajani et al., 1999a). Shown in figure 5 is the crystal 
structure of human SULT1A1 in the presence of the co-factor PAP and 4-
nitrophenol.  
1.7.1 PAPS binding region of SULTs 
The study of SULT crystal structures has revealed that SULTs are generally 
globular proteins with a single α/β domain that forms a five stranded parallel β 
sheet surrounded by α helices (Gamage et al., 2006) and a three loop region that is 
often very disordered in the absence of PAPS and/or substrate (Allali-Hassani et 
al., 2007). The active site of SULTs is in a long groove at the end of the β sheet and 
it contains both the co-factor and the substrate binding site. Three amino acid 
residues namely Thr228, Arg258 and Gly260 (SULT1A1 numbering) are 
absolutely conserved in the PAPS binding region and are thought to play role in 
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PAPS binding (Allali-Hassani et al., 2007). Another motif that is highly conserved 
in SULTs is the 5’-phosphosulfate  (PSB) binding loop which comprises 9 amino 
acid residues 45-TYPKSGTTW-54 (Kakuta et al., 1997)  (Figure 6). The lysine 
residue within this motif  (Lys 48) is believed to act as a catalytic acid in the 
reaction by protonating the phosphate-sulfate bridge oxygen of PAPS, thereby 
enhancing dissociation of the leaving group (Kakuta et al., 1998). The PSB loop is 
also thought to be important for orienting PAPS for sulfuryl transfer on to the 
acceptor substrate (Kakuta et al., 1998). The 3’ phosphate region of PAPS interacts 
with residues from different parts of the polypeptide chain. These include Arg130, 
Ser138, Arg257, Lys258 and Gly259.  The latter 3 residues are part of a highly 
conserved 257-RKGxxGxWK-265 motif. The catalytic centre of the enzyme is a 
histidine residue His108 that acts as a catalytic base abstracting a proton from the 
hydroxyl group on the acceptor substrate leaving behind a neucleophilic oxygen 
that ‘attacks’ the sulfur on PAPS. Mutating this residue abolishes enzyme activity 
(Kakuta et al., 1998). Recently Allali-Hassani et al revealed an unrecognised 
structural role for PAPS. They suggested that PAPS might play a role in priming 
the disordered substrate binding loop for subsequent interaction with potential 
substrates. This conclusion came from the finding that some substrates such as 
dopamine and 1-naphthol bound SULT1A3 and SULT1B1 respectively only in the 
presence of PAPS. The vice versa was not true however. Moreover it appears that 
PAPS binding orients the substrate binding loop to allow for specific binding. 
Enzymes that bind substrates in the absence of PAPS did not show activity 
towards its substrates. This suggests that PAPS affects substrate binding (Allali-
Hassani et al., 2007).  
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1.7.2 Dimerization of SULTs 
With the exception of mouse SULT1E1, the majority of the cytosolic SULTs exist as 
dimers in solution (Kakuta et al., 1997). They are capable of forming both 
homodimers as well as heterodimers. Cytosolic SULTs generally exist as 
homodimers in solution. They contain a conserved dimerization motif consisting 
of 10 residues near the C terminus represented by the consensus sequence 
KXXXTVXXXE called the KTVE motif (Petrotchenko et al., 2001). Mutation in the 
central Thr and Val in this motif resulted in the monomerization of human 
SULT1E1 that is known to exist as a dimer in solution. Similarly, mouse Sult1E1 
exists as a monomer in solution but the substitution of Thr and Val by Phe and Glu 
respectively resulted in the formation of a dimer in solution (Kakuta et al., 1997). 
This demonstrates the significance of the dimerization motif in cytosolic SULTs. 
However, the role of dimerization in SULT activity if any has not yet been 
elucidated.   
1.7.3 Substrate specificity of SULTs 
Members of the SULT family display broad substrate specificity and yet some 
isoforms can be characterised by having preference for a specific substrate. For 
example an enzyme such as SULT1A1 is able to sulfate a wide range of xenobiotics 
with high affinity and on the other hand enzymes such as SULT1E1, SULT2A1 and 
SULT1A3 are highly specific for 17β-estradiol, DHEA and catecholamines 
respectively(Coughtrie, 2002). Thus in contrast to the PAPS binding site which is 
highly conserved, the substrate binding pocket exhibits a great deal of variety 
across SULTs (Gamage et al., 2006). It is important to determine what controls 
substrate specificity from a number of reasons including being able to predict the 
metabolic fate of drugs metabolised by sulfation and to enable the design of 
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selective inhibitors (Coughtrie, 2002). Analysis of crystal structures solved thus 
far has revealed that sequence identity at the amino acid level is definitely not an 
indicator of structural similarity or substrate specificity exhibited by the enzyme. 
A fine example of this is SULT1A1 and SULT1A3. Both the enzymes share 93% 
sequence identity and yet exhibit distinct substrate preferences. SULT1A1 prefers 
small uncharged phenolic compounds such as 4-nitrophenol, 1-naphthol and p-
cresol whereas SULT1A3 prefers positively charged substrates such as dopamine 
and tyrosine (Brix et al., 1999; Dajani et al., 1998).  The crystal structure of 
SULT1A1 was solved complexed with both PAP and 4-nitrophenol (Gamage et al., 
2003). It was shown that the substrate binding site of the enzyme was very 
hydrophobic and plastic allowing the enzyme to adopt varying conformations so 
that it can interact with small aromatics (4-nitrophenol), L-shaped aromatics  
(diiodothyronines) and fused ring compounds such as 17β-estradiol (Gamage et 
al., 2003). On the other hand, the SULT1A3 structure was solved complexed with 
PAP. The structure was largely disordered mainly due to the absence of the bound 
substrate. The substrate binding site mostly contained acidic residues which 
favoured the binding of positive substrates (Dajani et al., 1999a). This explains the 
specificity of SULT1A3 towards positively charged residues such as dopamine.  
Mutation of amino acid Glu146 to its corresponding Ala residue in SULT1A1 
resulted in SULT1A3 displaying SULT1A1 like enzyme properties (Dajani et al., 
1998). Clearly Glu146 is a critical residue involved in determining the substrate 
specificity of SULT1A3 towards dopamine (Dajani et al., 1998).  Another major 
study on mouse SULT1E1 explains its selectivity for 17β-estradiol over DHEA. It 
was proposed that residues in the substrate binding site of mouse SULT1E1 
demonstrate a gating phenomenon whereby residues such as Tyr81 and Phe142 
form a narrow gate that allows the entry of small endogenous compounds like 
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17β-estradiol but prevents the entry of DHEA which has a large 19-methyl group. 
Phe142 is conserved in all SULTs but Tyr81 is specific to mouse SULT1E1 and is 
responsible for regulating the ‘gating’ phenomenon (Petrotchenko et al., 1999). 
  
Figure 5: Structure of human SULT1A1.  
The co-ordinates for  human SULT1A1 crystallised in the presence of one molecule of 
PAP and two molecules of 4-nitrophenol were obtained from the protein data bank  
(http://www.rcsb.org/pdb/, entry 1LS6) A representation of the structure of human 
SULT1A1 is shown with α-helices displayed as red ribbons and β-sheets as golden 
yellow arrows (Gamage et al., 2003) 
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SULT2A1cow      --------------------------MTGKFLWFEGIPFPSVDYSPELLREVQESFLIKD 34 
SULT2B1cow      MGEPAEPRNQAKWDPYEKKISAISQNLSGEYFRYKGILFPVGIYSPESISMVEN-AEVHD 59 
SULT1A1cow      -------------------MELIQDTSRPPAKYVKGIPLIKYFAEA---LGPLESFEAWP 38 
SULT1D1cow      -------------------MDSKLDIFRRELVDVQGIPLFWSIVEE---WSQVESFENRP 38 
SULT1C1cow      -----------MSLEEMKDLHLEEKYLQPETKEVNGILMTKMISDN---WDKIWNFQAKP 46 
SULT1C2cow      -------------------MALTTAGTQPSLGEVAGIPLPATTVDN---WHQIQGFEAQP 38 
SULT1B1cow      -------------------MTSPKDVLRKNLKLIHGCPITYAFANN---WEKIEQFQSRP 38 
SULT1E1cow      -------------------MSSSKPSFSDYFGKLGGIPMYKKFIEQ---FHNVEEFEARP 38 
SULT4A1cow      ------------MAESEAETPSTPGEFESKYFEFHGVRLPPFCRGK---MEEIANFPVRP 45 
SULT6B1cow      ----MTANSKFIDYIDEALEKSKETVLSHLFFTYQGIPYPVTMCTS-ETFKALDAFEARS 55 
                                                   *                         
 
SULT2A1cow      EDVLLLTFPKSGTNWLIETVCLIYSKGDPKWVQSEPIWDRSPWVETKHGY------ELLK 88 
SULT2B1cow      DDIFIVTYPKSGTNWMIEILSLILKDGDPSWIHSVPIWKRSPWCEAIMGA------FSLP 113 
SULT1A1cow      DDLLISTYPKSGTTWVSEILDLIYQEGDLEKCQRAPVFLRVPFLEFSAPG-VPTGVELLK 97 
SULT1D1cow      DDLLIATYPKSGTTWISEILDLIYNHGDVEKCKRDAIYKRVPFMELIIPR-LTNGVEDLN 97 
SULT1C1cow      DDLLIATYAKAGTTWTQEIVDMIQNDGDLQKCQRANTFDRHPFIEWALPPPLSSGLDLAN 106 
SULT1C2cow      DDLLICTYPKSGTTWIQEIVDLIEHSGDVDKCQRAAIQHRHPFLEWARPP-QPSGVEKAR 97 
SULT1B1cow      DDIMIVTYPKSGTTWISEIVDMVLHDGDVEKCKRDVITAKVPMLELALPGLRTSGLEQLE 98 
SULT1E1cow      DDLVIVTYPKSGTTWLSEIICMIYNNGDVEKCKEDVIFNRVPYLECSTEH-VMKGVKQLN 97 
SULT4A1cow      SDVWIVTYPKSGTSLLQEVVYLVSQGADPDEIGLMNIDEQLPVLEYPQPG-----LDIIK 100 
SULT6B1cow      DDIVLASYPKCGSNWILHIISELMFADSKQKYD----YPEFPVLECGDPE----KYQRMK 107 
                .*: : ::.*.*:.   . :  :    . .         . *  *                
 
SULT2A1cow      EKEGTRLISSHHPIQLFPKSFFKSKAKVIYLVRNPRDVFVSGYFFWKSAKFVKRPQSLEQ 148 
SULT2B1cow      NQPSPRLMSSHLPIQLFAKAFFNSKAKVIYMGRNPRDVAVSLYHYSKIARQLKDPGTPDQ 173 
SULT1A1cow      DTPAPRLLKTHLPLALLPKTLLDQKVKVIYIARNAKDVAVSYYHFYRMAKVHPDPGTWDS 157 
SULT1D1cow      DMQSPRLVKKHLPVQLLPSSFWKNNCKMVYVARNANDVAVSYYYFYQMAKMHPDPGTWEE 157 
SULT1C1cow      KMPSPRTLKTHLPVQMLPPSFWKENAKIIYVARNAKDCLVSYYHFSRMNKMVPDPGSWEE 166 
SULT1C2cow      AMPRPRVLRTHFPAQLLPPSFWESNCKFLYVARNAKDCLVSYYHFQRMNRTLPDPGTWDQ 157 
SULT1B1cow      KNPSPRVVKTHLPIDLIPKSFWENNCKIIYLARNAKDVAVSFYHFDLMNNLQPLPGTWGE 158 
SULT1E1cow      EMASPRIVKSHLPVKLLPVSFWEKNCKIIYLSRNAKDVVVSYYFLILMVTAIPDPDSFQD 157 
SULT4A1cow      ELTSPRLIKSHLPYRFLPSDLHNGDSKVIYMARNPKDLVVSYYQFHRSLRTMSYRGTFQE 160 
SULT6B1cow      QFPSPRILATHLHYDKLPGSIFKNKAKILVIFRNPKDTAVSFFHFHNDVPDIPSYGSWDD 167 
                    .* : .*     :.  : . . *.: : **..*  ** :             :  . 
 
SULT2A1cow      YFEWFIQGNMPFGSWFDHIRGWMSMRDKENFLVLSYEEMKWDTRSTVEKICQFLGKKLEP 208 
SULT2B1cow      FLENFLKGEVQFGSWFDHIKGWIRMKGKENFLFITYEEMQQDLRSSVQRICQFLSRPLGE 233 
SULT1A1cow      FLEKFMAGEVCYGSWYQHVQEWWELSHTHPVLYLFYEDIKEDPKREIQKILEFIGRSLPE 217 
SULT1D1cow      FLDKFMTGKVAFGSWYDHVKGWWEKKKDYCKLYLFYEDMKQDPKCEIQKLLKFLDKDLPE 217 
SULT1C1cow      YVETFKAGKVLWGSWYDHVKGWWHAKDQHRILYLFYEDMKEDPRREIRKILKFLEKEVSE 226 
SULT1C2cow      YFETFISGKVAWGSWFEHVRGWWELRDNVQMLFLFYEDIKRDPKQEIQKVMKFMEKNLDG 217 
SULT1B1cow      YLEKFLTGNVAYGSWFNHVKSWWKKKEGHPILFLFYEDMKENPKQEIKKVVRFLEKNLDD 218 
SULT1E1cow      FVEKFMDGEVPYGSWFEHTKSWWEKSKNPQVLFLFYEDMKENIRKEVMKLLEFLGRKASD 217 
SULT4A1cow      FCRRFMNDKLGYGSWFEHVQEFWEHHMDSNVLFLKYEDMHRDLVTMVEQLARFLGVSCDK 220 
SULT6B1cow      FFRQFMKGQVSWGSYFDFAINWNKHLDDENVMFILYEDLRENLATGIKRIAEFFGFSPSG 227 
                :   *  .:: :**:::.   :         : : **::: :    : :: .*:       
 
SULT2A1cow      EELNSVLKNNSFQVMKENNMSNFSLLKGQYLEE-NGLLLRKGVTGDWKNYFTVAQAEIFD 267 
SULT2B1cow      EALESVVAHSAFKAMKANPMSNFSLLPHSLLDQRHGAFLRKGVCGDWKNHFTLAQSEAFD 293 
SULT1A1cow      ETVDHIVQRTSFKEMKKNPMTNYSTIPTAVMDHSISAFMRKGITGDWKSTFTVAQNELFE 277 
SULT1D1cow      ETVDKILYHSSFDMMKQNPSANYTTMPKFCMDHSVSPFMRKGVSGDWKNQFTVVQYERFE 277 
SULT1C1cow      EVLDKIIHHTSFEVMKENPMANYTTLPTSIMDHSISPFMRRGMPGDWKNYFTVAQNEDFD 286 
SULT1C2cow      AVLDTIVQETTFEKMKANPMTNRSTAPKTILDQSISPFMRKGIVGDWKNHFTVAQNERFD 277 
SULT1B1cow      EILDKIIYHTSFEMMKDNPLVNYTHLPSEVMDHSKSSFMRKGIAGDWKNYFTVAQNEKFD 278 
SULT1E1cow      ELVDKIIKHTSFQEMKNNPSTNYTTLPDEVMNQKVSPFMRKGDVGDWKNHFTVALNEKFD 277 
SULT4A1cow      AQLESLTEHC---HQLVDQCCNAEALP-----------VGRGRVGLWKDIFTVSMNEKFD 266 
SULT6B1cow      EQIQTISARSTFHAMRAKSQETHGAVG--------PFLFRKGEVGDWKNLFSETQNQEMD 279 
                  :: :  .        .   .                . :*  * **. *:    : :: 
 
 
SULT2A1cow      KLFQEKMADLPQELFAWE----------------------------- 285 
SULT2B1cow      RAYREQMRGLP--TFPWDVDPEDASPDSDPGPGPSPNPDQASEAPHP 338 
SULT1A1cow      AHYAKKMRAATP-LRWEL----------------------------- 294 
SULT1D1cow      EDYEKKMKGSTLQFHSEI----------------------------- 295 
SULT1C1cow      KDYERKMAGSTLTFRTAL----------------------------- 304 
SULT1C2cow      EIYRQKMKGTSINFCTEL----------------------------- 295 
SULT1B1cow      AIYKKEMSETELQFRTEI----------------------------- 296 
SULT1E1cow      MHYEQQMKGSTLKFRTKI----------------------------- 295 
SULT4A1cow      LVYKQKMGKCDLTFDFYL----------------------------- 284 
SULT6B1cow      EKFKECLAGTALGTKLKYNSYCQP----------------------- 303 
                  : . :                                         
 (Figure 6: figure legend on next page) 
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Figure 6: Sequence alignment of major bovine SULT isoforms 
The regions highlighted are the ones that have important structural features. The 
yellow region corresponds to the highly conserved phosphate binding loop (PSB). It 
is involved in the binding of PAPS to the enzyme. The highlighted lysine acts as a 
catalytic acid in the reaction by enhancing dissociation of the leaving group. The 
histidine residue highlighted in green is an important catalytic residue in the active 
site of all SULTs. The turquoise region is the KXXXTVXXXE motif that plays a role in 
dimerization of SULTs. The PSB loop and the dimerization motif are fairly conserved 
in all SULTs except bovine SULT6B1.   
 
1.8 Role of sulfotransferases in bioactivation and toxicology  
Sulfation is predominantly recognised as a detoxification pathway where 
conjugating a sulfate moiety on to an endogenous or a xenobiotic compound 
increases its water solubility thereby facilitating excretion through bile and urine.  
However, bioactivation of dietary compounds, environmental pollutants, 
procarcinogens and therapeutic drugs by members of the sulfotransferase family 
to generate toxic metabolites has also been widely investigated.  
Chemicals such as safrole and estragole which are alkoxy derivatives of 
allylbenzene are known to be potent rodent carcinogens. Hydroxyl metabolites of 
these compounds are more potent and readily sulfated compared to the parent 
compound (Wakazono et al., 1998). Brachymorphic mice which have genetic 
mutation that reduces their ability to synthesise PAPS (Sugahara and Schwartz, 
1979) and hence the ability to carry out sulfation were resistant to tumour 
formation when fed with 1’-hydroxysafrole, the hydroxyl metabolite of the 
chemical safrole (Boberg et al., 1983). Mice treated with a sulfotransferase 
inhibitor named pentachlorophenol before being administered 1’-hydroxylsafrole 
showed a significant reduction in formation of DNA adducts and tumours (Boberg 
et al., 1983). In vitro experiments carried out by Glatt et al have shown that human 
purified and liver cytosol sulfotransferases sulfate and bioactivate a variety of 
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procarcinogens such as N-hydroxyarylamine, N-hydroxy-heterocyclic amines and 
arylhydroxamic acids (Gilissen et al., 1994a; Gilissen et al., 1994b; Meerman et al., 
1994). SULT1A1 is responsible for the preferential metabolism and subsequent 
bioactivation of the dietary compound N-OH-PhIP (Ozawa et al., 1994) whereas 
expressed human SULT2A1 preferentially sulfates benzylic alcohols of polycyclic 
aromatic hydrocarbons (Glatt et al., 1995). The above examples provide evidence 
for the role of sulfation in the bioactivation of carcinogens.  
Polyhalogenated aromatic hydrocarbons  (PHAHs) such as polychlorinated 
biphenyls  (PCBs), polychlorinated dibenzfurans  (PCDFs) and polychlorinated 
dibenzo-p-dioxins  (PCDDs) are environmental pollutants that have strong 
endocrine disrupting effects such as developmental and reproductive 
abnormalities(Neubert, 1997) and endocrine associated cancers such as breast 
cancer in animals and humans (Dorgan et al., 1999; Safe, 1995). They exert their 
endocrine disrupting effects in an estrogen receptor independent manner by 
inhibiting the activity of estrogen sulfotransferase, SULT1E1 (Kester et al., 2000; 
Kester et al., 2002). Indeed PHAHs are potent inhibitors of SULT1E1 and there is a 
possibility that they bring about endocrine disruption by regulating the 
bioavailability of 17β-estradiol. SULT1E1 is also known to sulfate iodothyronines 
(Kester et al., 1999b). Compromised thyroid function due to the effect of 
hydroxylated PHAHs during fetal development could possibly be explained by the 
inhibition of SULT1E1 by PHAHs (Darras, 2008).  
In addition to procarcinogens, dietary compounds and environmental pollutants, 
therapeutic drugs are also bioactivated by sulfation. A classic example is the 
antihypertensive drug minoxidil (Campese, 1981). Minoxidil is predominantly 
sulfated by SULT1A1 (Falany and Kerl, 1990) and it is the sulfated metabolite that 
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mediates the pharmacological actions of minoxidil such as smooth muscle 
relaxation and vasodilation (Meisheri et al., 1993).  
1.9  Sulfation of drugs 
Drugs containing hydroxyl or amine groups are very often sulfated by 
sulfotransferases. Although various SULT isoforms are involved in drug 
metabolism, SULT1A1 and 1A3 are considered to be the major enzymes 
responsible for sulfating drug compounds. SULT isoforms 1A1, 1E1 and 1B1 are 
involved in the sulfation of local anaesthetics such as lidocaine and ropivacaine 
(Falany et al., 1999). SULT1A1 is primarily responsible for the sulfation of the 
widely used painkiller paracetamol (Reiter and Weinshilboum, 1982) and it is 
reported that 35% of the original dose of paracetamol was excreted in the urine in 
humans. Salbutamol, a bronchodilator used in the treatment of asthma, is mainly 
eliminated by sulfation. In a study carried out by Morgan, DJ et al, 1986 (Morgan et 
al., 1986), it was found that plasma levels of salbutamol sulfate were higher than 
salbutamol itself. Budesonide is a synthetic glucocorticoid used in the treatment of 
asthma and allergy. It is predominantly sulfated by SULT2A1(Meloche et al., 
2002). This sulfation is all the more significant in budesonide metabolism when 
CYP3A predominantly responsible for its metabolism is inhibited by medical 
elements or dietary factors (Ameer and Weintraub, 1997).  
It has been shown that sulfation of drugs possessing a chiral atom is 
stereoselective. This stereoselectivity could be due to different rates of sulfation or 
different affinity of sulfotransferases towards the two enantiomers. Terbutaline is 
a β-adrenoreceptor agonist is used in the treatment of lung obstruction disease. 
Pharmacokinetic studies have shown that  (-)-terbutaline has a higher oral 
bioavailability than  (+)-terbutaline (Borgstrom et al., 1989). In addition to this, 
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the sulfation rate of  (+)- terabutaline in human liver is much higher than that of  (-
)-terbutaline (Walle and Walle, 1990). Salbutamol is a β-adrenoreceptor agonist 
whose target organ is the lung. SULT1A3 showed stereoselectivity in the affinity 
towards the two salbutamol enantiomers (Walle et al., 1993). In human lung 
cytosol, sulfation of (+) - salbutamol had a lower Km as compared to (-) - 
salbutamol. The Vmax for both these enantiomers was approximately similar 
(Pacifici et al., 1996). Very complex enzyme kinetics was observed for 4-
hydroxypropanolol (4-OHP) in vitro using human liver cytosol. 4-OHP, a 
metabolite of propanolol is a blocker of the β-adrenoreceptor. At low 
concentrations of the substrate  (3µM) (Walle and Walle, 1991), stereoselectivity 
was observed with  (+)- 4-OHP. However, no stereoselectivity was observed at the 
higher substrate concentration of 500µM. This led the authors to conclude that 
sulfation of 4-OHP at their respective concentration must be catalysed by different 
enzymes (Walle and Walle, 1991).  
As with other drug metabolizing enzymes, SULTs too can be inhibited by 
chemicals, drugs or dietary factors. Inhibition of SULTs can lead to the build-up of 
toxic phase I metabolites resulting in adverse drug reactions. Non-steroidal anti-
inflammatory drugs, mefenamic acid and salicylic acid are found to be potent 
inhibitors of SULT1A1 and 1A3 in human liver (Vietri et al., 2000). Flavonoids are 
chemicals present in fruit and vegetables. Quercetin , a natural flavonoid is a 
potent inhibitor of SULT1A1 activity in human liver (Walle et al., 1995). It affects 
the sulfation rates of salbutamol, paracetamol and minoxidil in human liver and 
duodenum (Eaton et al., 1996).     
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1.10  Interspecies differences in SULT expression and activity. 
Interspecies differences have been observed in many enzymes responsible for 
drug metabolism and sulfotransferases are no exception.  Differential expression 
of SULTs with respect to sex and tissue has been reported. Likewise, depending on 
species they belong to SULTs can have varying affinity for their substrates.  One of 
the major differences is that in species other than humans, SULT expression is 
highly sexually dimorphic or sex related. SULT1A1 content in adult male rat liver 
is 1.5 times higher than the female rat liver whereas on the other hand, expression 
of mouse SULT1A1 was about twice as high in females as compared to the males 
(Honma et al., 2001). SULT2A1 is expressed more in adult female rats as 
compared to male rats. Expression of SULT2A1 in rats is regulated by growth 
hormone and sex related differences in rats was observed due to differential 
expression of pituitary growth hormone between female and male rats (Ueda et 
al., 1997). Rat Sult1E1 is specifically expressed only in the liver cytosol of young 
adult males. It was found to be absent in prepubertal males (27days), senescent 
males (800 days) and in female liver cytosols (Demyan et al., 1992). Several 
studies have shown that mRNA levels of Sult1C1 were higher in male rats as 
compared to females (Klaassen et al., 1998; Liu and Klaassen, 1996). N-OH-2AAF, 
a carcinogen is metabolized to its sulfo conjugate and induces tumour formation in 
rats. However, due to a gender difference in Sult1c1 expression, tumours develop 
more rapidly in male mice as compared to females (DeBaun et al., 1970). In 
humans, SULT1C1 are expressed in kidney, liver, ovary, stomach and colorectum 
(Dooley et al., 2000). However, in rats Sult1c1 is mainly expressed in liver with 
little or no expression detected in kidney, lungs, intestine, spleen, brain or heart 
(Dunn and Klaassen, 1998). Sex related differences were observed not only in the 
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levels of expression but also in the sites of expression. Male dog expresses 
SULT1D1 in liver, jejunum, ileum, and colon and to a lesser extent in duodenum 
whereas the female dog expresses SULT1D1 to a higher extent in liver and 
duodenum but to a lesser extent in ileum and jejunum. SULT1D1 has so far been 
identified in rat, mouse and dogs but not humans (Oddy et al., 1997). Differences 
also exist in tissue distribution and abundance of SULT2B1 in rats and mice from 
that of human isoforms. High levels of SULT2B1b were detected in skin and 
intestine of all 3 species. In rats little or no SULT2B1a expression was detected in 
tissues except brain and testis in which SULT2B1a is expressed but not 2B1b 
(Kohjitani et al., 2006). In mice SULT2B1a message is highly expressed in brain 
and spinal cord whereas no SULT2B1 message or protein has been detected in 
human brain (Shimizu et al., 2003). To date SULT2B1 protein expression in mice 
or rat brain tissue has not been reported. SULT2B1b is predominantly expressed 
in human placenta and prostrate whereas SULT2B1b is barely expressed in the rat 
placenta and not in the prostrate (Kohjitani et al., 2006). In addition to this 
differences have also been observed in the SULT isoforms identified. For example, 
various members of the SULT1A family (SULT1A1, SULT1A2, SULT1A3, and 
SULT1A4) have been identified in humans as opposed to only a solitary SULT1A1 
being identified in other species. SULT1A3 exists only in humans and is known to 
sulfate endogenous compounds such as dopamine, norepinephrine and tyrosine. 
Conversely all other SULT1A members have very low affinity towards these 
chemicals suggesting a human specific role for SULT1A3 in the metabolism of 
catecholamine neurotransmitters. Rats have 4 members of the SULT2A family 
whereas only one member of this family (SULT2A1) has been identified in humans 
so far. No human equivalents of Sult5a1, Sult3a1 in mouse and the Sult6a1 gene in 
chicken have yet been identified (Gamage et al., 2006). Differences in the ability to 
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sulfate various endogenous and xenobiotic substrates also exist between humans 
and other species. Rat Sult1A1 is inactive for the sulfation of iodothyronines 
whereas human SULT1A1 is capable of catalysing iodothyronine sulfation. Canine 
and rat Sult1A1 have activity against dopamine which is in contrast to human 
SULT1A1 which has a very low affinity for dopamine. The SULT2B1a isoform in 
rats and humans sulfates cholesterol to a lesser extent as compared to Sult2B1a 
isoform in mice (Kohjitani et al., 2006)   
1.11  Sulfotransferases in cattle and other livestock animals 
In comparison to humans and laboratory animals, xenobiotic biotransformation 
has not been extensively studied in members of the livestock species.  Majority of 
the research carried out on livestock and other veterinary animals is centred on 
cytochrome P450 mediated biotransformation of drugs. A few reviews focus on 
phase 2 drug metabolising enzymes such as UGTs, N-acetyltransferases and 
glutathione-S-transferases but the literature on sulfotransferase mediated drug 
and xenobiotic metabolism in livestock species is currently very limited. Bovine 
SULT1E1 was the first cDNA cloned as a known sulfotransferase. The protein  was 
found to be 295 amino acids long and of approximately 34kDa molecular weight 
(Nash et al., 1988). Subsequently cDNA encoding phenol sulfotransferase (PST) 
was isolated from bovine lung. It was discovered that two forms of PST exist in the 
human lung. One which sulfates phenolic compounds such as 1-naphthol and p-
nitrophenol (SULT1A1) and the other was specific towards monoamine substrates 
such as catecholamines (dopamine) (SULT1A3). Bovine lung was found to have 
only the thermostable form of PST, i.e SULT1A1 (Baranczyk-Kuzma and Szymczyk, 
1987). A study carried out by Watkins and Klassen showed that cattle and sheep 
sulfotransferases had the highest activity towards 2-naphthol as the substrate 
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among a range of species tested (Watkins and Klaassen, 1986). Similiar 
observations were recorded by Sivapathasundaram et al 2003 where cytosolic 
SULT activity measured with 2-naphthol was significantly higher in cattle than in 
rat. Comparison of sulfation capacities of cattle, deer and rat showed that sulfation 
was similar in cattle and deer but differences were observed between the 
ruminants on one side and rat on the other (Sivapathasundaram et al., 2003).  
1.12 The need for studying SULT mediated drug metabolism in cattle  
For the elimination of a wide variety of chemicals, living organisms have evolved 
enzyme systems that bring about the biotransformation of these compounds to 
hydrophilic entities that can safely excreted from the body. This is termed as 
metabolism. To date numerous reviews have focussed on drug and xenobiotic 
metabolism in humans and laboratory animals. However, literature on 
metabolism in food producing animals/livestock species is very limited. Lack of 
comparative data on drug metabolism between food producing species results in 
the extra-label use of veterinary products labelled for use in other animal species. 
Due to the differences in expression and activities of drug metabolising enzymes, 
extrapolation of metabolism data between species is highly inaccurate. Extra label 
use of drugs between species without sufficient knowledge on drug metabolism in 
the target species could result in adverse drug reactions. Residues of 
drugs/xenobiotics can end up in edible tissues of food producing animals and 
reach humans through the food chain posing considerable risk to human health. 
This is of grave concern to the livestock and pharmaceutical industry. Authorities 
regulating the usage of veterinary drugs in livestock demand evidence for safe and 
effective use of these drugs prior to licensing and marketing of the drug. For all 
these reasons it becomes important to study drug metabolism in food producing 
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species. Sulfotransferases are the second most abundant phase 2 conjugating 
enzymes found in human liver and despite this very little research has been done 
on SULTs in food producing animals (Evans and Relling, 1999).  
1.13  UDP glucuronosyltransferases 
Like sulfation, glucuronidation also is a phase II conjugation reaction catalysed by 
a family of enzymes known as UDP glucuronosyltransferases (UGTs). UGTs are 
involved in the conjugation of glucuronic acid (UDPGA) onto lipophilic substrates, 
thereby increasing their water solubility and enhancing excretion through bile and 
urine.  Glucuronidation reactions are generally detoxification reactions as 
conjugation of glucuronic acid group on a toxic substrate makes it relatively 
nontoxic (Tukey and Strassburg, 2000). However in some instances 
glucuronidation can also lead to the bioactivation of substrates. For example 
morphine-6-glucuronide is pharmacologically more active than its parent 
compound (Shimomura et al., 1971). The addition of the glucuronic acid moiety 
generally occurs at hydroxyl, amine, carboxyl, carbonyl and thiol groups. UGTs can 
conjugate a variety of endogenous substrates such as bilirubin, thyroxine, 
estradiol, testosterone, androsterone and hyodeoxycholic acid. In addition to this 
xenobiotic compounds serve as UGT substrates including drugs such as morphine, 
chloramphenicol, acetaminophen, propofol and non-steroidal anti-inflammatory 
drugs (NSAIDs). Environmental compounds such as plant derived dietary 
flavonoids  and carcinogens such as N-OH-PhiP are also metabolised by UGTs 
(Tukey and Strassburg, 2000). Indeed about 35% of all drugs metabolized in 
phase II are biotransformed by UGTs (Evans and Relling, 1999). It is also involved 
in the direct clearance of 1 in 10 of the top 200 prescribed drugs in humans 
(Williams et al., 2004).   
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UGT enzymes are bound to the internal membrane of the endoplasmic reticulum  
(ER) and face the luminal side of the ER. UGTs possess a highly hydrophobic C 
terminus which is believed to anchor the protein to the cytoplasmic side of the ER. 
The N terminal region is not very well conserved and hence is thought to be 
involved in the binding of the substrate (Tephly and Burchell, 1990).  
1.13.1 UGT1 family 
The UGT gene superfamily is divided into 4 familes, UGT1, UGT2, UGT3 and UGT8 
based on sequence identities at the amino acid level (Mackenzie et al., 2008). The 
UGT1A locus contains a unique first exon and four common exons (2-5) This gives 
rise to a common C-terminus encoded by the 4 common exons. The first exon 
unique to every gene of the UGT1A family encodes the variable N-terminus of the 
UGT1A family (Mackenzie et al., 2005). In humans, 13 unique first exons have 
been identified (UGT1A1-13) that encode 9 functional proteins (Gong et al., 2001). 
In rats, 9 first exons encoding 9 functional proteins have been identified (UGT1A1-
9) (Emi et al., 1995) whereas in mice the Ugt1a subfamily contains 14 exons that 
code for 9 functional Ugt1a isoforms.  
Human UGT1A transcripts are highly expressed in liver, kidney and GI tract 
(Fisher et al., 2001; Mojarrabi and Mackenzie, 1998; Strassburg et al., 1998). 
Similarly, mRNA expression of rat UGT1A isoforms has been detected 
predominantly in the liver and intestine whereas in mice several Ugt1a transcripts 
have been detected in liver, kidney, stomach, esophaegus, small intestine and 
colon (Emi et al., 1995; Shelby et al., 2003). UGT1A isoforms demonstrate high 
substrate specific redundancy in the glucuronidation of phenolic compounds. The 
simple phenols such as 4-nitrophenol, 1-naphthol, and 4-methylumbelliferone 
serve as excellent substrates for majority of the UGT1A family members except 
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UGT1A4. Complex and bulky phenol form excellent substrates for UGT1A6, 1A8 
and 1A9. However, naturally occurring anthraquinones and flavonoids are not 
good substrates for UGT1A6. Glucuronidation of bilirubin is exclusively catalysed 
by UGT1A1. In addition to this primary amines form excellent substrates for 
UGT1A6 and UGT1A9 (Tukey and Strassburg, 2000).   
1.13.2 UGT2 family  
Unlike UGT1 genes, UGT2 genes are encoded by 6 individual exons and divided 
into 2 familes namely UGT2A and UGT2B. UGT2A1 mRNA is expressed in the nasal 
epithelia of humans and rats (Heydel et al., 2001; Jedlitschky et al., 1999). Gene 
duplication of UGT2A1 in humans results in the formation of UGT2A2 which is 
expressed in liver. Their function is not entirely known (Tukey and Strassburg, 
2001). Mice contain 3 Ugt2a gene duplication products that have resulted in the 
formation of Ugt2a1, Ugt2a2, Ugt2a3. Humans, rats and mice all contain seven 
unique Ugt2b genes (Mackenzie et al., 2005). UGT2B members are expressed not 
only in the liver and intestine but also in hormone responsive tissues such as 
testis, uterus, mammary gland and brain where they have been known to 
conjugate endogenous steroids (Shelby et al., 2003; Turgeon et al., 2001).  
1.13.3 UGT3 Family 
Unlike UGT1 and UGT2 familes that use UDP-glucuronic acid as a sugar donor, 
UGT3A1 was found to catalyse the transfer of N-acetylglucosamine from UDP-N-
acetyl glucosamine to ursodeoxycholic acid. In addition to ursodeoxycholic acid, 
UGT3A1 also had activity towards 17α-estradiol and 17β-estradiol and the 
substrates of UGT1 and UGT2 families such as 1-naphthol and 4-nitrophenol. 
UGT3A1 was predominantly expressed in the liver and kidney with minor 
expression in the gastrointestinal tract (GI tract) tract as well (Mackenzie et al., 
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2008). On the other hand, UGT3A2 transcripts have been detected in the thymus, 
testis and kidney but not in the liver or the GI tract. The absence of UGT3A2 in 
major drug metabolising tissues suggest that the enzyme might play a role in 
protecting organs against toxic elements rather than perform a traditional drug 
metabolism role. Like UGT3A1, UGT3A2 also does not prefer UDPGA as a sugar 
donor. UGT3A2 uses UDP glucose and UDP-xylose as sugar donors to glycosidate a 
wide range of substrates such as bioflavones, 1-hydroxypyrene, 4-
methylumbelliferone and estrogens. Unlike UGT3A1, UGT3A2 does not accept UDP 
N-acetylglucosamine as a sugar donor (MacKenzie et al., 2011).  
1.13.4 Species, tissue and gender differences in UGT expression and activity  
Species, gender and tissue specific differences in expression and activity of UGTs 
have been documented. Analysis of UGT activity in hepatic homogenate 
preparations from rat, sheep, cattle and swine towards varied substrates such as 
1-naphthol, 4-nitrophenol, morphine, diethylstilbesterol, bilirubin, estrone and 
testosterone revealed that sheep liver was the most efficient at glucuronidation of 
all the substrates except estrone where the highest activity was observed in cattle 
liver (Smith et al., 1984).  Apart from bilirubin, UGT activity towards all the above 
mentioned substrates was higher in the livestock species than rat (Smith et al., 
1984). Traditionally rodents such as rats and mice and non-primate species such 
as the dog have been used in toxicity testing of new chemical entities. Several 
studies have been carried out to address interspecies differences between dogs 
and humans with a view to make reasonable extrapolations of pharmacokinetic 
and toxicity data from dogs to humans. Ethinylestradiol glucuronidation, brought 
about mainly by UGT1A1 and UGT2B7 isoforms was twice as much in dogs as 
compared to humans (Sharer et al., 1995). No propofol glucuronidation was 
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detected in dog liver unlike the human liver. Stereo and regio-selective differences 
were seen in the glucuronidation of certain substrates such as oxazepam and 
morphine. In humans and dog the S-enantiomer was preferentially glucuronidated 
whereas in monkey it was the R-enantiomer of oxazepam that was preferred 
(Sisenwine et al., 1982). Human liver microsomes selectively metabolised 
morphine at the 3- and 6-positions whereas in dogs the 3 position of morphine 
was preferentially glucuronidated (Soars et al., 2001). Extra hepatic 
glucuronidation in dogs was poorer than in humans (Soars et al., 2001). Tissue 
specific differences were also observed in glucuronidation of 4-nitrophenol by 
UGT1A6 in mice and rats. The duodenum in rats was more efficient than the liver 
in 4-nitrophenol glucuronidation. Vice versa was noted for mouse liver (Shiratani 
et al., 2008). Gender differences in UGT expression and activity have been 
documented in rats. In Wistar rats, the rate of bilirubin glucuronidation was twice 
as much in females as compared to the males. Castration of males resulted in 
increased bilirubin glucuronidation (Muraca and Fevery, 1984). On the other hand 
ovariectamized female rats displayed a reduction in activity towards bilirubin 
(Muraca and Fevery, 1984). Expression of rat UGT2B3 was higher in males than in 
females which could be reduced by castration of males and restored by 
testosterone treatment (Buckley and Klaassen, 2007; Strasser et al., 1997).  
1.14  Aims and hypothesis  
This investigation was carried out to characterise SULT isoforms involved in the 
sulfation of xenobiotics and steroids in bovine liver. To date majority of the 
research in this field has been done on human sulfotransferase isoforms. 
Antibodies and probe substrates against major drug metabolising human SULT 
isoforms are available. There resources were used to study bovine SULT isoforms. 
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Given the high degree of sequence similarity between human and bovine SULTs 
(>70%), an assumption that bovine SULTs would be similar in activity to human 
SULTs was made. The following short aims were set out to accomplish the goal of 
the project and test the above mentioned hypothesis.  
1. Using human SULT antibodies and probe substrates, expression and 
activity of SULT1A1, 1B1, 1E1 and 2A1 in bovine liver was established. 
2. Recombinant bovine SULT1A1, 1B1, and 1E1 were cloned and expressed in 
E. coli. Their activity measured using human probe substrates was 
compared to recombinant human SULT isoforms.  
3. Steroid metabolism brought about by SULTs and UGTs was studied using 
estradiol (a commonly used cattle growth enhancer) and model systems 
such as microsomes, S9, cytosol and hepatocytes.  
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2 Materials and Methods 
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2.1 Bovine livers 
Given below are the details of bovine liver tissue used in this study 
No of livers Sex Age  Breed Treatment 
8 Male 2yrs old Angus Untreated 
8 Female 2yrs old Angus Untreated 
4 Female 2yrs old Angus 
Treated with an 
exogenous progestin 
 
Table 2: Information on bovine livers used in this study 
 
2.1.1 Preparation of cytosol and microsomes 
Big pieces of frozen liver (above) were received from Pfizer Animal health, 
Kalamazoo, Michigan, USA. On arrival they were immediately stored at -80°C until 
further use. Small pieces of frozen liver were obtained from the big piece using a 
hammer. The small piece obtained was then used in the preparation of cytosol and 
microsomes. Firstly, the small piece was weighed and resuspended in 20% (w/v) 
ice cold sucrose HEPES (4- (2-hydroxyethyl)-1-piperazineethanesulfonic acid) 
buffer (0.25M Sucrose, 10mM HEPES, 3mM 2-mercaptoethanol, pH 7.4). Once 
thawed, the tissue was chopped up into small pieces using a pair of scissors. The 
homogenate was transferred to a Teflon glass homogeniser and thoroughly 
homogenised using a mechanical homogenizer. The homogenate was then spun at 
10,000g for 15 minutes at 4°C to pellet the cell debris and plasma membrane. The 
supernatant was then spun at 100,000g for 1 hour at 4°C in an ultracentrifuge  
(Kontron-Centrikon T-2070) to separate microsomes (pellet) and cytosol  
(supernatant). The microsomes were resuspended in ice cold sucrose HEPES 
buffer. 1ml buffer was used for every 1g wet weight of original tissue. Both 
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microsomes and cytosol were divided into aliquots, snap frozen in liquid nitrogen 
and stored at -80°C until required.  
2.2 Radiolabelled enzyme assays for determination of bSULT activity  
2.2.1 General  
Radiolabelled assays were carried out to determine activity/kinetics of 
recombinant bovine SULTs and bovine liver cytosol against a battery of substrates. 
Radioisotopes such as sulfur 35 (35S) and tritium (3H) were used in this project. 
PAPS, the sulfuryl donor in sulfation reactions was labelled with 35S whereas 
steroid substrates such as 17β-estradiol and pregnenolone were labelled with 3H. 
Radiolabelled compounds were purchased from Perkin-Elmer NEN. Non 
radiolabelled PAPS (>99% purity) was obtained from Prof. H. Glatt (Institute for 
Human Nutrition, Potsdam, Germany). Enzyme kinetics assays carried out for 
every set of recombinant protein/ liver cytosol and a given substrate were 
optimised for protein concentration, incubation time, PAPS concentration, buffer 
and pH.  
2.2.2 Radiolabelled 35S PAPS assay 
2.2.2.1     Theory behind the assay 
The assay was developed by Folds and Meek in 1973 (Foldes, 1973). SULTs 
catalyse the transfer of the sulfuryl group from the co factor PAPS on to the 
substrate molecule in a typical sulfation reaction. The radiolabelled sulfate is 
transferred from PAPS on to the substrate, thus making the substrate more water 
soluble. Any unreacted radiolabelled PAPS are precipitated by the addition of 
barium acetate, barium hydroxide and zinc sulfate in a sequential manner. The 
substrate that has now become water soluble due to the addition of the sulfuryl 
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group remains in the aqueous solution. Radiolabelled product is then counted on a 
scintillation counter.  Given below is an illustration of this assay 
 
Figure 7: A schematic diagram of the 35S PAPS based assay. 
 The yellow star represents radioactivity. The reaction was carried out at 37°C and 
stopped by placing the tubes on ice. Supernatant containing soluble product is read 
on the scintillation counter. 
 
2.2.2.2     Performing the assay 
10-20µl of [35S] PAPS was diluted appropriately (usually made up to 1 or 1.5ml 
with water) such that the diluted stock produces counts per minute  (cpm) in the 
100,000-150,000 range. 10µl of this diluted stock were added to each reaction in 
addition to the non-radioactive PAPS.  
The reaction mixture was prepared in a total volume of 160µl containing 0.1M 
phosphate buffer, substrate, protein and PAPS. [35S] PAPS was prepared in a 1:1 
ratio with 20µM non radiolabelled PAPS. This was done because of the reduced 
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sensitivity of the scintillation counter at high amounts of radioactivity. The 
reactants were assembled as follows.  
Reactants Volume  (µl) 
0.1M KPO4 buffer  (pH various) 100 
Substrate  (various) 20 
Protein  (various) 20 
Hot and Cold PAPS  (various) 20 
Total  160 
 
Table 3: Reactants assembled in a typical 35S PAPS based assay. 
 
Reactions were started by the addition of PAPS and incubated at 37°C for 15-30 
minutes. Blank tubes containing everything but the substrate were set up to 
monitor the precipitation of the unreacted radiolabelled PAPS. Reactions were 
stopped and quenched by placing the tubes on ice and addition of 200µl of 0.1M 
barium acetate, barium hydroxide and zinc sulfate in the given sequence. The 
samples were then mixed and centrifuged at 16,000g for 4 minutes in order to 
precipitate any unreacted PAPS. 500µl of the resulting supernatant were added to 
4 ml scintillation fluid (Emulsifier safe, Perkin Elmer) and counted at 1 minute per 
vial on a scintillation counter (Beckman Coulter, High Wycombe, UK).  
2.2.3 Radiolabelled 3H solvent extraction assay 
2.2.3.1 Theory behind the assay  
As opposed to the [35S] PAPS assay where the cofactor PAPS was radiolabelled, the 
substrate was radiolabelled in the [3H] based assay. Steroid substrates used were 
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insoluble in aqueous solutions and hence cannot be precipitated easily. For this 
reason another assay was used which instead of precipitating the unreacted 
radioactivity separates it in the organic solvent while the product is partitioned in 
the aqueous phase. As the sulfation reaction proceeds, the sulfuryl group from 
PAPS is transferred onto the substrate, thus making the substrate  more water 
soluble than before. Addition of chloroform separates the unreacted radiolabelled 
steroid in the organic solvent while the radiolabelled product remains in the 
aqueous phase. It is this radiolabelled product that is counted on the scintillation 
counter. Given below is an illustration of the solvent extraction assay.  
 
Figure 8: A schematic diagram of the [3H] based assay. 
 The yellow star represents radioactivity. The reaction was carried out at 37°C and 
stopped by the addition of chloroform. Aqueous phase containing the soluble product is 
read on the scintillation counter.  
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2.2.3.2 Performing the assay 
10-20µl of [3H] substrate was diluted appropriately such that the diluted stock 
produces cpm in the 100,000-150,000 range. 10µl of this diluted stock were added 
to each reaction in addition to the non-radiolabelled substrate.  
Reaction mixtures were prepared in a total volume of 200µl containing 0.1M 
phosphate buffer, [3H] substrate, protein and PAPS. The reactants were assembled 
as follows 
Reactants Volume  (µl) 
0.1M KPO4 buffer  (pH various) 100 
[3H] Substrate  10 
Non-radiolabelled substrate  
(various) 20 
PAPS  (various) 20 
Protein  (various) 20 
dH2O 30 
Total  200 
 
Table 4: Reactants assembled in a typical 3H based assay. 
 
Reactions were started by the addition of PAPS and incubated at 37°C for 15-30 
minutes. Blank tubes containing everything but the PAPS were set up to monitor 
the extraction of radiolabelled substrate. Reactions were stopped and quenched 
by adding 300µl ice cold water and 3ml chloroform to each tube. The samples 
were then mixed and centrifuged at 700g for 4 minutes in order to separate any 
unreacted substrate in the chloroform while the radiolabelled product remains in 
the aqueous phase. 200µl of the aqueous solution was added to 4ml scintillation 
50 
 
 
fluid  (Emulsifier safe, Perkin Elmer) and counted at 1 minute per vial on a 
scintillation counter  (Beckman Coulter, High Wycombe, UK).  
2.2.4 Analysis of data obtained from radioactive assays 
Counts obtained from radioactive assays were used for activity and specific activity 
calculations. Radioactive counts were entered in an Excel spreadsheet and the 
equation given below was used for the calculation of specific activity.  
 
 (C-B/TCPM) x ratio count correction x Total PAPS/Substrate 
Protein x Incubation time 
 
Test Counts  C 
Blanks B 
Test count - Blank C-B 
Total count per minute TCPM 
 
Total count per minute is the number of counts generated by the radioactive 
component in an assay before the reaction is allowed to proceed.  
500µl out of the total 760µl (160µl reaction mixture plus 600µl of the total stop 
solution) were counted on the scintillation counter in the [35S] PAPS assay. Hence 
the ratio count correction for this assay is 760/500 = 1.52 
Similarly, 200µl of the total 500µl (200µl reaction mixture plus 300µl ice cold 
water) were counted on the scintillation counter in the solvent extraction assay. 
Hence the ratio count correction for this assay is 200/500 = 2.5 
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Total PAPS/ Substrate (pmol) is the total amount of labelled and unlabelled 
substrate used in the reaction. This parameter takes into account the fact that both 
labelled and unlabelled PAPS/substrate are turned over in a reaction whereas 
only the labelled component of the assay is reflected in the counts. Amount of 
PAPS/substrate added to the reaction is known but the amount of radioactivity 
added to the reaction in 10µl is calculated using values given in the data sheet 
obtained with the radioactive isotope from the manufacturer.  
For enzyme kinetics analysis, data was imported from the Excel spreadsheet into 
Graph Pad Prism software. GraphPad Prism was used to calculate Vmax and Km 
values using either the Michaelis-Menten equation or the partial substrate 
inhibition equation. The equations used are given below. Ki in the partial substrate 
inhibition equation stands for the inhibition constant. 
 
 
                                 
 
 
 
 
 
 
Michaelis-Menten equation 
Y= Vmax X/ (Km +X) 
Partial substrate inhibition 
Y=Vmax X/(Km+X(1+X/Ki)) 
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2.2.5 Radiolabelled 35S PAPS assays: List of substrates used in the substrate 
screen assays and the solvent used for dissolving them  
 
Substrate Solvent 
1-naphthol 3% DMSO plus dH2O 
2-aminophenol dH2O 
2-naphthol 3% DMSO plus dH2O 
2-nitrophenol dH2O 
2-phenylphenol 3% Ethanol plus dH2O 
3-nitrophenol dH2O 
4-amylphenol 100% Ethanol 
4-isopropylcatechol dH2O 
4-isopropylphenol dH2O 
4-nitrophenol dH2O 
4-phenylazophenol 100% Ethanol 
17β-estradiol 1,2 Propanediol 
Apomorphine dH2O 
Dobutamine dH2O 
Paracetamol dH2O 
Pregnenolone 1,2 Propanediol 
Sesamol dH2O 
 
Table 5: Substrates used in substrate specificity profiling assays 
List of substrates used and the corresponding solvents that were required to dissolve 
them. dH2O refers to distilled water and DMSO stands for dimethyl sulfoxide. 
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2.3 Sodium dodecyl sulfate (SDS)-PAGE gel electrophoresis and 
immunoblotting of recombinant bSULTs  (and in liver cytosol)  
 
 
 
Figure 9: Overview of immunoblotting 
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2.3.1 Purpose 
 Detect the presence of purified recombinant bovine SULT and of 
recombinant SULTs in cell free/crude extract. 
 Determine SULT expression in bovine liver cytosol 
2.3.2 Lowry assay for quantification of total protein  
No Reagents Storage 
BSA standards  
(mg/ml) 
1 CuSO4.5H2O, 2%  (w/v) 4°C 0.02 
2 NaK tartrate, 2%  (w/v) 4°C 0.05 
3 
Na2CO3 in 0.1M NaOH, 2% 
(w/v) 4°C 0.1 
4 Reagent 4 Made fresh 0.15 
5 
Folin's Ciocalteu: dH20  
(1:1) Made fresh 0.2 
 
Table 6: Details of reagents used in Lowry assay 
 
 Reagent 4 was prepared by mixing reagents 1, 2 and 3 in the ratio of 1:1:100. 
250µl of reagent 4 were added to duplicate 50µl aliquots of Bovine Serum Albumin  
(BSA) standards and samples that were diluted appropriately  (1:50, 1:100, and 
1:200). All the samples and standards were mixed in a vortex mixer and left to 
incubate at room temperature for 10 minutes. 25µl of reagent 5 was added to each 
tube and the tube was mixed immediately. After addition of reagent 5 the 
standards and samples were incubated at room temperature for minimum of 30 
minutes. The OD600 was read on a plate reader (SpectraMax 190, Molecular 
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Devices) and the software  (SoftMax Pro 2.6.1) was used to generate a standard 
curve and derive the sample protein concentration from the standard curve.  
2.3.3 Pouring and running SDS-PAGE gel 
2.3.3.1 Small format gels 
The maximum number of samples that could be loaded on these gels was 15. 15% 
SDS-PAGE gel was prepared as follows. TEMED stands for NN’N’-
tetramethylethylenediamine and in combination with ammonium persulfate  
(APS) helps in the cross linking of acrylamide.  
 
Table 7: Reagents required for SDS gel electrophoresis (small). 
 
Samples to be loaded on gels were mixed with 2X loading buffer containing SDS  
(100mM Tris-HCl pH6.8, 20%  (v/v) glycerol, 0.2%  (w/v) bromophenol blue, 4%  
(w/v) SDS, 20%  (v/v) mercaptoethanol) and incubated at 100°C for 5 minutes. 
Reagents  (ml) Details 
Separating 
gel 
volume 
(ml) 
Stacking 
gel volume  
(ml) 
Water None 3.5 4 
Acrylamide 
30% acrylamide, 
0.8% bis  4 0.5 
Lower Tris buffer 1.5M Tris-HCl, pH 8.8 0 0 
Upper Tris buffer 0.5M Tris-HCl, pH 6.8 2.5 0.5 
Ammonium persulfate 10% 0.1 0.07 
TEMED - 0.01 0.007 
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The gels were run at 200V in BioRad electrophoresis tanks filled with running 
buffer (25mM Tris, 191mM Glycine, 1% SDS).  
2.3.3.2 Large format gels 
The maximum number of samples that could be loaded on these gels was 30. 11% 
SDS-PAGE gels were prepared as follows 
 
Table 8:  Reagents required in the making of SDS gel electrophoresis  (large). 
 
Unlike small gels, the separating and the stacking gels were degassed for 20 
minutes before the addition of APS and TEMED. This was done to get rid of the 
oxygen which inhibits polymerisation. As with the small gels, the samples were 
mixed with the same 2X loading buffer and incubated at 100°C for 5 minutes prior 
to loading. The gels were run at 200V in BioRad electrophoresis tanks filled with 
running buffer.  
 
Reagents  (ml) Details 
Separating 
gel volume 
(ml) 
Stacking gel 
volume  (ml) 
Water None 22 12.7 
Acrylamide 30% acrylamide, 0.8% bis  22 2 
Lower Tris buffer 1.5M Tris-HCl, pH 8.8 15 0 
Upper Tris buffer 0.5M Tris-HCl, pH 6.8 0 5 
Ammonium persulfate 20mg/ml in dH20 0.9 0.3 
TEMED - 0.02 0.02 
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2.3.4 Coomassie stain and destain 
 In order to view the protein on gels, they were stained with Coomassie blue 
containing 20%  (v/v) methanol, 5%  (v/v) glycerol, 0.25%  (w/v) Coomassie 
Brilliant Blue R250 for 20-60 minutes before being destained with several 
volumes of destain  (10% acetic acid, 30% methanol). The gel was then dried and 
fixed using the gel drying kit (Promega) and following the manufacturer’s 
instructions. This procedure of staining, destining and drying was not carried out 
if there was intention of immunoblotting. Instead the protein on the gel was 
transferred on to a suitable membrane.    
2.3.5 Gel analysis using Quantiscan 
After Coomassie staining and destaining the gel was dried, analysed and scanned 
using Quantiscan software (Biosoft, Cambridge). A rectangular box was drawn 
around every band to measure the density of that band. This box was then moved 
to the neighbouring uninduced lane that contained the same amount of uninduced 
protein fraction. Uninduced lane contained total protein from E. coli not induced 
with IPTG. Any band density recorded in this lane was due to leaky expression of 
the protein and hence was set as background. The background density for every 
amount of induced protein loaded was subtracted from its respective uninduced 
lane to get a net band density value.  
2.3.6 Transfer conditions 
Polyvinylidene fluoride (PVDF) membrane (Immobilon-P, Millipore, IPFL 00010) 
was cut to the size of the gel and then prepared by incubating in methanol until 
translucent (hydrophilic state), washed in dH2O for 2 minutes followed by 
incubation in transfer buffer (25mM Tris, 191mM Glycine, 20% methanol) for a 
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minimum of 5 minutes. The transfer apparatus was assembled in transfer buffer 
following the manufacturer’s instructions (BioRad). The small gels were 
transferred at 100V for 1-2 hours at 4°C whereas the big gels were transferred at 
40V overnight at 4°C.  
2.3.7 Immunoblotting 
 After completion of transfer, the PVDF membrane was blocked in 1%  (w/v) BSA 
or 5%  (w/v) dried skimmed milk prepared in TBS buffer  (0.1M Tris pH 7.9, 0.3M 
NaCl) containing 0.1% (w/v) Triton-X100 or Tween20 (T). This was done to 
prevent any nonspecific binding of antibodies to the membrane. The membrane 
was then incubated with the primary antibody prepared in the blocking buffer 
solution for 1-2 hours at room temperature. For small gels the membrane was 
washed 3 times for 15 minutes each in TBS-T. For large gels the membrane was 
washed 5 times for 15 minutes each. Secondary antibody was prepared in the 
same blocking buffer solution and the membrane incubated with it at room 
temperature for 1-2 hours. Again the small membranes were washed 3 times for 
15 minutes each and the large membranes were washed 5 times for 15 minutes 
each prior to chemiluminescent staining and development.  
2.3.8 Chemiluminescent staining and development of blots 
After secondary antibody incubation and subsequent washes, the membrane was 
incubated in enhanced chemiluminescent (ECL) reagent for a minute. ECL reagent 
was prepared by mixing solution 1 and 2 together 
Solution 1  
 88µl Coumaric acid  (0.149g Coumaric acid in 10 ml DMSO) and 200µl 
luminol  (0.443g 3-aminophthalyhydrazine in 10ml DMSO) to 10ml in dH2O 
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Solution 2 
 1ml 1M Tris-HCl, pH8.8 and 6.4µl H2O2 to 10 ml dH2O 
 
The PVDF membrane was placed in between an acetate sheet and a laminated 
piece of card with glow in the dark stickers. The membrane was then exposed to 
film  (Fujifilm X-ray medical film, Super RX) in a closed cassette for as little as 10 
seconds to anywhere up to 10 minutes. The film was then developed for a minute 
in Kodak GBX developer and replenisher (made 1:5 with water) for 1 minute, 
washed with water and then fixed using Kodak fixer (made 1.25:5 with water) 
until clear. The film was then allowed to dry before being lined up with the help of 
the glow in dark stickers and molecular weight markers to tell the exact position 
of the bands of interest.  
 
2.3.9 Affinity purification of anti-human SULT1E1 IgG in sheep serum on CnBr 
sepharose coupled to bovine serum proteins.  
2.3.9.1 Isolation of human SULT1E1 IgG from sheep serum 
Serum from sheep immunized with human SULT1E1 (bleed 2) was diluted in a 1:1 
ratio with phosphate-buffered saline solution, PBS buffer (0.1M potassium 
phosphate, 0.9%NaCl, pH 7.4). An equal volume of saturated ammonium sulfate 
was added drop wise while mixing on ice. The solution was stirred for a further 30 
minutes at room temperature and then centrifuged at 20,000g for 15 minutes at 
4°C. Ammonium sulfate suppresses the charge on proteins making them more 
insoluble . The pellet obtained was resuspended in 10ml PBS buffer and dialysed 
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overnight in SnakeSkinR pleated dialysis tubing with 3 changes of PBS. 1ml of 
dialysed IgG was used for further purification on CnBr sepharose column coupled 
to bovine serum proteins. The rest of IgG samples obtained were aliquoted and 
stored at -80°C for further use.   
2.3.9.2 Preparation of CnBr sepharose coupled to bovine serum proteins 
1g of CnBr-Sepharose 4B  (Pharmacia) was added to 30 ml of 1mM HCl and 
washed on a scintered glass funnel over vacuum with 800 ml 1mM HCl. 5mg/ml 
adult bovine serum and new-born bovine serum  (Sigma) were mixed together 
was made up in a total volume of 10 ml with coupling buffer  (0.1M NaHCO3, pH 
8.3 containing 0.5M NaCl). Washed Sepharose was added to the bovine serum 
mixture and left to mix for 2 hours at room temperature or 4°C overnight. The 
resultant gel was washed on a scintered glass funnel over vacuum with 100 ml 
coupling buffer. The gel was then transferred to 100 ml of blocking buffer (1M 
ethanolamine/HCl, pH 8) and mixed for 2 hours at room temperature. Alternate 
washes in coupling buffer and acetate buffer were carried out 5 times for a total 
volume of 500ml each. The gel was finally washed with 200ml PBS before packing 
it on to a column (syringe plugged with glass wool).  
2.3.9.3 Affinity purification of anti-human SULT1E1 IgG 
The column containing CnBr sepharose coupled to bovine serum protein was 
initially washed with 5 volumes of PBS. The column was loaded with 1ml IgG 
preparation and left to stand at room temperature for 1 hour. IgG was eluted with 
PBS buffer. 1ml fractions were collected and a Lowry assay was performed on 
them. Fractions containing activity were pooled and the total protein content 
estimated with Lowry again.  
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Table 9: Blotting conditions for the detection of bovine SULT isoforms.        
 Anti-human SULT antibodies were used in the detection of bSULT isoforms. *MAP stands for multiple antigenic peptides. ¥MBP stands for maltose 
binding protein.  Anti MBP was used along with anti-human SULT1A3 and anti-human SULT2A1 in the detection of MBP tagged proteins. All the 
secondary antibodies used are horseradish peroxidise conjugates  (HRP) that were purchased from Sigma-Aldrich.
Bovine SULT  
(bSULT) 1A1 1B1 1E1 2A1 MBP-1A1 MBP-2A1 
Primary 
antibody used  
  
anti-human SULT1A3  
(whole protein) 
MAP* for  
MLSPKDILRKDLKLVHG                  
anti-human 
SULT1E1  (whole 
protein) 
anti-human SULT 
2A1  (whole 
protein) 
Commercial anti 
MBP¥  (whole 
protein, Sigma) 
Commercial anti MBP  
(whole protein, Sigma) 
anti minipig SULT1A1  
(whole protein) None None None 
anti-human 
SULT1A3  (whole 
protein) 
anti-human SULT 2A1  
(whole protein) 
Purification IgG  IgG and CPG IgG IgG serum  serum  
Host Sheep sheep Sheep sheep rabbit  rabbit 
Dilution 
1:5000  (both 
antibodies) 1:1000 1:10,000 1:10,000 1:10,000  1:10,000  
Blocking agent 1% BSA 1% BSA 1%BSA 5% Milk 5%milk  5% milk  
Wash buffer TBS-Triton X TBS-Triton X TBS-Triton X TBS-Triton X TBS-Tween 20 TBS-Tween 20 
Secondary 
antibody rabbit anti goat HRP rabbit anti goat HRP 
rabbit anti goat 
HRP 
rabbit anti goat 
HRP goat anti rabbit HRP goat anti rabbit HRP 
Dilution 1:5000 1:5000 1:5000 1:5000 1:20,000 1:20,000 
References for 
primary 
antibodies (Richard et al., 2001) (Riches et al., 2009) 
(Rubin et al., 
1999) 
(Forbes et al., 
1995) (Richard et al., 2001) (Forbes et al., 1995) 
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2.4 Cloning and expression of recombinant bovine SULT isoforms in a 
microbial expression system 
 
 
Figure 10: Overview of the cloning procedure 
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2.4.1 Image Clones  
Image clones containing 5 different bovine sulfotransferase genes were purchased 
from Source BioScience plc, Nottingham. The table below lists information on the 
NCBI accession numbers, vectors used, the strain, sex, age and tissue of the cattle 
whose mRNA was used in making of the Image clone.  
 
Table 10: Information on the Image clone DNA used in the cloning of bovine 
SULTs 
 
2.4.2 Vectors and Tags 
Untagged SULTs were cloned into the expression vector pET-17b and expressed in 
BL21 (DE3) pLysS. Along with the untagged expression, bSULT1A1 and bSULT2A1 
were also expressed as a maltose binding protein (MBP) fusion. In the pMAL-c2x 
vector used for the expression of the MBP fusion protein, the cloned gene is 
Image 
Clone ID 
Accession 
# 
Bovine 
isoform Vector Strain 
Sex, Age and 
Tissue 
information 
7945971 BC102274 SULT1A1 pCMV.SPORT6.0 
Cross 
bred x 
angus 
Female, 
6months old, 
Ileum 
7989385 BC102939 SULT1E1 pCMV.SPORT6.0 Hereford 
Male, 6 month 
old, Liver 
7944770 BC102208 SULT1B1 pCMV.SPORT6.0 
Cross 
bred x 
angus 
Female, 
6months old, 
Ileum 
8013931 BC112644 SULT2A1 pCMV.SPORT6.0 Hereford 
Male. 7 years 
old, Testis 
8478800 BC126756 SULT2B1 PExpress1 
L1 
Hereford 
Female, 
6months old, 
skin 
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inserted downstream from the MalE gene of E. coli that encodes MBP resulting in 
the expression of an MBP fusion protein. The TB1 strain of E. coli was used for 
expression of MBP fusion proteins.  
2.4.3 Primer design 
Some basic rules were applied to primer design . Primers were designed such that 
they had a similar Tm, ideally between 60°-70°C to allow binding to the template. 
In addition to this, primers were designed such that they did not form any dimers 
or secondary structures. They were also initiated with either a G or a C in order to 
enhance ligation efficiency into subsequent subcloning vectors.  
Firstly, the Expasy translation tool (http://expasy.org/tools/dna.html) was used to 
choose the appropriate reading frame and hence determine the correct coding 
region of the gene of interest. Once the coding region was selected, restriction 
enzymes were chosen. Restriction enzymes (REs) that produced sticky ends were 
preferred given their ease to work with. Using the web based tool, webcutter  
(http://users.unimi.it/~camelot/tools/cut2.html) REs that did not cut the insert but 
cut the expression vector at unique sites were chosen. These sites were then 
incorporated into the primer sequence.  
Primers sequences with similar Tms were designed with the aid of Invitrogen 
Oligoperfect http://tools.invitrogen.com/content.cfm?pageid=9716. Desalted primers 
were purchased from Sigma Genosys.  
 
2.4.4 Amplification of cDNAs encoding bovine SULTs 
As the first step towards cloning, cDNAs encoding different SULT isoforms  (Table 
1 except bSULT2B1) were amplified from the Image clone using the primers 
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designed. After optimization of annealing temperatures, a 50 µl PCR reaction was 
set up. Given below is a typical PCR reaction.  
Reactants 
Stock 
concentration 
Final assay 
concentration  Supplier 
Volume   
(µl) 
Buffer 10X 1X  Bioline 5 
MgCl2 50mM 2mM Bioline  2 
dNTP mix 
10mM each 
dNTP, 40mM 
total 0.02mM Promega 1 
Forward 
primer 100µM 0.2µM 
Sigma 
Genosys 1 
Reverse 
primer 100µM 0.2µM 
Sigma 
Genosys 1 
Template DNA variable 30-40ng  NA variable 
BIO-X-ACT 
polymerase  4U/µl  4u  Bioline 1 
Nuclease free 
water  NA  NA  Ambion variable 
 
Table 11: PCR reaction mixture for amplification of bovine 
Sulfotransferases. 
 NA stands for not applicable 
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Temperature/time # Cycles 
95°C, 5min x1 
95°C, 30sec X°C, 30 
sec 68°C, 1min 
                               
x35     
68°C, 7min x1 
6°C, HOLD  - 
 
Table 12: Thermocycler program settings used for PCR 
 
PCR products were subsequently run on a 0.1% agarose gel, excised and purified 
using the QIAquick gel extraction and purification kit (Qiagen)
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Gene  Nt primer name Vector Tag 
Sigma 
Tm  
(°C) 
Actual Tm 
used  (°C) 
Restriction 
enzymes Sequence 5'-3'  
bSULT1A1 29 pET-17b bSULT1A1for pET-17b None 74.1  79.3 
  
NdeI CATATGGAACTGATCCAGGATACCTCCCG 
bSULT1A1 25 pET-17b bSULT1A1rev pET-17b None 74.5 HindIII AAGCTTTCACAGCTCCCAGCGGAAG 
bSULT1A1 25 MBP-bSULT1A1for pMAL-c2x MBP 67.8  67.8 
  
XmnI GAAGGATTTCAATGGAACTGATCCA 
bSULT1A1 24 MBP-bSULT1A1rev pMAL-c2x MBP 74.3 HindIII AAGCTTTCACAGCTCCCAGCGGAAG 
bSULT2A1 28 pET-17b bSULT2A1for pET-17b None 67.9  65.4 
  
NdeI CATATGACAGGAAAGTTTCTGTGGTTTG 
bSULT2A1 24 pET-17b bSULT2A1rev pET-17b None 69.6 HindIII AAGCTTTTATTCCCACGCGAACAG 
bSULT2A1 33 MBP-bSULT2A1for pMAL-c2x MBP 73.2   67.1  
  
XmnI GAAGGATTTCAATGACAGGAAAGTTTCTGTGGT 
bSULT2A1 24 MBP-bSULT2A1rev pMAL-c2x MBP 69.6 HindIII AAGCTTTTATTCCCACGCGAACAG 
bSULT2A1 29 Yeast_bSULT2A1for pYES2 None 68.2  63.2 
  
HindIII AAGCTTATGACAGGAAAGTTTCTGTGGTT 
bSULT2A1 24 Yeast_bSULT2A1rev pYES2 None 68.2 EcoRI GAATTCTTATTCCCACGCGAACAG 
bSULT1B1 29 pET-17b bSULT1B1for pET-17b None 68.2 65.7  
  
NdeI CATATGACTTCTCCAAAAGATGTCCTGAG 
bSULT1B1 29 pET-17b bSULT1B1rev pET-17b None 69 HindIII AAGCTTTCAAATCTCTGTACGGAACTGAA 
bSULT1E1 29 pET-17b bSULT1E1for pET-17b None 68.6  68.6 
  
NdeI CATATGAGTTCTTCCAAACCATCCTTTTC 
bSULT1E1 31 pET-17b bSULT1E1rev pET-17b None 68.8 EcoRI GAATTCCTAGATCTTAGTTCGGAACTTCAGG 
 
Table 13:  Primers used in the cloning of various tagged and untagged isoforms of bovine sulfotransferases. 
   (All primers purchased from Sigma Genosys)
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2.4.5 Sub cloning  (pSCA-Amp/Kan, Stratagene) 
2.4.5.1 Poly A tail addition 
The Strata clone PCR cloning vector mix used contains vector pSCA-Amp/Kan that 
has two DNA arms which have a modified uridine  (U) overhang. Taq amplified 
products that have a 3’ adenosine overhang can be efficiently ligated into these 
vectors. Hence a Poly ‘A’ tail was added to the purified PCR products before 
ligation. The reactants were assembled as follows. The reaction was carried out at 
72°C for 30 min 
Reactants 
Stock 
concentration 
Final assay 
concentration  Supplier 
Vol  
(µl) 
Colourless GoTaq 
buffer  5X 1X Promega 4 
MgCl2 25mM 2.5mM Promega 2 
dATP 2mM 0.2mM Promega 2 
Go taq polymerase  5u/µl  5u Promega 1 
Purified PCR product - - -  11 
Total - - - 20 
 
Table 14: Details of reactants used in poly A tail addition 
 
2.4.5.2 Ligation and Transformation 
Following Poly ‘A’ tail addition, the PCR product was ligated into pSCA using the 
StrataClone protocol for ligation (StrataClone PCR Cloning Kit, Stratagene, 
240205). The construct was subsequently transformed into StrataClone SoloPack 
competent cells using the StrataClone protocol for transformation. Colonies were 
selected from the transformed plates the next day and used to inoculate a 5ml 
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small culture. In order to obtain DNA from these colonies for subsequent 
screening, minipreps were done according to the manufacturer’s instructions  
(Qiagen miniprep kit). 
2.4.5.3 Restriction endonuclease digest to screen colonies for the presence of 
insert   
A digest using miniprep DNA as template and EcoR1 restriction endonuclease was 
performed to screen colonies for positive clones. EcoR1 was chosen for the digest 
because it contained restriction sites in the multiple cloning region and it flanked 
either side of the PCR product insertion site in pSCA.  A single product around 
1000 base pairs was expected to be seen in positive clones. A typical digest is 
shown below. Once the positive clones were identified, 500 µl from the positive 
small culture was used to inoculate a 50 ml culture. This 50 ml culture was used 
for subsequent midiprep to generate large quantities of plasmid DNA from the 
positive clones for sequencing. A typical digest is shown below 
Reactants 
 Volume  
(µl) 
 10X BSA  1 
10 X buffer  1 
DNA  2 
ECoRI  0.5 
Nuclease-free water  5.5 
 
Table 15: Typical Restriction endonuclease digest. 
It was carried out to screen for positive colonies containing the desired pSC-A insert 
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2.4.5.4 Sequencing 
Sequencing of insert was carried out to ensure that the DNA is free of any 
nucleotide base pair changes that could affect gene expression. The pSCA 
construct midiprep was sent to be sequenced. Sequencing was performed by ( The 
Sequencing Service, University of Dundee, Scotland , www.dnaseq.co.uk ) using 
Applied Biosystems  Big dye Ver 3.1 chemistry on an Applied Biosystems model 
3730 automated capillary DNA sequencer. Some of the sequencing was also 
performed by the DNA Analysis Facility Ninewells Hospital and Medical School, 
Dundee. pSC-A constructs were sequenced using T3 and T7 primers, pET-17b 
constructs using T7 and T7 term primers and pMAL-c2x constructs sequenced 
using MalE primers. 
 
Table 16: Forward and reverse primers used for sequencing inserts of given 
constructs. 
 
 
Primer name  Sequence  (5’ – 3’) Used for  
MalE Forward 
GGTCGTCAGACTGTCGATGA
AGCC  
pMAL-c2x_bSULT2A1 
pMAL-c2x_bSULT1A1 
MalE reverse 
 CGCCAGGGTTTTCCCAGTCA
CGAC 
pMAL-c2x_bSULT2A1 
pMAL-c2x_bSULT1A1 
T7 TAATACGACTCACTATAGGG  
All pET-17b, pSC-A  
constructs 
T3  AATTAACCCTCACTAAAGGG pSC-A constructs 
T7 terminator  CTAGTTATTGCTCAGCGGT pET_17b constructs 
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2.4.6 Cloning and expression 
2.4.6.1 Restriction digests and dephosphorylation of the expression vector. 
Following satisfactory results from analysis of the sequencing data, preparations 
were made to insert the gene of interest into the expression vector used. Firstly, 
the midi prep subclone and the expression vector were cut with the appropriate 
restriction enzymes (refer to the section on primer design). The products were 
run on a 0.8% agarose gel. Ideally 3 distinct bands one corresponding to the cut 
expression vector and other to the insert and cut pSCA were seen. Bands 
corresponding to the gene of interest and the expression vector was viewed and 
cut under UV light. DNA from cut bands was extracted and purified using QIAquick 
PCR purification kit.  
2.4.6.2 Dephosphorylation, ligation and transformation of the expression 
construct into competent E .coli  
Cut expression vector was dephosphorylated using the enzyme CIAP (Calf 
Intestine Alkaline Phosphatase). This was done to prevent religation of the 
expression vector without the insert. The dephosphorylation was set up as below 
and the reaction was allowed to proceed at 37°C for an hour. This was followed by 
Qiagen PCR clean up.  
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 Reagents 
Volume  
(µl) 
DNA  (Elution from gel 
clean up) 30 
CIAP 2 
CIAP buffer 10X 4 
Nuclease-free water 4 
Total 40 
 
Table 17: A typical dephosphorylation reaction set up 
 
Typically, several ligation reactions containing variable amount of insert were 
carried out to increase the chances of successful ligation. All the ligation reactions 
were carried out at 4°C overnight as these were established to be optimum 
conditions in previous experiments. The ligated products were then transformed 
into competent E. coli using standard protocol described in section 2.4.7.1                                                      
                                                                                             Volume (µl) 
Dephosphorylated 
vector 1 1 1 1 1 
Insert 0 2 4 6 8 
T4 ligase buffer  
(10X) 2 2 2 2 2 
T4 Ligase 1 1 1 1 1 
Nuclease -free water 16 14 12 10 8 
Total  20 20 20 20 20 
 
Table 18: A typical ligation reaction set up 
A ligation reaction set up with increasing amount of the insert to increase the 
efficiency and ensure successful ligation. 
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Upon transformation, all the procedure such as midiprep of DNA from positive 
clones and subsequent sequencing of the expression construct was carried out in 
the same way as it was for pSCA (subclone) constructs with the only exception 
being the restriction enzyme digest. Where possible a double digest was 
performed, i.e. when two restriction endonucleases from the same manufacturer 
had 100% compatibility in the same buffer, they were used together in one digest. 
When this was not the case, sequential digests were performed. Here one digest 
was performed with one endonuclease and the resulting product was cleaned up 
using a PCR clean up column (Qiagen) and used as a template for the reaction with 
the second endonuclease. 
Glycerol stocks were made for future use from all the expression constructs 
created as described in section 2.4.7.3.   
2.4.6.3 Expression of recombinant bovine SULT isoforms 
Glycerol stocks of recombinant bovine SULTs were streaked onto plates 
containing 100µg/ml ampicillin. Colonies were formed on these plates after an 
overnight incubation at 37°C. A randomly chosen colony was used to inoculate a 5 
ml LB broth containing 100µg/ml ampicillin at 37°C overnight.  2 ml of this small 
culture was used to inoculate a 200 ml culture containing 100µg/ml ampicillin. 
The culture was grown at 37°C in a shaking incubator until it reached an optical 
density (OD) of 0.6-0.9. At this point it was induced with isopropyl-β-D-
thiogalactopyranoside (IPTG) and shifted to 30°C overnight. The protein was 
harvested by using two different methods. One used lysozyme and the other 
sonication for cell lysis. 
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Isoform 
IPTG  
(mM) ODinduction 
bSULT1A1 1 0.9 
bSULT1B1 0.5 0.6 
bSULT1E1 1 0.6 
MBP_bSULT2A1 1 0.65 
 
Table 19: Conditions used for the expression of various bovine SULTs 
 
2.4.6.4 Making cell free extract (lysozyme) 
Induced bacterial cultures were spun at 900g in 50 ml centrifuge tubes. The pellet 
obtained was resuspended in 2ml of 40mM Tris/2mM EDTA, pH 8. 100µl of 
10mg/ml freshly made lysozyme was added to each tube and incubated for 15 
minutes at room temperature. Further, 100µl of 5% BRIJ 58/200mM MgSO4 was 
added to the tube followed by 15 minute incubation at room temperature. In order 
to get rid of any genomic DNA, 10µl of RNase free DNase was added and the 
mixture was incubated at 37°C for 3min and then at room temperature for 2min. 
The mixture was then divided into 1.5ml eppendorf tubes and spun at 6500g for 
5min. A Lowry assay was carried out on the supernatant to measure the amount of 
protein obtained.  
2.4.6.5 Making crude extract (sonication) 
Induced bacterial cultures were spun at 4000g for 20 minutes. The pellet obtained 
was resuspended in 2ml column buffer (20mM Tris-HCl, 200mM NaCl, 1mM 
EDTA). The samples were placed on ice and sonicated in 4 short pulses of 15 
seconds (4X15) each pulse followed by a minute incubation on ice to prevent 
protein degradation caused due to excess heat. The number of sonication pulses 
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and the duration of the pulse were optimised for every isoform. 4x15 second 
pulses were found to be optimum for all isoforms used. Prior to sonication, 
protease inhibitors (Protease inhibitor cocktail tablets, Roche) were added to the 
lysate. 100µl of 25X stock solution made by dissolving 1 tablet in 2ml water, was 
added to the lysate to prevent protein degradation resulting due to protease 
activity. The sonicated mixture was spun at 9000g for 30 min to pellet the cell 
debris. A Lowry assay was performed on supernatant obtained.  
2.4.7 Standard techniques used in cloning  
2.4.7.1 Transformation 
50-100µl of competent cells were incubated with 50-500ng plasmid DNA and left 
on ice for 20min. The mixture was then heat shocked at 42°C for 45seconds and 
then placed on ice again for 2min. LB broth containing no antibiotic was added to 
the mixture and shaken in a 37°C incubator for at least an hour. After heat shock, 
SoloPack competent cells from Strataclone were resuspended in 250µl LB as per 
the manufacturer’s instructions whereas competent BL21 (DE3) pLysS, JM109 and 
TB1 were resuspended in 1ml LB. The cells were centrifuged at 10,000g for 1min. 
5 and 100µl of competent cells were plated on LB plates containing 100ug/ml 
ampicillin. These plates were incubated overnight at 37°C.  
2.4.7.2 Making competent cells  
Supercompetent JM109, BL21 (DE3) pLysS, and TB1 cells were made using 
standard protocols. A 10ml overnight culture of non-competent cells was used to 
inoculate a 200ml culture of LB broth. It was incubated at 37°C until an OD of 0.3-
0.5 was reached. The inoculant was chilled on ice and then spun at 3000 rpm for 
5min at 4°C. The pellet was resuspended in 80 ml of TFBI buffer and kept on ice 
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for a further 20 min. Cells were once again pelleted and resuspended in 8ml TFBII. 
They were kept on ice for an hour before aliquoting them into pre chilled 
microfuge tubes. Resultant competent cells were snap frozen in liquid nitrogen 
and stored at -80°C.  
 
Table 20: Content of buffers used in the making of competent cells 
 
2.4.7.3 Making glycerol stocks 
A single positive clone containing the desired construct was used to inoculate 5ml 
LB broth (with antibiotic). The culture was grown at 37°C overnight and aliquoted 
into cryovials. 80% (v/v) glycerol was added to the culture in a ratio of 1:4. The 
cryovials were then snap frozen in liquid nitrogen and stored at -80°C until further 
use. A small amount of the glycerol stock was scraped from the top of the tube  
(without thawing) using an inoculation needle with a loop as and when needed.  
TFBI   
Potassium acetate 30mM 
Rubidium chloride RbCl2 100mM 
Calcium chloride 
CaCl2.2H2O 10mM 
Manganese chloride 
MnCl2.4H2O 50mM 
Glycerol 15ml 
dH2O 80ml 
Adjust to pH5.8 with 0.2M 
acetic acid and filter 
sterilise   
TFB II  
MOPS 10mM 
Rubidium chloride RbCl2  10mM 
Calcium chloride 
CaCl2.2H2O 75mM 
Glycerol 15ml 
dH2O 80ml 
Adjust to pH 6.5 with 1M 
KOH and filter sterilise   
77 
 
 
2.4.8 Primary and secondary structure analysis of bovine SULTs 
In order to compare the primary structure of bovine SULTs with that of human  
(and mouse Sult1e1), amino acid sequences were obtained from NCBI.  
(http://www.ncbi.nlm.nih.gov/nuccore). The sequences were aligned using 
ClustalW2  (http://www.ebi.ac.uk/Tools/msa/clustalw2 ). Critical residues were 
subsequently identified. Crystal structure files of proteins were downloaded from 
protein data bank  (http://www.pdb.org/pdb/home/home.do ). The structure file 
was downloaded in pdb format and opened using a structural tool called 
Discovery Studio Visualizer (DS Visualizer 3.1, Accelrys software, Cambridge). This 
software was also used for analysis of the downloaded structures.   
 
2.5 Protein Purification: A two-step procedure for purification of 
recombinant bSULTs expressed in E. Coli 
2.5.1 General 
Purification of SULTs from crude extracts was carried out using ion exchange and 
affinity chromatography with Q sepharose and ADP agarose columns respectively. 
Ammonium sulfate precipitation, a crude form of purification is usually the first 
step in any purification protocol. ADP agarose columns are the only ones used 
here that bind SULTs specifically. Buffer A (50mM Tris, pH 8, 78µl 
mercaptoethanol/L) was the primary buffer used in this purification. Buffer B 
containing 1M NaCl in buffer A was also used.  
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2.5.2 Ammonium sulfate precipitation 
Cell free extract obtained by expressing recombinant bovine sulfotransferases in 
E. Coli were initially subjected to ammonium sulfate precipitation also termed as 
the ‘salting out’ reaction. Proteins precipitate according to their solubility at 
different salt concentrations. A two stage ammonium sulfate precipitation was 
carried out. Finely ground solid ammonium sulfate was added to the cell free 
extract at 35% saturation (0.197g/ml) at 4°C over a period of 40 min. The mixture 
was then left to incubate on ice for 1 hour. It was then centrifuged at 16000g for 
15 minutes. The pellet was discarded and more ammonium sulfate at 70 % final 
saturation (0.245g/ml) was added to the supernatant. The procedure was 
repeated exactly as stage 1. After centrifugation, the supernatant was discarded 
and the pellet containing the precipitated protein was resuspended in 5ml buffer A 
The solution was dialysed overnight in SnakeSkinR pleated dialysis tubing with 
three changes of buffer A to remove salt. A Lowry assay was carried out to 
measure the amount of protein present in the mixture after ammonium sulfate 
precipitation 
2.5.3 Q Trap ion exchange chromatography  
Ion exchange chromatography was used in the second stage of protein 
purification. The separation of proteins is based on the reversible binding of their 
charged molecules to oppositely charged groups attached to an insoluble matrix. 
This stage of purification was carried out using a strong anion exchange column. 
An anion exchange column contains positively charged groups and binds 
negatively charged molecules in the protein mixture. A 5ml Hi-Trap Q sepharose  
(GE healthcare) column attached to FPLC AKTA purification system was used. 
Prior to loading of protein, the column was washed with 30 ml high salt buffer B to 
79 
 
 
get rid of any bound protein. The column was then re equilibrated with 60 ml 
Buffer A. Protein up to 50mg/ml was injected manually on to the column via an 
injection port on the AKTA. Buffers A and B were mixed appropriately in a 
gradient mixer on the AKTA to generate a salt gradient of 0-1M NaCl that was 
passed onto the column over 150ml. A fraction collector was used to collect 
protein eluted in 3ml fractions. All the fractions were run on a 15% SDS PAGE gel 
and assayed for SULT activity. Fractions containing the protein of interest were 
pooled together and concentrated to 3ml using an Amicon concentrator (Amicon) 
and following the manufacturer’s instructions. The sample was dialysed overnight 
with 3 changes of buffer A. A small fraction of sample was withdrawn at every 
stage of purification and used for the determination of protein enrichment and 
purification.  
2.5.4 ADP agarose affinity chromatography 
2.5.4.1 Pouring the column 
15mg of 3’5’-ADP agarose (Sigma) were resuspended in buffer A and poured into 
the column. Agarose beads were washed with excess buffer that was allowed to 
drain from the column. The column was left to stand for an hour in order to settle 
the agarose. A stopper from the top of the column was pressed down gently to 
avoid forming any air bubbles. The newly poured column was equilibrated with 
buffer A. At the end of every run, the column was always washed with 2M NaCl to 
get rid of any bound protein.  
2.5.4.2 Running the column 
Before loading the protein, the column was washed with 90ml buffer B to get rid of 
bound protein. It was then re equilibrated with 130ml buffer A. Protein was 
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injected manually onto the column via the injection port on the AKTA. Once onto 
the column, the protein was washed at a flow rate of 2ml/min with buffer A 
containing 0.05M KCl for a period of 15 minutes. This was done to get rid of any 
nonspecific binding to the column. 100µM PAPS in 5ml buffer A was used to elute 
the protein. SULTs bind ADP agarose with a lower affinity compared to PAPS. 
Hence when PAPS is added to the ADP agarose column the SULTs bound to the 
column dissociate from it and bind PAPS.  The column was then washed with 
0.05M NaCl for 15 minutes followed by 0.5M NaCl for another 15 minutes in order 
to elute the SULT of interest. Once again fractions were analysed on a 15% SDS 
PAGE gel and assayed for SULT activity. Fractions containing the desired protein 
were pooled together and concentrated using the Amicon concentrator. The 
concentrated sample was then desalted on a PD-10 column (GE healthcare) 
according to the manufacturer’s instructions. The purified protein was aliquoted 
and snap frozen in liquid nitrogen. A Lowry assay was performed to measure the 
amount of purified protein. The purified protein was then run on a 15% SDS PAGE 
gel alongside pooled crude extract, ammonium sulfate and Q trap fractions to 
assess its purity. Activity assays were carried out on fractions pooled after each 
stage in order to determine fold purification.   
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2.6 In vitro metabolism of 17α/β-estradiol in microsomes, cytosol and 
hepatocyte samples 
 
Figure 11: Conjugative metabolism of 17β-estradiol. 
Outline of the procedure employed to study conjugative metabolities of 17β-estradiol in 
microsomes, cytosol and hepatocytes. All the reactions were carried out in 96 well plates 
and set up in triplicates 
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2.6.1 Liver procurement and hepatocyte preparation: 
A segment of liver tissue was obtained from a 14-month old heifer of an Angus 
Cross  (mixed) breed  (Pfizer Inc.), perfused to remove blood and placed on ice 
prior to hepatocyte isolation.  Cryopreserved hepatocytes were prepared from this 
tissue by Piedmont Research Centre (Lot No. Bov-10-0001, Charles 
River Discovery & Imaging Services Morrisville, NC) and stored under liquid 
nitrogen. 
2.6.2 Hepatocyte harvest 
Hepatocytes were thawed and cell suspensions transferred to pre-warmed (37 C ) 
Clonetics® HMM™ media supplemented with 10-7M insulin and 10-7M 
dexamethsome  (Hepatocyte Maintenance Media  (HMM) with UltraGlutamine-1, 
Lonza  Lot No. 0000176054 Catalog No. CC-3197) containing 30% Percoll  (Sigma 
Chemical Company, St. Louis, MO) and centrifuged at 130 x g for 20 minutes at 
room temperature. The supernatant containing non-viable cells was carefully 
aspirated, and the resulting pellet was washed with pre-warmed HMM, diluted to 
approx. 2 × 106 viable cells/mL and cell viability was assessed using trypan blue 
dye exculsion methods.  
2.6.3 Incubation of hepatocytes with 17α/β-estradiol 
Stock 17 -estradiol was prepared at a 2 times final concentration in pre-warmed 
HMM buffer.  To start the reactions, a 50 µL aliquot of the hepatocyte suspension 
was added to a 50 µL aliquot of substrate solution into a 1 mL, 96-well round-
bottom plate  (Costar) resulting in a cell concentration of 1x106 cells/mL and 
incubated in a 37 C  incubator water bath for 3 minutes.  The reaction was 
terminated with the addition of 100µL of ice cold 80:20 acetonitrile: methanol 
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containing internal standard (10ml of 5µg/ml 7-hydroxycoumarin-glucuronide 
was added to 75 ml acetonitrile: methanol and 10ml 200µg/ml 7-
hydroxycoumarinsulfate was added to 10 ml acetonitrile: methanol) to 100µL of 
cell suspension. The mixture was centrifuged at approximately 3000g for 15 
minutes at 4 C, 80µL of the supernatant was transferred to a clean 96-well v-
bottom 0.5mL plate (Costar) and evaporated to dryness under nitrogen gas using a 
TurboVap® concentration workstation (Caliber Life Sciences). The samples were 
resuspended in 100µL of  95:5 water: acetonitrile containing 0.1% formic acid and 
analysed by LC-MS multiple reaction monitoring for estradiol glucuronide or 
sulfate. 
2.6.4 Incubation of microsomes and cytosol with 17α/β-estradiol 
2.6.4.1 Microsome incubations 
Reactants (-drug) were incubated with alamethicin on ice for approx. 15 min. 
Alamethicin introduces pores in the membrane, thus facilitating the passage of 
drug through the microsomal membrane to reach the UGT active site. After 
incubation, the plate transferred to a 37°C water bath and the drug (17α/β-
estradiol) was added. When the temperature in wells in the plate reached 37°C, 
reaction was started by the addition of UDPGA (uridine 5’-diphospho-glucuronic 
acid). Control reactions containing no UDPGA were also set up in triplicate. The 
reaction was terminated by adding 100µL of 25% formic acid in water. 20µl of 
5µg/ml 7-hydroxycoumarin-glucuronide were added as internal standard (IS) to 
every reaction. The samples were centrifuged at 3000g for 15 minutes before 
being injected on the UPLC/MS. The reactants for the incubation were set up as 
follows: 
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Ingredients Final  in assay 
Bovine Liver 
Microsomes Variable 
UDPGA 0.5mM 
Alamethicin 50ug/mg protein 
MgCl2 1mM 
Drug Variable 
Incubation 
volume 200µl 
 
Table 21: Example of a reaction set up for bovine liver microsome 
incubation with 17α/β-estradiol 
 
2.6.4.2 Cytosol incubations 
All reactants given above were assembled at 37°C. Reactions were started by the 
addition of 20µl PAPS and stopped with 100µL acetonitrile containing 20µL of 
200µg/ml 7-hydroxycoumarinsulfate as an internal standard. After termination of 
reaction, 180µl from each well were transferred to a fresh 2ml vial. The vials were 
then spun at 10,000g in a minicentrifuge for 15 minutes. The supernatant was 
transferred back to a fresh clean plate and samples were dried in TURBOVAP 
nitrogen dryer prior to resuspending them in 100µL, 0.1% aqueous formic acid. 
All this was done to improve the signal intensity upon injection into the UPLC/MS 
system.  
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Ingredients Final  in assay 
Incubation 
Volume 200uL 
Bovine Liver 
cytosol Variable 
PAPS 0.1mM 
Drug Variable 
 
Table 22: Example of a reaction set up for bovine liver cytosol incubation 
with 17α/β -estradiol 
Data obtained from UPLC/MS was analysed using Analyst 1.4.2 (AB Sciex) software 
package.   
2.6.5 UPLC/ Mass Spectrometry Conditions for Glucuronidation and sulfation 
reactions 
2.6.5.1 Chromatography 
Ultraperformance liquid chromatography was performed on ACQUITYTM UPLCTM 
SYSTEM (Waters Corp., Milford, MA, USA). ACQUITY UPLCTM HSS T3 column (100 
X 2.1mm, 1.8µM) was used for glucuronidation and ACQUITY UPLCTM BEH shield 
RP18 column (50 x 2.1mm, 1.7µM) was used for sulfation. Chromatographic 
separations were achieved with a gradient elution using the mobile phase 
composed of water and acetonitrile (both containing 0.1% formic acid). The 
chromatographic separation for the ACQUITY UPLCTM HSS T3 column was started 
at 10% acetonitrile for 0.1min and then ramped to 70% within 5min and then 
returned to 10%.  (table 23) For the ACQUITY UPLCTM BEH shield RP18 column, 
the chromatographic separation was started at 10% acetonitrile for 2min and then 
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ramped up to 70% acetonitrile within 0.1 min (table 24). For both the columns, 
the flow rate was set at 0.6ml/min and the injection volume was 10µl.  
Time  
(min) 
Flow rate  
(ml/min) %A2 %B2 
Initial 0.6 90 10 
0.1 0.6 90 10 
5 0.6 30 70 
5.1 0.6 30 70 
5.2 0.6 90 10 
10 0.6 90 10 
60 0.6 90 10 
 
Table 23: Details of chromatographic conditions used with the UPLC/MS for 
glucuronidation reactions. 
 
Time  
(min) 
Flow rate  
(ml/min) %A2 %B2 
Initial 0.6 90 10 
0.1 0.6 90 10 
2 0.6 90 10 
2.1 0.6 30 70 
2.2 0.6 30 70 
4 0.6 90 10 
60 0.6 90 10 
 
Table 24: Details of chromatographic conditions used with the UPLC/MS for 
sulfation reactions.  
 
87 
 
 
2.6.5.2 Mass Spectrometry 
Mass spectrometric detection was carried out on a triple quadruple instrument  
(API 4000, Applied Biosystems SCIEX) with an electrospray ionisation  (ESI) 
interface. The ESI source was set in negative ionization mode and the 
quantification mode was multiple reaction monitoring (MRM). The following 
precursors to product ion transitions were used for MRM transition: 7-
hydroxycoumaringlucuronide (internal standard), m/z 336.9161; 7-
hydroxycoumarinsulfate (internal standard), m/z 241161; 17β-estradiol-3-
glucuronide, m/z 447.2271.10; 17β-estradiol-17-glucuronide, m/z 447.2     
271.10; 17β-estradiol-3-sulfate, m/z 351271. All data collected was acquired 
and processed using the software Analyst® (Applied Biosytems SCIEX) 
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3 Characterization of recombinant 
bovine sulfotransferases  
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3.1 Introduction  
The development of new therapeutic drugs requires a thorough preclinical testing 
stage where the pharmacodynamic, pharmacokinetic and toxicological properties 
of the candidate are evaluated. This preclinical investigation can involve the use 
of both in vitro as well as in vivo approaches. An ideal in vitro model should 
accurately resemble the biotransformation of a particular drug in the tissue of 
interest. Although other organs may also be involved in the biotransformation of 
drugs, the liver is the most predominant organ in which the majority of foreign 
compounds are metabolised. Hence several in vitro human liver models such as 
recombinant enzymes, microsomes, cytosol, S9 fraction, liver cell lines, 
hepatocytes, liver slices and perfused liver have been developed in the past 
(Brandon et al., 2003; Ekins et al., 2000). A great advantage of the availability of 
such in vitro model systems is that they allow the study of drug biotransformation 
in a system that is less complex than that found in vivo.  
One way of understanding a complex process like drug metabolism is to take the 
reductionist viewpoint and isolate the smallest possible unit which in this case is 
the drug metabolising enzyme itself. This is where enzymes generated using 
recombinant DNA technology finds their benefit. They can be used for isoform 
specific drug biotransformation studies (Ekins et al., 2000). This information is 
particularly useful since in combination with expression profile of DMEs in 
various tissues will allow drug companies to make accurate prediction on the 
metabolic fate of a particular drug in vivo. Companies such as Simcyp already has 
a technology platform which incorporates data on quantification of drug 
metabolising enzymes in various tissues to help predict the metabolic  fate of a 
drug in vivo (Jamei et al., 2009). Recombinant enzymes can also be purified and 
subsequently crystallised in the presence of the drug of interest to reveal 
90 
 
 
important structural features involved in drug binding and catalysis, thus aiding 
the design of better and safer drugs. Drug-drug interactions (DDIs) can lead to 
severe side effects, refusal of approval, severe prescribing restrictions and 
withdrawal of drugs from the market. They usually result from the action of one 
drug affecting the metabolism uptake or the removal of another drug (Friedberg, 
2000). With respect to DDIs, UGTs are the most investigated phase 2 enzymes. 
Some common DDIs include inhibition of acetaminophen glucuronidation by 
drugs such as propranolol and ranitidine. Valproic acid inhibits the 
glucuronidaton of the anticonvulsant drug carbamazepine and the anti-viral drug 
AZT. Rifampin is known to increase the glucuronidation of codeine whereas 
estrogen containing oral contraceptives increase the glucuronidation of 
acetaminophen (Kiang et al., 2005). As compared to glucuronidation, DDIs 
affecting sulfation are not very well researched due to limited availability of 
recombinant enzymes and because of lack of substrate/inhibitor specificity. 
Compounds such as mefanamic acid and quercetin have been identified as potent 
inhibitors and drugs such as phenobarbital and rifampicin are known to induce 
the action of sulfotransferases, however no clinical drug-drug interaction 
resulting from their use has yet been reported (Bjornsson et al., 2003). 
Availability of individual isoforms of recombinant drug metabolising enzymes will 
allow DDIs as a result of biotransformation of one or more compounds to be 
studied at the enzyme level, thus aiding the design of drugs with lesser side 
effects.  
Genetic polymorphisms in drug metabolising enzymes can result in enhanced or 
decreased glucuronidation activity in patients possessing the allelic variants. 
UGT1A1*28 is an allelic variant of UGT1A1 and is associated with reduced 
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elimination of SN-38 a toxic metabolite of the anti-cancer drug irinotecan (Iyer et 
al., 2002). Similarly genetic polymorphism in SULT1A3 has been implicated in 
changes of action of levosalbutamol, an R-enantiomer of the β2-adrenergic 
receptor agonist salbutamol (Boulton and Fawcett, 2001). Mutant recombinant 
enzymes can be generated to include these allelic variants and potential drugs can 
be tested on them to assess the activity relative to the wild type. Upon successful 
extrapolation to in vivo conditions in the clinic, it will enable patients to be 
segregated on basis of their potential response to treatment.  
In the following series of experiments, bovine sulfotransferase (SULT) isoforms 
such as SULT1A1, SULT1E1, SULT1B1 and SULT2A1 which have been previously 
implicated in human drug and xenobiotic metabolism were cloned and expressed 
in E. coli.  All the above isoforms except SULT2A1 were expressed as untagged 
proteins. Due to the difficulty associated with obtaining soluble expression of 
untagged SULT2A1, it was decide to express SULT2A1 as a fusion with maltose 
binding protein (MBP) in an attempt to improve its solubility.  Fusion of insoluble 
proteins to MBP has been known to improve their solubility on expression in 
bacteria (Esposito and Chatterjee, 2006; Hayhurst, 2000; Kapust and Waugh, 
1999).  Kinetic analysis was also performed on the recombinant isoforms in 
addition to substrate specificity profiling for each of the recombinant isoforms 
generated. In order to see if a correlation exists between the functional properties 
and structural features of recombinant bovine SULTs, primary sequence 
alignment with human SULTs was carried out using ClustalW. To see the effect of 
differences in primary sequence on the overall protein structures, tools such as 
the Discovery Studio Visualizer 3.1 (DS visualizer)  
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(http://accelrys.com/products/discovery-studio/visualization-download.php) were 
used to analyse the crystal structures of the relevant human and mouse SULTs.   
3.2 Expression of recombinant bovine sulfotransferases 
Untagged bSULT1A1, bSULT1B1, bSULT1E1 and bSULT2A1 were cloned into the 
expression vector pET17b and expressed in E. Coli. All the untagged bSULTs were 
expressed in the soluble fraction except for bSULT2A1 whose presence was 
detected in the total cell lysate but not in the soluble fraction of the cell suggesting 
it was present in inclusion bodies.  Hence it was decided to expresses bSULT2A1 
as a fusion with maltose binding protein (MBP). Expression as an MBP fusion 
resulted in the soluble expression of bSULT2A1, however, no activity in the MBP 
fusion or recombinant bSULT2A1 was detected against known SULT2A1 
substrates such as DHEA, androsterone and pregnenolone. All the other isoforms 
expressed untagged and in the soluble fraction were found to be active towards 
known substrates for their human orthologs. Shown in figure 12 is an SDS-PAGE 
gel containing uninduced and induced bovine SULT isoforms.  
Figure 12: Expression of recombinant bovine SULTs 
 Bovine SULTs before (uninduced, U) and after (Induced, I) induction with IPTG. 
20µg of protein was loaded in every well. Molecular weight markers were loaded in 
the first well on the left hand side.  
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Given below are western blots showing detection of recombinant bovine SULTs 
using anti human SULT antibodies.   
 
 
 
 
 
 
 
 
                 
 
 
 
 
         
Figure 13: Detection of bovine SULTs using anti human SULT antibodies. 
 Anti-human SULT1A3 (1:5000) was used in the detection of bSULT1A1  (a), anti-
human SULT1B1  (1:1000) MAP peptide antibody used in the detection of bSULT1B1  
(b), anti-human SULT1E1  (1:10,000) used in the detection of bSULT1E1  (c) and 
anti-human SULT2A1  (1:10,000) used in the detection of bSULT2A1 expressed as a 
MBP fusion protein  (d).   
 
a) 
Anti-human SULT1A3 
5 10 15 20 30 35 (µg)  
a) 
Anti-human SULT1B1 
0.01 0.02 0.03 0.05 0.08 0.1 0.15 0.2 
(µg)  
b) 
Anti-human SULT1E1 
0.5 1 1.5 2 3 4 
(µg)  
c) 
Anti-human SULT2A1  
1 5 10 15 20 25 30 40 (µg)  
d) 
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3.3 Analysis of sequence identity between bovine and human SULT 
isoforms  
Due to the lack of availability of antibodies against bovine SULTs, it was decided 
to use human SULT antibodies. Anti-human SULT1A3 was used in the detection of 
bSULT1A1. It was raised against purified recombinant human SULT1A3 in sheep 
(Richard et al., 2001).  Anti-human SULT1A3 has been used previously in the 
detection of both human SULT1A1 and human SULT1A3 (Riches et al., 2009).  
Anti-human SULT2A1 and anti-human SULT1E1 raised against purified 
recombinant human SULT2A1 and human SULT1E1, respectively, in sheep were 
used in the detection of bovine SULT2A1 and bovine SULT1E1. To determine if 
these antibodies would bind successfully to human SULTs, sequence alignment of 
whole protein was carried out between major human SULTs and their 
corresponding bovine isoforms. Results revealed a sequence identity ranging 
from 60-80% with SULT1B1 having the highest identity percentage of 81 whereas 
the SULT1E1 enzymes were the least identical at 62% (table 25). Although the 
bovine SULT isoforms were highly identical to their respective human SULTs, 
they were only 40-60% identical to each other. Sequence alignment analysis 
carried out to assess identity between different isoforms of bovine SULTs 
revealed that members of the same bovine SULT family were more identical to 
each other as compared to members of different families. SULT2A1 and SULT2B1 
had the highest identity at 57% whereas SULT1A1 and SULT2A1 had the lowest 
at 40% (table 26).  
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SULT isoform Amino acid 
sequence 
identity  (%) 
SULT1A1 78 
SULT1B1 81 
SULT1E1 62 
SULT2A1 70 
 
Table 25: Sequence identity between bovine SULTs and their human 
counterparts.  
Analysis was carried out using ClustalW2 
 
Table 26: Sequence identity between isoforms of bovine sulfotransferases.  
Analysis was carried out using ClustalW2.  
 
A multiple antigenic peptide antibody (MAP) directed towards a 17 amino acid 
sequence unique to human SULT1B1 and sharing very low identity to other 
human SULTs has been previously used in the detection of human SULT1B1. The 
antigenic agent consists of many copies of the 17 amino acid sequence attached to 
a poly-lysine chain which increases the size of the antigenic peptide so that it 
becomes big enough to elicit an immune response(Riches et al., 2009). In order to 
use the human SULT1B1 MAP antibody for the detection of bovine SULT1B1, it 
has to have high sequence identity with bovine SULT1B1 and have a very low 
SULT 
sequence 
number 
Bovine SULT SULT 
sequence 
number 
Bovine SULT Sequence 
similarity 
score 
1 SULT1A1 2 SULT2A1 40 
1 SULT1A1 3 SULT1E1 44 
1 SULT1A1 4 SULT1B1 54 
1 SULT1A1 5 SULT2B1 54 
2 SULT2A1 3 SULT1E1 49 
2 SULT2A1 4 SULT1B1 44 
2 SULT2A1 5 SULT2B1 57 
3 SULT1E1 4 SULT1B1 56 
3 SULT1E1 5 SULT2B1 48 
4 SULT1B1 5 SULT2B1 47 
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identity with other bovine SULT isoforms. Sequence alignment analysis was 
carried out on the MAP peptide sequences from human SULT1B1 and bovine 
SULT1B1 revealed a 76% identity between the two (see table 27). Human 
SULT1B1 MAP peptide shared less than 30% identity with the rest of the bovine 
SULTs. Like the human SULT1B1 MAP peptide, the bovine sequence 
corresponding to the human SULT1B1 sequence used for synthesis of the MAP 
shared low identity  (<25%) with rest of the bovine SULT isoforms. 
bSULT1B1        MTSP-KDVLRKNLKLIHG 17 
bSULT1A1        MELI-QDTSRPPAKYVKG 17 
bSULT1E1        MSSS-KPSFSDYFGKLGG 17 
bSULT4A1        MAES-EAETPSTPGEFES 17 
bSULT2B1        MGEPAEPRNQAKWDPYE- 17 
bSULT2A1        MTGKFLWFEGIPFPSVD- 17 
                                  
 
   Table 27: Summary of sequence alignment of MAP region of human 
SULT1B1 with the corresponding region in other bovine SULTs 
 Sequence alignment of MAP region of human SULT1B1 with the corresponding 
sequence in other bovine SULTs (a) carried out using Clustalw2. The bovine 
sequence had a 76% sequence identity to the human SULT1B1 sequence used for the 
synthesis of the MAP antibody. It however had a low sequence identity with the 
corresponding MAP region of other bovine SULTs.  (b)       
SULT Amino acid sequence 
corresponding to the human 
SULT1B1 MAP peptide 
Sequence 
identity score  
(%)  relative to 
human 
SULT1B1_MAP 
Sequence 
identity score  
(%) relative to 
bovine 
SULT1B1_MAP 
Human 
SULT1B1  
MLSPKDILRKDLKLVHG 100   
Bovine 
SULT1B1 
MTSPKDVLRKNLKLIHG 76 100 
Bovine 
SULT1A1 
MELIQDTSRPPAKYVKG 29  23 
Bovine 
SULT1E1 
MSSSKPSFSDYFGKLGG 23  23 
Bovine 
SULT2A1 
MTGKFLWFEGIPFPSVD 5  5 
Bovine 
SULT2B1 
MGEPAEPRNQAKWDPYE 11  11 
Bovine 
SULT4A1 
MAESEAETPSTPGEFES  5 5 
* b) 
a) 
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3.4 Cross-reactivity of anti-human SULT antibodies with bovine 
SULTs 
In order to see if anti-human SULT antibodies cross reacted with their bovine 
counterparts, 5µg bSULT1A1, 0.1µg bSULT1B1, 1µg bSULT1E1 and 15µg MBP-
bSULT2A1 were loaded on to each of 4 gels  (figure 14). The gels were then 
blotted with anti-human SULT1A3, anti-human SULT1B1 (MAP peptide), anti-
human SULT2A1 and anti-human SULT1E1 antibodies. Anti-human SULT1A3 and 
anti- human SULT2A1 were specific for their respective SULT isoforms. The anti-
human SULT1B1 peptide antibody cross reacted with bSULT1B1 but also bound 
non specifically to other unrelated proteins on the membrane. The anti-human 
SULT1E1 antibody strongly cross reacted with bSULT1E1 but also reacted with 
bSULT1A1 and bSULT1B1. 
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Figure 14: Detection of recombinant bovine SULTs in E. Coli cell free extract 
using anti human SULT antibodies.  
5 µg bSULT1A1, 0.1µg of bSULT1B1, 1µg bSULT1E1 and 15µg of MBP-bSULT2A1 
fusion was loaded on to every gel. Anti-human SULT1A3 cross reacts with 
bSULT1A1. Anti-human SULT1E1 cross reacts strongly with bSULT1E1 but also with 
bSULT1A1 and bSULT1B1 
 
3.5 Optimization of conditions for enzyme kinetics with expressed 
recombinant bovine SULT isoforms.  
SULT enzyme activity is affected by many factors such as protein concentration, 
concentration of the co-factor PAPS, incubation time, buffers used and pH of 
buffer used. Optimization for each of the above factors was done for recombinant 
bovine SULT enzymes, bSULT1A1, bSULT1B1 and bSULT1E1 used in this study. 
Protein concentration and incubation time were chosen such that they fell within 
the linear range of the reaction phase where increase in protein concentration 
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and incubation time would result in an increase in enzyme activity. Concentration 
of PAPS to be used was chosen such that it was not rate limiting. Enzyme activity 
is also heavily dependent on the pH of the buffer used. Biological buffers were 
made up in the physiological pH range from 5.2-9. Tris Maleate was used to buffer 
in the pH range of 5.2-5.6 Phosphate buffer, 5.8-8 and Tris HCl, 8-9. The buffer 
and pH in which highest enzyme activity was seen was chosen to be used. Table 
28 shows an example of optimization with each of the above mentioned factors.  
 
Table 28: Summary of optimised conditions used for enzyme kinetics assays 
for recombinant SULT isoforms.  
 
3.6 Bovine SULT1A1, SULT1B1 kinetics with 4-nitrophenol 
Upon optimization of parameters affecting enzyme activity, kinetic analysis was 
performed on recombinant bSULT1A1 and bSULT1B1. Probe substrates of human 
SULTs were used for assessing the enzyme activity of the bovine counterpart. To 
date no known probe substrate has been identified that is exclusively metabolised 
by bSULT1B1. However, SULT1B1 is known to metabolise majority of the 
compounds turned over by bSULT1A1 (Fujita et al., 1999; Wang et al., 1998). 4-
nitrophenol (4NP) was used as a substrate for assessing the activity of both 
bSULT1A1 and bSULT1B1. bSULT1A1 demonstrated partial substrate inhibition 
with 4-nitrophenol with a Km of 33 µM and a Ki of 24µM  (figure 15).  A lower Km 
of 4µM and a higher Ki of 34µM was recorded in a previous study for recombinant 
Recombinant 
bovine 
sulfotransferase Substrate pH 
PAPS  
(µM) Buffer 
time  
(min) 
protein  
(µg) 
bSULT1A1 4-Nitrophenol 6.2 20 phosphate 20 20 
bSULT1B1 4-Nitrophenol 6.2 20 phosphate 20 20 
bSULT1E1 17β-estradiol 6.2 20 phosphate 20 30 
c) 
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purified human SULT1A1(Riches et al., 2007). However, it should be noted that 
recombinant human SULT1A1 used was purified whereas bovine SULT1A1 used 
here was not. Kinetic parameters for bSULT1A1 activity were calculated by fitting 
the enzyme curve to the partial substrate inhibition equation (refer to section 
2.2.4 of Materials and Methods). Vmax (3512 pmol/min/mg) and Km (31µM) for 
bSULT1B1  (figure 16) were calculated by fitting the curve to Michaelis-Menten 
equation for enzyme kinetics  (refer to section 2.2.4 of Materials and Methods).   
 
 
 
 
 
 
 
 
 
Figure 15: Rate of formation of 4-nitrophenol sulfate as a function of 
increasing 4-nitrophenol concentration (recombinant bSULT1A1).  
 [35S] PAPS assay was used to determine sulfation of 4-nitrophenol. Each assay was 
carried out in duplicate. Data points are the average of the two values. Michaelis-
Menten equation with partial substrate inhibition was used to analyse results as 
substrate inhibition was observed beyond 20µM 4-nitrophenol. 
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Figure 16: Rate of formation of 4-nitrophenol sulfate as a function of 
increasing 4-nitrophenol concentration (recombinant bSULT1B1)  
 [35S] PAPS assay was used to determine sulfation of 4-nitrophenol. Each assay was 
carried out in duplicate. Data points are average of the two values. Michaelis-
Menten equation was used to analyse results.  
 
3.7 Substrate specificity profiling of recombinant bovine SULT1A1 
and SULT1B1 
In humans, both SULT1A1 and SULT1B1 are known to sulfate planar phenols with 
overlapping substrate specificities (Riches et al., 2007; Taskinen et al., 2003). In 
order to determine which of the two recombinant bovine SULTs was better at 
sulfation, a battery of phenolic compounds was screened for activity against 
recombinant bSULT1A1 and bSULT1B1.  In order to make a valid comparison, it 
was necessary to do a substrate screen on equal amounts of recombinant 
bSULT1A1 (rbSULT1A1) and rbSULT1B1. This was achieved by loading 
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increasing amount of induced and uninduced bSULT1A1 and bSULT1B1 on the 
same gel (figure 17a) and using the software Quantiscan to measure the band 
density.  The net band density volume was plotted against amount of induced 
protein loaded on to the gel. The experiment was repeated several times to 
ensure that the band densities fell within the linear range of the protein.  The 
linear equation giving rise to the highest R2 value was chosen  (0.9912) to 
calculate the amount of bSULT1A1 present in the crude extract relative to the 
amount of bSULT1B1  (figure 17b). Using the equation, y=959.69x-7869.9 and 
20µg of bSULT1B1 an equivalent of approximately 40µg bSULT1A1 protein of 
was calculated.  
 
 
 
 
 
 
 
 
 
 
 
Figure 17: Calculation of amount of bovine SULT1A1 relative to bovine 
SULT1B1. 
11% polyacrylamide SDS-PAGE gel containing 10-50µg of expressed recombinant 
bSULT1A1 and bSULT1B1 (a). The gel was scanned and imported into Quantiscan to 
obtain a net band density value. The band density values were plotted against the 
amount of protein for both bSULT1A1 and bSULT1B1.  (b).  
b) 
a) 
50 50 40 40 30 30 20 20 10 10 
bSULT1A1 bSULT1B1 
B 
(µg) 
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Enzyme activity was seen for bSULT1B1 with the majority of the tested 
compounds (figure 18). These were normally about twice that of bSULT1A1 
indicating that bSULT1B1 was better at sulfation of phenolic compounds as 
compared to bSULT1A1. However, certain substrates such as 4-isopropylphenol, 
2-aminophenol, 4-amylphenol and 4-phenylazophenol had higher activity with 
recombinant bSULT1A1. 2-aminophenol has already been established as a better 
probe substrate for human SULT1A1 since it does not undergo partial substrate 
inhibition kinetics like 4-nitrophenol with SULT1A1. It is more specific for human 
SULT1A1 and is metabolised to a lesser extent by SULT1B1. Unfortunately no 
potential probe substrates that are exclusively metabolised by SULT1B1 were 
detected. Paracetamol was the only substrate not metabolised by either enzyme. 
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Figure 18: Substrate specificity profiling of recombinant bovine SULT1A1 
and SULT1B1 with phenolic substrates.  
A battery of phenolic substrates was screened for activity against 20µg of expressed 
recombinant bSULT1B1 (a) and 40µg of expressed recombinant bSULT1A1 (b) using 
the [ 35S]  PAPS assay. The substrates were used at 1, 10 and 100µM.  
 
a) 
b) 
a) 
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Figure 19: Substrate screen carried out on recombinant human SULT1A1 
and SULT1B1 at 3 different concentrations  (1, 10 and 100µM).  
Sulfotransferase activity was measured with cell free extract expressing SULT1A1  
(a) and SULT1B1  (b). Data are mean of experiments carried out in duplicate. This 
work was carried out by Zoe Riches and was published in Riches et al , 2007 
(Riches et al., 2007). The graphs have been included in this thesis to aid 
comparison with recombinant bovine SULT1A1 and SULT1B1 data from figure 
18.  
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3.8 Recombinant bovine SULT1E1 kinetics with 17β-estradiol and 
substrate specificity profiling with other xenobiotic substrates 
using [35S] PAPS assay 
In humans, 17β-estradiol is sulfated by SULT1E1 in the physiological  
(nanomolar) range. The recombinant purified human SULT1E1 has a Km of 5nm 
and substrate inhibition is observed at concentrations above 80nM(Zhang et al., 
1998). Expressed human SULT1E1 is capable of sulfating other steroids such as 
DHEA, pregnenolone, diethylstilbestrol and equilenin at micromolar substrate 
concentrations (Falany et al., 1995b; Falany et al., 1994). In addition to steroids, 
human SULT1E1 also has activity towards other xenobiotic compounds such as 
apomorphine, 4-tert-butyl-5-methoxycatechol, 3,4-dihyroxybenzoic acid ethyl 
ester and 4-isopropylcatechol (Taskinen et al., 2003).  In this study, it was found 
that expressed recombinant bovine SULT1E1 metabolised 17β-estradiol in the 
micromolar range with a Vmax of 1003 pmol/min/mg and a Km of 2.3 µM. The 
enzyme demonstrated Michaelis-Menten kinetics and no substrate inhibition was 
observed (figure 20). To test the sulfation capacity of recombinant bovine 
SULT1E1 towards various other xenobiotic compounds, we screened a battery of 
substrates against bovine SULT1E1 using the [35S] PAPS assay (figure 21). 
Substrates such as apomorphine and 4-isopropylcatechol known to have activity 
against recombinant human SULT1E1 were also used. A substrate concentration 
range of 0.01-10µM was chosen. Bovine SULT1E1 extensively metabolises 4-
phenylphenol and does so in the micromolar range, 4-phenylazophenol, 
apomorphine and 4-isopropylcatechol are also metabolised. Sesamol was the only 
substrate not to be metabolised by recombinant bSULT1E1.  
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Figure 20: Rate of formation of 17β-estradiol sulfate as a function of 
increasing 17β-estradiol concentration.  
 [3H] based solvent extraction assay was used to determine sulfation of 17β-
estradiol. Each assay was carried out in duplicate. Data points are the average of 
the two values. Michaelis-Menten equation was used to analyse results.  
 
 
 
 
Figure 21: Substrate specificity profiling of recombinant bovine SULT1E1. 
A battery of xenobiotic substrates was screened for activity against 30µg of 
expressed recombinant bSULT1E1 using the [35S] PAPS assay. The substrates were 
used at 0.01, 0.1, 1, 10 µM.  
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Recombinant 
bovine SULT 
Substrate 
tested 
Vmax  
(pmol/min/mg) Km  (µM) Ki  (µM)  
SULT1A1 4-nitrophenol 8494 ± 3812 33 ± 20 24 ± 14.5 
SULT1B1 4-nitrophenol 3512 ± 55 31 ± 1.2 NA 
SULT1E1 17β-estradiol 1003 ± 41.4 2.3 ± 0.6 NA 
SULT2A1 
DHEA and 
pregnenolone ND ND ND 
 
Table 29: Summary of recombinant bovine SULT kinetics.  
Kinetic assays were performed on the given substrates using optimized conditions 
listed in table 3.4, the Michaelis-Menten equation was used to calculate Vmax and 
Km for all except SULT1A1 where partial substrate inhibition equation was applied. 
Each assay was carried out in duplicate. Values given above are ± standard error. 
ND refers to activity not detected and NA = Not applicable  
 
3.9 Structural analysis of recombinant bovine sulfotransferase 
isoforms 
Once expressed, radiolabelled enzyme assays were performed on recombinant 
bovine SULTs using substrates established for activity in humans and other 
species. It was discovered that the enzymatic properties of these enzymes 
differed markedly from those of the corresponding human SULTs. In order to 
understand the underlying structural aspects that could possibly govern some of 
these findings, it was decided to perform a structural analysis. This involved 
carrying out a primary amino acid sequence alignment of bovine SULTs with 
SULTs from humans and other species followed by a tertiary structure analysis to 
see the effect of primary amino acid changes on the overall structure.  
3.9.1 Structure of bovine SULT1E1 compared to those of mouse Sult1e1 and 
human SULT1E1.  
SULT1E1, more commonly known as estrogen sulfotransferase, has a very high 
affinity for the endogenous substrate 17β-estradiol which it sulfates in the low 
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nanomolar range(Forbes-Bamforth and Coughtrie, 1994). Multiple sequence 
alignment using ClustalW was carried out between SULT1E1 from human, mouse 
and cow (See figure 22).  The conserved TYPKSGTTW motif (grey) known as the 
phosphosulfate binding loop (PSB), is involved in PAPS binding. The entire motif 
including the critical lysine residue at position 48 (yellow) is absolutely 
conserved in SULT1E1 from the 3 species. The KXXXTVXXXE motif (264-273, 
human SULT1E1 numbering) plays an important role in the dimerization of 
SULTs. Human SULT1E1 exists as a dimer in solution in contrast to mouse 
SULT1E1 which is a monomer(Kakuta et al., 1997). The ‘TV’ in this motif is 
replaced by a ‘PE’  in mouse SULT1E1. It appears that bovine SULT1E1 might exist 
as a dimer in solution since the dimerization motif of human and bovine SULT1E1 
are identical. Critical residues that are conserved and involved in substrate 
binding of SULT1E1 have been highlighted in green. His108 is absolutely 
conserved in all SULTs and mutation of this residue abolishes SULT activity. 
Residues that are involved in substrate binding but are not very well conserved 
are highlighted in blue. Phe231 (human SULT1E1 numbering) in the substrate 
binding pocket of SULT1E1 is replaced by a Leucine (figure 24). Since 
phenylalanine contains an aromatic ring it confers more hydrophobicity to the 
highly non polar substrate binding pocket by forming greater van der Waals 
forces with the surrounding residues. Substitution of an aromatic residue like 
phenylalanine to an aliphatic leucine means lesser van der Waals interactions that 
reduce the overall hydrophobic nature of the binding pocket which in turn could 
affect substrate binding.  
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                                                                48 
SULT1E1human      -MNSELDYYEKFEEVHGILMYKDFVKYWDNVEAFQARPDDLVIATYPKSGTTWVSEIVYM 59 
Sult1e1mouse      METSMPEYYEVFGEFRGVLMDKRFTKYWEDVEMFLARPDDLVIATYPKSGTTWISEVVYM 60 
SULT1E1cow        MSSSKPSFSDYFGKLGGIPMYKKFIEQFHNVEEFEARPDDLVIVTYPKSGTTWLSEIICM 60 
                    .*  .: : * :. *: * * * : :.:** * ********.*********:**:: * 
                                      
SULT1E1human      IYKEGDVEKCKEDVIFNRIPFLECRKENLMNGVKQLDEMNSPRIVKTHLPPELLPASFWE 119 
Sult1e1mouse      IYKEGDVEKCKEDAIFNRIPYLECRNEDLINGIKQLKEKESPRIVKTHLPPKVLPASFWE 120 
SULT1E1cow        IYNNGDVEKCKEDVIFNRVPYLECSTEHVMKGVKQLNEMASPRIVKSHLPVKLLPVSFWE 120 
                  **::*********.****:*:*** .*.:::*:***.*  ******:*** ::**.**** 
                                      141 
SULT1E1human      KDCKIIYLCRNAKDVAVSFYYFFLMVAGHPNPGSFPEFVEKFMQGQVPYGSWYKHVKSWW 179 
Sult1e1mouse      KNCKMIYLCRNAKDVAVSYYYFLLMITSYPNPKSFSEFVEKFMQGQVPYGSWYDHVKAWW 180 
SULT1E1cow        KNCKIIYLSRNAKDVVVSYYFLILMVTAIPDPDSFQDFVEKFMDGEVPYGSWFEHTKSWW 180 
                  *:**:***.******.**:*:::**::. *:* ** :******:*:******:.*.*:** 
 
SULT1E1human      EKGKSPRVLFLFYEDLKEDIRKEVIKLIHFLERKPSEELVDRIIHHTSFQEMKNNPSTNY 239 
Sult1e1mouse      EKSKNSRVLFMFYEDMKEDIRREVVKLIEFLERKPSAELVDRIIQHTSFQEMKNNPSTNY 240 
SULT1E1cow        EKSKNPQVLFLFYEDMKENIRKEVMKLLEFLGRKASDELVDKIIKHTSFQEMKNNPSTNY 240 
                  **.*..:***:****:**:**:**:**:.** **.* ****:**:*************** 
 
SULT1E1human      TTLPDEIMNQKLSPFMRKGITGDWKNHFTVALNEKFDKHYEQQMKESTLKFRTEI 294 
Sult1e1mouse      TMMPEEMMNQKVSPFMRKGIIGDWKNHFPEALRERFDEHYKQQMKDCTVKFRMEL 295 
SULT1E1cow        TTLPDEVMNQKVSPFMRKGDVGDWKNHFTVALNEKFDMHYEQQMKGSTLKFRTKI 295 
                  * :*:*:****:*******  *******. **.*:** **:**** .*:*** :: 
Figure 22: Multiple sequence alignment of SULT1E1 from human mouse and 
cow.  
The highlighted regions show important structural features. Residues 45-53 form 
the PSB loop which is involved in binding PAPS. The region highlighted in pink is the 
KXXXTVXXXE motif that is involved in the dimerization of the protein. Upstream of 
this motif is the well conserved GXXGXXK motif that also plays a role in PAPS 
binding. Residues highlighted in green are conserved in the active site whilst those 
highlighted in blue are residues in the active site which are not very well conserved. 
Phe141 is conserved in human and mouse but not in the cow.  
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Figure 23: Crystal structure of mouse Sult1e1 complexed with the co factor 
PAPS and the substrate 17β-estradiol. 
 The figure has been downloaded from protein data bank. www.pdb.org ID:1AQU. 
The alpha helices are shown as red ribbons and β-sheets as turquoise strands. The 
active site of the protein is highlighted in yellow. Also shown in yellow is a ball and 
stick model of Phe142 which is substituted by a leucine in bovine SULT1E1(Kakuta 
et al., 1997) 
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Figure 24: Positions for the co-factor PAPS, the substrate 17β-estradiol and the residue Phe142/Leu142 in the active site of mouse 
Sult1e1/bovine SULT1E1.  
The file for visualising the crystal structure was downloaded from www.pdb.org , 1AQU(Kakuta et al., 1997). For the purpose of clarity the 
remainder of the protein is not shown here.  In mouse Sult1e1, Phe142 (yellow) is in a position to form van der Waals interactions with 17β-
estradiol  (a). Phe 142 is substituted for Leu 142  (yellow) in bovine SULT1E1 and a depiction of  this substitution is shown above in the active site 
of mouse Sult1e1  (b). This substitution could affect the binding of 17β-estradiol. His108 is a critical residue in the active site. 
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Polychlorinated biphenyls (PCBs) are environmental pollutants found in 
terrestrial and aquatic systems. They interfere with sexual development and 
reproduction by exerting their endocrine disrupting effects. It was found that 
some hydroxylated PCBs (OH-PCBs) can inhibit SULT1E1 by binding to it in a 
position similar to that of 17β-estradiol. We identified that Phe141 in human 
SULT1E1 is in a critical position in the active site of the enzyme. The aromatic 
hydrocarbon ring of phenylalanine is in a position to form stronger van der Waals 
interactions with the substrate than compared to Leu141 in bovine SULT1E1. 
This substitution could affect the binding of the inhibitor as well as 17β-estradiol  
(see figure 25 and 26). 
 
 
 
 
 
 
 
Figure 25: Crystal structure of human SULT1E1 complexed with the co 
factor PAPS and the inhibitor 4,4-OH 3,5,3’,5’-tetra CB  (OH-PCB). 
 The inhibitor OH-PCB binds in the active site of human SULT1E1 in a position 
similar to that of 17β-estradiol. The data file view to generate this figure has been 
downloaded from protein data bank. www.pdb.org ID:1G3M(Shevtsov et al., 2003). 
The alpha helices are shown as red ribbons and β-sheets as turquoise strands. The 
active site of the protein is highlighted in yellow. Also shown in yellow is a ball and 
stick model of Phe141 which is substituted by a Leucine in bovine SULT1E1 
114 
 
 
 
 
 
 
 
 
 
 
Figure 26: Positions for the co-factor PAPS, the inhibitor OH-PCB and the residues Phe141/Leu141 in the active site of human 
SULT1E1. 
 The data file view to generate this figure was downloaded from www.pdb.org , 1G3M(Shevtsov et al., 2003). For the purpose of clarity the 
remainder of the protein is not shown here.  Phe 141 (a) is substituted for Leu 141  (b)  (yellow) in bovine SULT1E1 and a representation of this 
substitution is shown above in the human SULT1E1 active site. His107 is a critical residue in the active site. 
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3.9.2 Primary and tertiary structure of bovine SULT2A1 compared to that of 
human SULT2A1 complexed with the co-factor PAP and the substrate 
lithocholic acid 
SULT2A1 is known as the bile acid sulfotransferase due to its ability to sulfate bile 
acids. In addition to bile acids, it also sulfates steroids such as DHEA and 
androsterone. Sequence alignment using ClustalW was carried out between 
SULT2A1 from human and cow (figure 27). Important motifs involved in PAPS 
binding and dimerizations were conserved. Conserved critical residues involved 
in substrate binding have been highlighted in green. Residues that were critical to 
substrate binding in human SULT2A1 but are not conserved in bovine SULT2A1 
are shown in blue. In human SULT2A1, region 231-253 has been identified as the 
substrate binding pocket. Sequence analysis results revealed that majority of the 
residues in this region were not conserved between human and bovine. These 
included Tyr231, Ser235, Val240, Asp241, Lys242, Ala243, Glu244 and Ser251  
(figure 28 and 29). Some of these changes were not considered very significant 
because the substituted amino acid had similar properties i.e. Asp241Glu both 
have side chains that are positively charged. However, changes such as Ser235Lys 
and Val240Glu were thought to be more significant since the substituted amino 
acid was a charged one. This has the potential to disturb the hydrophobic nature 
of the pocket. Tyr231 is an important residue in the active site of human 
SULT2A1. It has been known to play a role in PAPS binding, dimerization and 
stabilization of the enzyme substrate complex (Rehse et al., 2002). Substitution of 
this residue with phenylalanine in the cow could mean loss of the above 
mentioned functions. Indeed, this could possibly be the reason why we were 
unable to express recombinant bovine SULT2A1. A deeper analysis of this region 
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was carried out using the structural tool DS visualizer to look closely at the active 
site of human SULT2A1 and compare it to that of bovine SULT2A1.  
SULT2A1human      MSDDFLWFEGIAFPTMGFRSETLRKVRDEFVIRDEDVIILTYPKSGTNWLAEILCLMHSK 60 
SULT2A1cow        MTGKFLWFEGIPFPSVDYSPELLREVQESFLIKDEDVLLLTFPKSGTNWLIETVCLIYSK 60 
                  *:..*******.**::.: .* **:*::.*:*:****::**:******** * :**::** 
 
SULT2A1human      GDAKWIQSVPIWERSPWVESEIGYTALSETESPRLFSSHLPIQLFPKSFFSSKAKVIYLM 120 
SULT2A1cow        GDPKWVQSEPIWDRSPWVETKHGYELLKEKEGTRLISSHHPIQLFPKSFFKSKAKVIYLV 120 
                  **.**:** ***:******:: **  *.*.*..**:*** **********.********: 
 
SULT2A1human      RNPRDVLVSGYFFWKNMKFIKKPKSWEEYFEWFCQGTVLYGSWFDHIHGWMPMREEKNFL 180 
SULT2A1cow        RNPRDVFVSGYFFWKSAKFVKRPQSLEQYFEWFIQGNMPFGSWFDHIRGWMSMRDKENFL 180 
                  ******:********. **:*:*:* *:***** **.: :*******:***.**:::*** 
 
SULT2A1human      LLSYEELKQDTGRTIEKICQFLGKTLEPEELNLILKNSSFQSMKENKMSNYSLLSVDYVV 240 
SULT2A1cow        VLSYEEMKWDTRSTVEKICQFLGKKLEPEELNSVLKNNSFQVMKENNMSNFSLLKGQYLE 240 
                  :*****:* **  *:*********.******* :***.*** ****:***:***. :*:  
 
SULT2A1human      DKAQLLRKGVSGDWKNHFTVAQAEDFDKLFQEKMADLPRELFPWE 285 
SULT2A1cow        ENGLLLRKGVTGDWKNYFTVAQAEIFDKLFQEKMADLPQELFAWE 285 
                  ::. ******:*****:******* *************:***.** 
 
Figure 27: Multiple sequence alignment of SULT2A1 from human and 
bovine.  
The highlighted regions show important structural features. Residues 45-53 form 
the PBS loop which is involved in binding PAPS. Region highlighted in dark green is 
the KXXXTVXXXE motif that is involved in the dimerization of the protein. Upstream 
of this motif is the well conserved GXXGXXK motif that also plays a role in PAPS 
binding. Residues highlighted in green are conserved in the active site whilst those 
highlighted in blue and red are residues in the active site which are not conserved. 
Region 231-253 shown in red box constitutes the substrate binding site. The region 
is not very well conserved between human and bovine.  
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Figure 28: Crystal structure of human SULT2A1 complexed with the co- 
factor PAPS and the bile acid lithocholic acid.  
Lithocholic acid binds in the active site of human SUL2A1 in a position similar to 
that of dehydroepiandrosterone (DHEA). The data file to generate this figure has 
been downloaded from protein data bank. www.pdb.org ID:3F3Y  (To be published). 
The alpha helices are shown as red ribbons and β-sheets as turquoise strands.  
Shown in yellow is a ball and stick model of Tyr 231 which is substituted by a 
phenylalanine in bovine SULT2A1. Also shown is the ball and stick model of other 
amino acids in the substrate binding pocket such as Tyr238, Ser235 and Val240.  
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Figure 29: Effect of the substitution of critical residues in the active site of human SULT2A1.  
Positions for the co-factor PAPS, the substrate lithocholic acid and residues Tyr231, Tyr238, Ser235 and Val240 in the active site of human 
SULT2A1 (a). The data file to generate this figure was downloaded from www.pdb.org , 3F3Y (To be published). For the purpose of clarity, the 
remainder of the protein is not shown here.  In the amino acid sequence of bovine SULT2A1, the following substitutions were seen, Tyr231Phe, 
Ser235Lys, and Val240Glu.  The effect of these substitutions is shown above on the active site of human SULT2A1 (b). His99 is a critical residue in 
the active site.  
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3.9.3 Primary and tertiary structure of bovine SULT1A1 compared to that of 
human SULT1A1 complexed with the co-factor PAP and two molecules of 
the substrate 4-nitrophenol 
SULT1A1, the major human SULT, involved in drug metabolism, is known to 
metabolise a wide range of xenobiotic and endogenous compounds but 
specifically prefers small planar phenolic compounds. The crystal structure of 
human SULT1A1 solved in complex with the co-factor PAPS and the substrate 4-
nitrophenol revealed that the enzyme accommodated not one but two molecules 
of 4-nitrophenol in its active site (Gamage et al., 2003). This was supported by 
kinetic data which showed that the enzyme exhibited substrate inhibition with 4-
nitrophenol, a phenomenon whereby there is an impediment to catalysis when 
more than one molecule of the substrate binds to the active site. This is 
responsible for slowing the rate of reaction.  It was also found that human 
SULT1A1 had a flexible substrate binding site that could adopt varying 
conformations to accommodate diverse substrates with varying sizes and shapes 
such as 17β-estradiol and diiodothyronine (Gamage et al., 2003). A sequence 
alignment was carried out between human and bovine SULT1A1 (figure 30). The 
PSB loop highlighted in grey was conserved. The KXXXTVXXXE motif highlighted 
in green was substituted for the KXXXSVXXXE motif in the bovine protein. 
Residues shown in blue are part of the active site which is involved in the binding 
of the first molecule of 4-nitrophenol (pNP1) whereas those in yellow are involved 
in binding of the second molecule (pNP2). Substitutions such as Ile89Val and 
Phe247Val in the active site of bovine SULT1A1 could affect the binding of pNP2  
(figure 31).        
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SULT1A1human      MELIQDTSRPPLEYVKGVPLIKYFAEALGPLQSFQARPDDLLISTYPKSGTTWVSQILDM 60 
SULT1A1cow        MELIQDTSRPPAKYVKGIPLIKYFAEALGPLESFEAWPDDLLISTYPKSGTTWVSEILDL 60 
                  *********** :****:*************:**:* ******************:***: 
 
SULT1A1human      IYQGGDLEKCHRAPIFMRVPFLEFKAPGIPSGMETLKDTPAPRLLKTHLPLALLPQTLLD 120 
SULT1A1cow        IYQEGDLEKCQRAPVFLRVPFLEFSAPGVPTGVELLKDTPAPRLLKTHLPLALLPKTLLD 120 
                  *** ******:***:*:*******.***:*:*:* ********************:**** 
 
SULT1A1human      QKVKVVYVARNAKDVAVSYYHFYHMAKVHPEPGTWDSFLEKFMVGEVSYGSWYQHVQEWW 180 
SULT1A1cow        QKVKVIYIARNAKDVAVSYYHFYRMAKVHPDPGTWDSFLEKFMAGEVCYGSWYQHVQEWW 180 
                  *****:*:***************:******:************.***.************ 
 
SULT1A1human      ELSRTHPVLYLFYEDMKENPKREIQKILEFVGRSLPEETVDFMVQHTSFKEMKKNPMTNY 240 
SULT1A1cow        ELSHTHPVLYLFYEDIKEDPKREIQKILEFIGRSLPEETVDHIVQRTSFKEMKKNPMTNY 240 
                  ***:***********:**:***********:**********.:**:************** 
 
SULT1A1human      TTVPQEFMDHSISPFMRKGMAGDWKTTFTVAQNERFDADYAEKMAGCSLSFRSEL 295 
SULT1A1cow        STIPTAVMDHSISAFMRKGITGDWKSTFTVAQNELFEAHYAKKMR-AATPLRWEL 294 
                  :*:*  .******.*****::****:******** *:*.**:**  .: .:* ** 
 
Figure 30: Multiple sequence alignment of human and bovine SULT1A1. 
The highlighted regions show important structural features. Residues 45-53 form 
the PSB loop which is involved in binding PAPS (grey). The region highlighted in 
dark green is the KXXXTVXXXE motif that is involved in the dimerization of the 
protein. Upstream of this motif is the well conserved GXXGXXK motif that also plays 
a role in PAPS binding. Residues highlighted in blue are involved in binding one 4- 
nitrophenol (pNP1) whilst those highlighted in yellow are residues in the active site 
which bind to the other 4-nitrophenol (pNP2) molecule. 
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Figure 31: Effect of critical amino acid residue substitutions in the active site of human SULT1A1. 
 Shown above are the positions for the two 4-nitrophenol substrates and residues Phe76 (1), Phe84  (2), Lys106  (3), His108  (4), Val148  (5), 
Met248  (6) and Phe247  (7) and Ile89  (8) in the active site of human SULT1A1 (a). The crystal structure was downloaded from www.pdb.org , 
3F3Y(Gamage et al., 2003). For the purpose of clarity the remainder of the protein is not shown here.  In the amino acid sequence of bovine 
SULT2A1, Phe247 and Ile89 is replaced by valine. The effect of these substitutions is shown above on the active site of human SULT1A1  (b). 
His108 is a critical residue in the active site. 
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3.9.4 Primary structure of bovine SULT1B1compared to that of human SULT1B1  
The human form of SULT1B1 was shown to be the major thyroid hormone 
sulfotransferase that has a higher affinity for tri-iodothyronine than SULT1A1. 
Along with thyroid hormone, the enzyme also metabolises other substrates such 
as tyrosine, dopamine and 4-nitrophenol. It has huge overlapping substrate 
specificity with SULT1A1. To date, no substrate exclusively metabolised by 
SULT1B1 has been discovere(Gamage et al., 2006). A sequence alignment analysis 
was carried out between human and bovine SULT1B1 (figure 32). Crystal 
structure of human SULT1B1 complexed with resveratrol was downloaded from 
protein data bank into the structural tool, DS visualizer (figure 33) and important 
residues in the active site were identified (highlighted in blue). All of them were 
found to be conserved between human and bovine. 
SULT1B1human      MLSPKDILRKDLKLVHGYPMTCAFASNWEKIEQFHSRPDDIVIATYPKSGTTWVSEIIDM 60 
SULT1B1cow        MTSPKDVLRKNLKLIHGCPITYAFANNWEKIEQFQSRPDDIMIVTYPKSGTTWISEIVDM 60 
                  * ****:***:***:** *:* ***.********:******:*.*********:***:** 
 
SULT1B1human      ILNDGDIEKCKRGFITEKVPMLEMTLPGLRTSGIEQLEKNPSPRIVKTHLPTDLLPKSFW 120 
SULT1B1cow        VLHDGDVEKCKRDVITAKVPMLELALPGLRTSGLEQLEKNPSPRVVKTHLPIDLIPKSFW 120 
                  :*:***:*****..** ******::********:**********:****** **:***** 
 
SULT1B1human      ENNCKMIYLARNAKDVSVSYYHFDLMNNLQPFPGTWEEYLEKFLTGKVAYGSWFTHVKNW 180 
SULT1B1cow        ENNCKIIYLARNAKDVAVSFYHFDLMNNLQPLPGTWGEYLEKFLTGNVAYGSWFNHVKSW 180 
                  *****:**********:**:***********:**** *********:*******.***.* 
 
SULT1B1human      WKKKEEHPILFLYYEDMKENPKEEIKKIIRFLEKNLNDEILDRIIHHTSFEVMKDNPLVN 240 
SULT1B1cow        WKKKEGHPILFLFYEDMKENPKQEIKKVVRFLEKNLDDEILDKIIYHTSFEMMKDNPLVN 240 
                  ***** ******:*********:****::*******:*****:**:*****:******** 
 
SULT1B1human      YTHLPTTVMDHSKSPFMRKGTAGDWKNYFTVAQNEKFDAIYETEMSKTALQFRTEI 296 
SULT1B1cow        YTHLPSEVMDHSKSSFMRKGIAGDWKNYFTVAQNEKFDAIYKKEMSETELQFRTEI 296 
                  *****: *******.***** ********************:.***:* ******* 
Figure 32: Multiple sequence alignment of SULT1B1 from human and 
bovine.  
The highlighted regions show important structural features. Residues 45-53 form 
the PBS loop which is involved in binding PAPS. Region highlighted in dark green is 
the KXXXTVXXXE motif that is involved in the dimerization of the protein. Upstream 
of this motif is the well conserved GXXGXXK motif that also plays a role in PAPS 
binding. Residues highlighted in blue are conserved in the active site of human and 
bovine SULT1B1. 
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Figure 33: Crystal structure of human SULT1B1 complexed with the co 
factor PAPS and the substrate resveratrol.  
The figure has been downloaded from protein data bank. www.pdb.org ID: 3CKL  
(To be published). The alpha helices are shown as red ribbons and β-sheets as 
turquoise strands.  Shown in yellow are the residues present in the active site of the 
protein.   
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3.10 Discussion 
In this chapter, bovine sulfotransferases were successfully cloned and expressed 
as recombinant proteins in an E. Coli expression system. Antibodies previously 
raised against human SULTs were used in the detection of the recombinant 
bovine SULTs. Amino acid sequence alignment of human and bovine SULTs was 
carried out to determine overall sequence identity and critical residues known to 
be involved in sulfation. Overall, a 60-80% sequence identity was noted between 
human SULTs and their corresponding bovine isoforms. Further to this, crystal 
structures of human SULT1A1, SULT1E1, SULT2A1, SULT1B1 and mouse Sult1e1 
complexed with PAPS/substrate were downloaded from protein data bank and 
analysed to try and identify the structural implications critical residue 
modifications could have on the recombinant bovine sulfotransferases. 
Radiolabelled enzyme assays using substrates established for activity with human 
SULTs were used for carrying out functional studies on recombinant bovine 
SULTs. Thus an effort was made to establish a relationship between the structural 
and functional characteristics of some of the major sulfotransferases implicated in 
drug metabolism in humans and cattle. 
Overall, the amount of bovine SULT immunoreactive protein detected using anti 
human SULT antibodies was less than the amount of human SULT 
immunoreactive protein detected using human SULT antibodies. Differences in 
primary amino acid sequence between human and bovine SULTs could mean that 
bovine SULT isoforms fold differently to that of human SULT isoforms such that 
anti human SULT antibodies do not bind as specifically to the bovine isoforms as 
they bind to the human ones. Results from structural analysis revealed that the 
PAPS binding loop (PBS) was conserved in all isoforms studied. The region known 
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to be involved in the dimerization of SULTs was also conserved in all except 
mouse Sult1e1 which is known to exist as a monomer in solution (Kakuta et al., 
1997). The substrate binding region of human and bovine SULTs was the one that 
was the most variable. In SULT1E1, phenylalanine at position 141 in the active 
site of the protein is conserved in human and mice. However, in the bovine 
enzyme it is replaced by a leucine. Phenylalanine contains an aromatic ring that 
contributes to the hydrophobic nature of the active site. In mouse Sult1e1 and in 
human SULT1E1 it is in a position to form van der Waals interactions with the 
substrate. Substitution with a leucine decreases the overall hydrophobicity of the 
active site and it is highly possible that this could affect substrate binding. 17β-
estradiol, the preferred substrate of SULT1E1 is usually sulfated in the low 
nanomolar range because of the high affinity that SULT1E1 has towards this 
substrate (Song and Melner, 2000). In this study, kinetic analysis of bovine 
SULT1E1 with 17β-estradiol revealed that the reaction had a Km of 2.3µM and was 
predominantly sulfated in the micromolar range. This could quite possibly be the 
result of Phe141Leu substitution.  
Of all the isoforms studied, SULT2A1 had the most variable substrate binding site. 
It was decided to study the following substitutions in detail as they were thought 
to be the most significant. Tyrosine at position 231 in human SULT2A1 is a very 
critical residue. In a substrate bound state this residue is involved in the 
stabilization of the enzyme substrate complex whereas in a non-bound state, the 
aromatic ring of Tyrosine orients itself away from the substrate binding region 
and plays a role in dimerization of SULT2A1(Rehse et al., 2002). It is also 
speculated that the hydroxyl group of tyrosine could form a hydrogen bond with 
the phosphate group of PAP, thus aiding the binding of PAPS (Rehse et al., 2002). 
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Replacement of tyrosine with phenylalanine means that there is no OH group 
available to interact with PAP. Also it remains to be established whether Phe231 
can perform the other two roles of Tyr231.  Apart from this, other substitutions in 
the active site of bovine SULT2A1 such as Ser235Lys and Val240Glu which 
introduce charged residues in the hydrophobic substrate binding pocket of 
bovine SULT2A1 could also have serious implications on the conformation of the 
active site and this in turn could affect substrate binding.  
One of the characteristics of human SULT1A1 is that it displays extensive 
substrate inhibition with small planar phenolic compounds. The crystal structure 
of SULT1A1 complexed with 4-nitrophenol and PAPS showed that it binds 2 
molecules of 4-nitrophenol (pNP1 and pNP2) in a catalytically competent manner 
in its active site and this is most likely responsible for substrate inhibition 
(Gamage et al., 2003). The hydroxyl group of pNP1 is hydrogen bonded to the side 
chains of His108 and Lys106 whereas the nitro group forms van der Waals 
interactions with Val148, Phe247 and Met248. On the other hand pNP2 binds 
weakly in to the active site with no interactions with the major catalytic residues. 
The aromatic ring of pNP2 slots between the side chains of Phe84 and Phe76 
whereas the nitro group forms van der Waals interactions with the side chains of 
Ile89 and Phe247 (Gamage et al., 2003). In bovine SULT1A1, Ile89 and Phe247 are 
substituted for valine. Valine although non polar like isoleucine and 
phenylalanine has a smaller and a non-aromatic side chain and will form lesser 
van der Waals interactions with pNP2. This means that pNP2 will not bind to the 
active site of bovine SULT1A1 as strongly as it binds to that of human SULT1A1. 
Substrate inhibition occurs when both pNP molecules bind to SULT1A1 and there 
is an impediment to catalysis. If pNP2 binds weakly to bovine SULT1A1 compared 
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to human SULT1A1, the profound substrate inhibition seen with human SULT1A1 
and 4-nitrophenol will not be observed with bovine SULT1A1. Indeed, kinetic 
analysis carried out in this chapter with recombinant bovine SULT1A1 using 4-
nitrophenol as a substrate showed reduced substrate inhibition in comparison to 
its human counterpart.  
The substrate binding site of bovine SULT1B1 was very well conserved with that 
of human SULT1B1. No major substitutions of critical residues in the active site 
were detected. Functional characteristics of recombinant bovine SULT1B1 
assessed using 4-nitrophenol and a battery of other phenolic substrates was not 
very different  (as compared to human SULT1A1 and bovine SULT1A1) to that of 
human SULT1B1 previously published (Riches et al., 2007)  (figure 18 and 19).  
In this chapter, strong correlation between the structural features and functional 
properties of bovine SULTs was established. Nevertheless in order to confirm our 
speculations with strong scientific evidence additional experiments need to be 
performed. For example side-directed mutagenesis of some of the above 
mentioned critical bovine SULT residues to their human counterpart followed by 
functional studies will prove useful in validating some of the above findings. 
 
 
 
 
 
128 
 
 
 
 
 
 
 
 
 
 
 
4. Characterisation of cytosolic 
Sulfotransferases in bovine liver 
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4.1 Introduction 
The pharmaceutical industry has always relied on the extrapolation of 
pharmacokinetic data from laboratory animals to humans and other larger 
animals to predict drug toxicity (Smith, 1984). As our knowledge of drug 
metabolising enzymes and drug transporters increases, the complexity of 
interspecies differences becomes evident and making such extrapolations to 
predict in vivo drug toxicity has the potential to be seriously flawed. Extrapolation 
of drug metabolising capabilities between animals of different species is more 
complicated than extrapolation of pharmacokinetic data from animals to human. 
This is because of the wide variety of species out there with diverse anatomical 
and physiological attributes than humans (Lin, 1998). In order to minimize 
human health risk due to ADRs in livestock species it is essential to deliver safer 
drugs to animals of the livestock species. This can in part be achieved by having a 
thorough understanding of drug metabolism in animals of the livestock species. 
Since many drugs in humans and several other species are eliminated from the 
body as sulfate conjugates, it becomes very necessary to study drug metabolism 
brought about by SULTs. Knowing the amount of SULTs expressed in drug 
metabolizing organs is helpful as it allows commercial software tools such as 
Simcyp (www.simcyp.com) to incorporate the quantification data in their 
databases to predict the in vivo fate of drugs. Immunochemical quantification of 
CYPs and SULTs has been done in the past in human liver (Riches et al., 2009; 
Shimada T, 1994). Due to lack of bovine SULT specific antibodies it was not 
possible to immunoquantify SULTs in the bovine liver. Instead we made use of 
enzyme assays and existing SULT specific antibodies against other species 
including humans that cross reacted with bovine SULTs to identify major SULT 
isoforms present in bovine liver.  
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In the following series of experiments we have attempted to study the major drug 
metabolising isoforms of sulfotransferases. We focussed our attention on to 
SULT1A1, SULT1B1, SULT1E1 and SULT2A1. Using antibodies successfully 
developed against human SULT isoforms by previous lab members we detected 
expression of each of the above isoforms in male and female bovine liver. 
Progestins are synthetic progesterones that are used for synchronisation of estrus 
in cattle either alone or in combination with estrogen (Patterson et al., 1989). In 
humans SULT1E1 expression in the endometrium is tightly regulated under the 
influence of progesterones (Falany and Falany, 1996b). To investigate the effect 
of progestins on bovine SULT isoforms, a comparison of expression and activity 
was made between untreated female livers and female livers treated with an 
exogenous progestin*. Substrates established for activity with human SULT 
isoforms were used to determine activity of the 4 major drug metabolising SULTs 
in cattle. Conditions were optimized for pH, PAPS concentration, buffer, and 
incubation time and protein concentration in each liver set and with every 
substrate used. This was done to ensure that subsequent kinetics was performed 
at optimal conditions. Overall, an attempt was made to identify major SULT 
isoforms in bovine liver and relate their expression to activity in order to assess 
the validity of the substrates used.  
4.2 Optimization of enzyme assay conditions  
In order to carry out kinetics at optimal conditions, it is important to optimize 
assay conditions for parameters that could affect enzyme activity. pH, 
concentration of non-radiolabelled PAPS, choice of buffer, incubation time and 
protein concentration were optimised with 4-nitrophenol (SULT1A1, 1B1), 17β-
                                                          
*
 Exogenous progestin: Identity of this drug is confidential to Pfizer.Inc 
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estradiol (SULT1E1) and pregnenolone (SULT2A1). Assay conditions in male 
bovine liver, female bovine liver (untreated) and female bovine liver (treated) 
were optimised separately with each substrate  (Table 30) because of the 
potential for each of the 3 bovine liver set to have a different expression profile.  
Bovine 
Liver 
cytosol Substrate pH 
PAPS  
(µM) Buffer 
time  
(min) 
protein  
(µg) 
male 4-nitrophenol 5.8 20 phosphate 30 15 
male 17β-estradiol 6.2 20 phosphate 30 30 
male pregnenolone 6.2 20 phosphate 30 30 
female   (UT) 4-nitrophenol 6.4 20 phosphate 15 30 
female   (UT) 17β-estradiol 6.2 20 phosphate 30 30 
female   (UT) pregnenolone 6.2 20 phosphate 30 30 
female   (T) 4-nitrophenol 6.4 20 phosphate 15 30 
female   (T) 17β-estradiol 6.2 20 phosphate 30 30 
female   (T) pregnenolone 6.2 20 phosphate 30 30 
 
Table 30: Summary of optimised conditions used in bovine liver enzyme 
assays 
Enzyme activity assays were optimised for pH, PAPS concentration, time protein and 
buffer for substrates listed above in male and female livers. UT stands for untreated 
female bovine liver and T for female bovine livers treated with an exogenous 
progestin. All male bovine livers used in this study were untreated.  
 
4.3 Detection of expression of SULT2A1 in bovine liver using anti 
human SULT2A1 antibody  
The hydroxysteroid sulfotransferase, SULT2A1 is commonly referred to as 
dehydroepiandrosterone  (DHEA) sulfotransferase since it preferentially 
metabolises DHEA despite having a broad substrate predilection with other 
steroids such as pregnenolone, estradiol, estrone, testosterone and androsterone 
(Falany, 1997; Falany et al., 1995a; Falany et al., 1994). In some species such as 
the mouse and rabbit, SULT2A1 has a greater propensity for other steroids such 
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as pregnenolone(Kouichi Yoshinari, 1998; Shimizu et al., 2003), hence labelling 
SULT2A1 as a DHEA SULT would be very arbitrary.  
SDS-PAGE gel electrophoresis was performed on 20 (male and female) bovine 
liver tissue cytosol samples of which 12 were female and 8 male. Of the 12 female 
bovine livers, 8 belonged to untreated females whereas the other 4 were from 
females treated with an exogenous progestin. All the 8 male livers were 
untreated. 8 untreated female and 8 male samples were analysed on the same gel  
(figure 34). Similarly, 8 untreated female and 4 treated female livers were also 
analysed on one gel (figure 36). This was done so that differences arising due to 
inter-gel or inter-blot variation can be minimised. Immunoblot analysis was 
carried out using anti human SULT2A1 antibody raised previously in our lab 
against purified recombinant human SULT2A1 (Richard et al., 2001).  Blots were 
scanned using a standard desktop scanner (Hewlett Packard) and the software 
package QuantiScan32 (Biosoft) was used to calculate the densitometric volume 
of bands. This was performed in a similar manner to that described in chapter 3. 
SULT2A1 was detected in both male and female bovine liver. A considerable 
amount of variation was seen in the expression of SULT2A1 in between samples. 
In order to determine if the expression of bSULT2A1 in male livers was 
significantly different from the female livers a 2 tailed t-test assuming unequal 
variance was carried out (Table 31). The average net band density of male bovine 
SULT2A1 was almost twice that of female bovine liver SULT2A1. Statistical 
analysis (t-tests) results showed that there was a significant difference in 
expression of bSULT2A1 in the male and female liver. On the other hand no 
significant difference was observed in bSULT2A1 expression in females as a result 
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of treatment with an exogenous progestin. All the western blots shown here in 
this chapter were repaeated several times.  
 
 
 
 
 
Figure 34: Bovine SULT2A1 expression in 8 untreated female and male 
livers.  
30µg of liver cytosol was loaded for every liver sample. a, b and c contains 5, 3 and 
1µg of  recombinant bSULT2A1 respectively.  
   
 
 
 
 
 
 
 
 
 
 
Figure 35: Net band density values as an indication of expression levels of 
bovine SULT2A1 in male and female bovine liver cytosol. 
Net band density values were calculated by quantifying the band density of the 
scanned western blots and subtracting it from a set background value. For more 
information on this refer to chapter 3. Shown above are the net band density values  
(bovine SULT2A1 expression) for the 8 untreated bovine male and bovine female liver 
samples.  
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Figure 36: Bovine SULT2A1 expression in 8 untreated female and 4 treated 
female livers.  
30µg of liver cytosol was loaded for every liver sample. a and b contains 3, 1 µg of  
recombinant bSULT2A1 respectively.  
 
 
 
 
 
 
 
 
 
 
Figure 37: Net band density values as an indication of expression levels of 
bovine SULT2A1 in untreated and treated female bovine liver cytosol. 
Shown above are the net band density values for bovine SULT2A1 expression in 8 
untreated female (1-8) and 4 treated female  (9-12) bovine liver samples.  
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Liver 
cytosol 
No of 
samples  
(n) 
Average 
net band 
densities 
Standard 
deviation P value Result 
Female  
(UT) 8 105200 73925 
0.56 
Null 
hypothesis 
accepted 
Female  
(T) 4 136260 86285 
Male  (UT) 8 119220 31550 
0.03 
Null 
hypothesis 
rejected 
Female  
(UT) 8 67090 51775 
 
Table 31: Expression levels  (average band densities) of bSULT2A1 in male 
and female bovine liver samples.  
UT= Untreated and T= Treated. Null hypothesis (Ho) =There is no difference in 
expression levels of bSULT2A1 between male and female or between female  (UT) 
and female  (T). A two tailed t-test assuming unequal variance was carried out. Null 
hypothesis was rejected if P < 0.05 
 
4.4 Analysis of bovine SULT activity towards pregnenolone in bovine 
liver samples 
SULT2A1 specifically metabolizes dehydroepiandrosterone (DHEA) in humans 
and several other species. Using anti human SULT2A1 antibodies, SULT2A1 was 
detected in the bovine liver however; activity towards DHEA was not seen. 
Pregnenolone is metabolised by both human SULT2A1 and SULT2B1. It was 
decided to see if there was any activity towards pregnenolone in the bovine livers.  
Kinetic studies were performed on pregnenolone sulfation in bovine livers using 
the optimized conditions listed in table 30. Substrate inhibition was observed in 
female bovine liver samples (figure 38 and 39) but not with male bovine liver 
samples (figure 40) which displayed Michaelis-Menten kinetics. Vmax and Km 
values were calculated for untreated female, treated female and male liver 
samples. No difference was seen in the Vmax and Km values between untreated and 
treated female livers (table 32) suggesting that probably the same set of enzyme 
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(s) were involved in pregnenolone metabolism in both. However, this cannot be 
said for pregnenolone metabolism in male bovine livers which had different 
kinetic properties to female bovine livers.  
Liver  
No of samples  
(n) 
Vmax  
(pmol/min/mg) 
Km  
(µM) Ki  (µM) 
Female  
(untreated) 8 39.8 ± 10.8 2.4 ± 1.2 12.4 ± 6.8 
Female  
(treated) 4 46.1 ± 35.3 4 ± 4.7 6.9 ± 8.3 
Male  
(untreated) 8 31 ± 2.1 1.5 ± 0.4 NA 
 
Table 32: Summary of kinetics with pregnenolone in bovine liver cytosol.  
Each assay was carried out in duplicate. Vmax, Km and Ki values ± standard error for 
the liver samples is shown.   
 
 
 
 
 
 
 
 
 
Figure 38: Enzyme kinetics of pregnenolone in untreated female bovine 
liver cytosol.  
Rate of formation of pregnenolone sulfate as a function of pregnenolone concentration 
in female (untreated) bovine liver cytosol. Data points are ± standard error. n=8 
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Figure 39: Enzyme kinetics of pregnenolone in treated female bovine liver 
cytosol 
Rate of formation of pregnenolone sulfate as a function of pregnenolone concentration 
in female (treated) bovine liver cytosol. Data points are ± standard error. n=4 
 
 
 
 
 
 
 
Figure 40: Enzyme kinetics of pregnenolone in male bovine liver cytosol 
Rate of formation of pregnenolone sulfate as a function of pregnenolone concentration 
in male bovine liver cytosol. Data points are ± standard error, n=8 
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4.5 Detection of expression of SULT1B1 in bovine liver using anti 
human SULT1B1 peptide antibody.  
SULT1B1, the major isoform of the SULT1B family and the second most abundant 
SULT1 enzyme present in human liver is known to have broad substrate 
specificity towards a range of phenolic compounds such as 4-nitrophenol, 2-
aminophenol and 1-naphthol. It has huge overlapping substrate specificities with 
SULT1A1, the major drug metabolising enzyme present in human liver (Riches et 
al., 2009). This makes finding an exclusive substrate to assess the activity of 
SULT1B1 in liver or other drug metabolising tissues extremely difficult. 4-
nitrophenol was used as a substrate of choice to probe SULT1B1 activity in bovine 
livers. Using anti-human SULT1A3 and anti-minipig SULT1A1 antibody raised 
against purified recombinant human SULT1A3 and minipig SULT1A1 
respectively, expression of SULT1A1 was not detected in any of the bovine livers. 
Lack of expression of SULT1A1 in bovine liver suggested that SULT1B1 could 
possibly be the major enzyme involved in 4-nitrophenol metabolism although 
there might be other SULT isoforms that contribute towards 4-nitrophenol 
metabolism in the bovine liver such as members of the SULT1C family (Tabrett 
and Coughtrie, 2003).  
SDS-PAGE gel electrophoresis was performed in a similar manner to that 
described earlier in this chapter. Immunoblot analysis was carried out using a 
multiple antigenic peptide (MAP) antibody raised against a specific unique 
sequence in human SULT1B1 (Riches et al., 2009).  The antibody was cleared 
against bovine serum proteins to reduce nonspecific binding. SULT1B1 was 
detected in both male as well as female livers with considerable amount of 
variation in each set of livers (figure 41). A difference as high as 30-fold was 
139 
 
 
observed between the untreated female livers and a 7 fold difference between 
bSULT1B1 expressions in male bovine liver was seen. Fold difference was 
calculated by subtracting the lowest value from the highest one and dividing it by 
the number of samples. On calculation of average band densities for male and 
female bovine livers, no significant sex difference was noted (figure 42). This was 
proved statistically using a 2-tailed t-test assuming unequal variance (table 33). 
Comparison of untreated and treated female bovine livers revealed a 32 fold 
difference between the untreated female livers and a 1.5 fold difference between 
the treated. Upon calculation of average band densities, it was found that average 
expression of SULT1B1 in the treated livers was 3 times lower than the average 
expression in the untreated livers (table 33). However, due to the high amount of 
variation seen in the two sets of female livers it would be inappropriate to link 
this finding to differential SULT1B1 expression between the untreated and 
treated livers especially in such a small sample size.  
 
 
 
Figure 41: SULT1B1 expression in bovine livers. 
 Bovine SULT1B1 expression in 8 untreated female and 8 untreated male livers. 30µg 
of liver cytosol was loaded for every liver sample. a contains 0.1 µg of  recombinant 
bovine SULT1B1.  
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Figure 42: Net band density values as an indicator of SULT1B1 expression in 
male and female bovine liver.  
Graph above shows the net band density values (bovine SULT1B1 expression) for the 
8 untreated male and female bovine liver samples. 
 
 
 
 
Figure 43: Bovine SULT1B1 expression in 8 untreated and 4 treated female 
livers.  
30µg of liver cytosol was loaded for every liver sample. a, b contains 0.2 µg and 
0.5µg of  recombinant bovine SULT1B1 respectively. 
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Figure 44: Net band density values as an indicator of SULT1B1 expression in 
untreated and treated female bovine liver. 
Net band density values for bovine SULT1B1 expression in 8 untreated female  (1-8) 
and 4 treated female  (9-12) bovine liver samples.  
 
Liver 
cytosol 
No of 
samples  
(n) Average 
Standard 
deviation P value Result 
Female  (UT) 8 113770 78910 
0.09 
Null 
hypothesis 
accepted Female  (T) 4 42170 51980 
Male  (UT) 8 56280 31800 
0.75 
Null 
hypothesis 
accepted Female  (UT) 8 63700 56950 
 
Table 33: Expression levels (average band densities) of bSULT1B1 in male 
and female bovine liver samples. 
 UT= Untreated and T= Treated. Null hypothesis (Ho) = There is no difference in 
expression levels of bSULT1B1 between male and female or between female (UT) 
and female  (T). A two tailed t-test assuming unequal variance was carried out. Null 
hypothesis was rejected if P < 0.05 
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4.6 Analysis of bovine SULT1B1 activity towards 4-nitrophenol in 
bovine liver samples 
Using conditions optimized in table 30, kinetic analysis was performed on male 
and female bovine livers using 4-nitrophenol as the substrate. Once again, the 
female bovine livers demonstrated partial substrate inhibition (figure 45 and 46) 
whereas the male livers followed Michaelis-Menten kinetics (figure 47). No 
significant difference was seen in the Vmax values between male and female livers. 
Considerable amount of variation was seen in activity towards 4-nitrophenol 
between female bovine livers as compared to their male counterpart. Given below 
is a table listing the Vmax, Km and Ki values for 4-nitrophenol in bovine liver tissue.  
Liver  
No of samples  
(n) 
Vmax  
(pmol/min/mg) Km  (µM) Ki  (µM) 
Female  
(untreated) 8 3071 ± 3601 
22.6 ± 31.4 4.8 ± 7.1 
Female  
(treated) 4 
1411  ± 903 6 ± 6 14  ± 15.5 
Male  
(untreated) 8 
3621 ± 236.7  12.9 ± 1.6 - 
 
Table 34: Summary of kinetics with 4-nitrophenol in bovine liver cytosol.  
Each assay was carried out in duplicate. Vmax, Km and Ki values ± standard error for 
the liver samples is shown.   
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Figure 45: Kinetics of 4-nitrophenol in female (untreated) bovine liver 
cytosol 
 Rate of formation of 4-nitrophenol sulfate as a function of 4-nitrophenol 
concentration in female (untreated) bovine liver cytosol. Data points are ± standard 
error. n =8 
 
 
 
 
 
 
 
Figure 46: Kinetics of 4-nitrophenol in female (treated) bovine liver cytosol 
Rate of formation of 4-nitrophenol sulfate as a function of 4-nitrophenol concentration 
in female (treated) bovine liver cytosol. Data points are ± standard error, n=4.  
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Figure 47: Kinetics of 4-nitrophenol in male bovine liver cytosol 
Rate of formation of 4-nitrophenol sulfate as a function of 4-nitrophenol concentration 
in male bovine liver cytosol. Data points are ± standard error, n=8. 
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4.7 Detection of expression of SULT1E1 in bovine liver using anti 
human SULT1E1 antibody.  
In humans, estrogen sulfotransferase (SULT1E1), unlike SULT1B1 or SULT1A1 is 
highly specific and almost exclusively metabolises its substrate 17β-estradiol in 
the nanomolar concentration range. Immunoblot analysis was carried out using 
anti-human SULT1E1 antibody raised against purified recombinant SULT1E1. The 
anti-human SULT1E1 used cross reacts with bSULT1B1 and bSULT1A1. Although 
all the 3 bands are distinguishable from each other on a western blot, 
desitometric scanning using QuantiScan becomes difficult. Since expression levels 
vary significantly between samples, it becomes difficult to load equal amounts of 
protein on the gel without compromising with the clarity of the western blot. For 
example loading 30µg of F10 instead of the 3µg that was actually loaded creates a 
strong band that smears into the adjacent lane thus making it difficult to see 
bSULT1E1 expression clearly. If different amount of protein is loaded per sample 
then making a fair comparison with desitometric scanning would not be possible. 
Hence it was decided to not analyse the bSULT1E1 blots using QuantiScan.  
 
 
Figure 48: Bovine SULT1E1 expression in 8 untreated female and male 
livers.  
Male livers M1-M8 and female livers are F1-F8. 30µg of liver cytosol was loaded for 
every liver sample except F1 (10µg) and F7 (5µg). * contains 0.1µg of recombinant 
bovine SULT1E1.  
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Expression of bSULT1E1 was clearly detected in some of the untreated female 
bovine livers such as F1 and F7 (figure 48). Expression was also detected in livers 
F2, F3, F4 and F5 but to a much lesser extent than F1 and F7. F1 and F7 were 
loaded at 10 and 5µg respectively compared to the rest that were loaded to a final 
concentration of 30 µg. Slight expression of bSULT1E1 was probably seen in some 
of the male livers such as M1, M2, M5 and M6. However, presence of multiple 
bands with higher intensity than the band of interest makes it difficult to have 
confidence in the expression of bSULT1E1 in the male liver.  
 
 
 
 
Figure 49: Bovine SULT1E1 expression in 8 untreated female and 4 treated 
female livers.  
30µg of liver cytosol was loaded for every liver sample except F1 (10µg), F7  (5µg) 
and F10  (3µg). a and b contains 0.5, 0.3 µg of recombinant bovine SULT1E1 
respectively. 
Within the treated female bovine livers, expression of bSULT1E1 was strongly 
detected in liver F10 (figure 49). Only 3µg of F10 was loaded to give rise to a 
strong band seen in figure 4.16. Slight expression was also detected in liver F11. 
Considerable amount of variation was seen in bSULT1E1 expression in the female 
liver, with expression only in livers F1, F2, F5 and F7.   
4.8 Analysis of bovine SULT1E1 activity towards 17β-estradiol in 
bovine liver samples 
Both male and female livers followed Michaelis-Menten kinetics for enzyme 
activity towards 17β-estradiol. Activity in the male liver was lower than the 
activity in female livers. A two-tailed t-test assuming unequal variance was 
  
Untreated Treated 
Female 
F1 F8 F9 F12 
F10 
 a b   
F7 F1 
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carried out (see figure 50) which supported this initial observation. Activity in 
female livers treated with the exogenous progestin had thrice as much activity 
towards 17β-estradiol as compared to the untreated bovine livers; however from 
table 36 it appears that liver F10 was alone responsible for the high level of 
activity seen with 17β-estradiol in treated female livers (see region highlighted in 
yellow in table 35). A two tailed t-test assuming unequal variance showed that the 
difference in activities of untreated and treated female livers was statistically 
insignificant. Variability in female livers ranged from 0.8-31 pmol/min/mg 
whereas those in male livers ranged from 0.8-1.8 pmol/min/mg (table 35). 
Individual analysis of activity led to the observation that only certain livers such 
as F10 > F1 and F7 had a high level of activity.  
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Table 35: Kinetics with 17β-estradiol as the substrate for each of the 20 
liver samples analysed individually.  
F1-F8 are the 8 untreated bovine liver samples. F9-F12 are 4 female bovine liver 
samples treated with an exogenous progestin. M1-M8 are the 8 male liver samples. All 
female (untreated), female (treated) and male bovine livers were also analysed 
together. Each assay was carried out in duplicate. Vmax, Km and Ki values ± standard 
error for each of the liver samples is shown.   
 
 
 
 
Liver 
Vmax 
 (pmol/min/mg) 
Km 
 (µM) 
F1 8.4 ± 0.5 0.03 ± 0.01 
F2 5.3 ± 2.8 0.8 ± 0.7 
F3 2.8 ± 0.2 0.05 ± 0.02 
F4 2.6 ± 0.3 0.1 ± 0.04 
F5 2.2 ± 0.13 0.03 ± 0.01 
F6 2.8 ± 0.14 0.1 ± 0.02 
F7 7.4 ± 0.4 0.03 ± 0.006 
F8 0.8 ± 0.1 0.02 ± 0.02 
F9 4.3 ± 2.4 0.6 ± 0.6 
F10 31 ± 1.4 0.14 ± 0.02 
F11 6 ± 1 0.4 ± 0.1 
F12 1.8 ± 0.6 0.2 ± 0.2 
M1 0.8 ± 0.2 0.2 ± 0.1 
M2 2.1 ± 0.2 0.1 ± 0.02 
M3 0.4 ± 0.1 0.07 ± 0.04 
M4 0.4 ± 0.1 0.05 ± 0.03 
M5 1.3 ± 0.12 0.05 ± 0.02 
M6 1.1 ± 0.14 0.05 ± 0.02 
M7 1.8 ± 0.6 0.4 ± 0.2 
M8 1.7 ± 0.05 0.1 ± 0.007 
Female  
(untreated) 
n=8 4 ± 0.5 0.04 ± 0.02 
 
Female  
(treated) 
n=4 11 ± 4.7 0.2 ± 0.2 
 
Male  
(untreated) 
n=8 1.2 ± 0.2 0.08 ± 0.05 
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Figure 50: Activity towards 17β-estradiol in male and female bovine livers. 
Scatter plot showing distribution of Vmax for each of the livers. UT= Untreated and 
T= Treated. Null hypothesis (Ho) = There is no difference in the activity towards 17β-
estradiol between male and female livers. A two tailed t-test assuming unequal 
variance was carried out. Null hypothesis was rejected if P < 0.05. 
Liver 
cytosol 
No of 
samples  
(n) 
Average 
Vmax  
(pmol/min/mg) STDEV 
T-test 
unequal 
variance Result 
Female  
(UT) 8 4.03 2.70 0.40 
Null hypothesis 
accepted 
Female  (T) 4 10.78 13.59 
Male  (UT) 8 1.20 0.64 
0.02 Null hypothesis 
rejected 
Female  
(UT) 8 4.03 2.70 
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Figure 51: Kinetics of 17β-estradiol in male bovine liver cytosol 
Rate of formation of 17β-estradiol sulfate as a function of 17β-estradiol concentration 
in male bovine liver cytosol. Data points are ± standard error, n=8. 
 
 
 
 
 
 
 
Figure 52: Kinetics of 17β-estradiol in female (treated) bovine liver cytosol 
Rate of formation of 17β-estradiol sulfate as a function of 17β-estradiol concentration 
in female (treated) bovine liver cytosol. Data points are ± standard error, n=4. 
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Figure 53: Kinetics of 17β-estradiol in female  (untreated) bovine liver 
cytosol 
Rate of formation of 17β-estradiol sulfate as a function of 17β-estradiol concentration 
in female  (untreated) bovine liver cytosol. Data points are ± standard error, n=8. 
 
4.9 Substrate specificity profiling with bovine liver 
Comparison of sulfation between the 3 different categories of livers might provide 
useful insights in SULTs that might be involved in sulfation in male and female 
bovine livers. A substrate screen using a battery of xenobiotic compounds  
(mostly phenolic compounds given their compatibility with [35S] assay) was 
carried out on male and female bovine liver cytosol. The compounds chosen to be 
screened were selected on the basis of activity seen with the compounds in 
human liver cytosol. The same assay conditions were applied to both male and 
female livers. Activity assays were performed using the same optimised 
conditions that were applied to kinetic reactions (table 30). Male bovine livers 
were better at sulfation compared to the female livers (figure 54 and 55). Male 
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bovine livers had twice as much activity towards most of the substrates compared 
to the female livers. Substrates such as paracetamol, dobutamine and 
apomorphine were not metabolised in both sets of livers. No significant difference 
was observed in bovine female livers treated with an exogenous progestin as 
compared to the untreated ones (figure 55 and 56). Rate of sulfation of 4-
nitrophenol and 2-aminophenol in the male bovine liver was almost similar 
However, in the female liver, both treated and untreated rate of 2-aminophenol 
sulfation was twice as much as that of 4-nitrophenol sulfation.  
 
Figure 54: Substrate specificity profiling in bovine male liver cytosol using 
phenolic substrates 
 A battery of phenolic substrates was screened for activity in 30µg of bovine male liver 
cytosol using the [ 
35
S] PAPS assay. The substrates were used at 1, 10 and 100µM 
concentrations.  
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Figure 55: Substrate specificity profiling in bovine female  (untreated) liver 
cytosol using phenolic substrates 
A battery of phenolic substrates was screened for activity in 30µg of bovine female 
liver  (untreated) cytosol using the [
35
S] PAPS assay. The substrates were used at 1, 10 
and 100µM concentrations.  
 
 
Figure 56: Substrate specificity profiling in bovine female  (treated) liver 
cytosol using phenolic substrates 
A battery of phenolic substrates was screened for activity in 30µg of bovine female 
liver  (treated) cytosol using the [
35
S] PAPS assay. The substrates were used at 1, 10 
and 100µM concentrations. 
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4.10 Discussion  
The ability to reliably predict the in vivo fate of drugs in livestock would be of 
considerable value to the pharmaceutical, livestock industry as well as the 
regulatory bodies. Since sulfation is considered to be one of the major drug and 
xenobiotic clearance pathway in humans and other species it is important to 
understand drug metabolism brought about by sulfotransferases in the liver 
which is the prime organ involved in drug metabolism. In this chapter, expression 
and activity of 4 major drug metabolising isoforms namely SULT1B1, SULT1E1, 
SULT2A1 and SULT1A1 have been investigated. Substantial variation in 
expression was noted among bovine livers for all the isoforms studied. Variation 
in expression was especially high for female bovine livers compared to the male. 
A significant sex difference was seen in bovine SULT2A1 expression in liver but 
no difference was noted in activity towards pregnenolone.  
4.10.1 Presence of SULT1A1 and SULT1B1 in bovine liver 
Although metabolised by SULT1B1, 2-aminophenol is a more specific substrate 
for human SULT1A1. It has a higher Vmax and a lower Km for SULT1A1(Riches et 
al., 2007). 2-aminophenol has a much higher intrinsic clearance value with 
SULT1A1 compared to SULT1B1 suggesting that in cytosol where many other 
SULTs are present, 2-aminophenol sulfation measured would be predominantly 
due to SULT1A1 activity. It was also shown that in human liver cytosol where 
both SULT1B1 and SULT1A1 are present SULT1B1 had a greater influence in 
sulfating 4-nitrophenol than compared to 2-aminophenol (Riches et al., 2007). 
Results from the substrate screen here showed that 2-aminophenol was 
metabolised twice as much as 4-nitrophenol in the female liver. In the bovine 
male liver, no significant difference was observed in the sulfation of the two 
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substrates. Moreover, kinetic studies carried out in the previous chapter on 
recombinant bovine SULT1A1 and SULT1B1 with 4-nitrophenol as the substrate 
showed that bovine SULT1A1 underwent partial substrate inhibition whereas 
SULT1B1 followed Michaelis-Menten kinetics. Male bovine liver cytosol also 
demonstrated Michaelis-Menten kinetics with similar Vmax values and kinetics of 
4-nitrophenol with female bovine liver cytosol demonstrated partial substrate 
inhibition. Activity data analysis indicates that probably SULT1A1 is the major 
drug metabolising enzyme present in the female bovine liver whereas SULT1B1 
might be the major one in the male bovine livers. Immunoblot analysis carried out 
with anti-human SULT1A3 and anti-minipig SULT1A1 antibody have not been 
able to detect the presence of the SULT1A1 isoform in the male and female liver. 
Bovine SULT1B1 was detected in both the sexes using anti human SULT1B1 
peptide antibody. There is a lot of sequence similarity between the human, 
minipig and bovine SULT proteins. Although the antibodies used cross react with 
bovine SULTs, they might not be as sensitive to SULT expression in cattle as 
compared to their own SULT isoforms. In such a case it is difficult to correlate 
expression with activity. Development of bovine SULT isoform specific antibodies 
might provide deeper insights into expression of SULT1A1 and SULT1B1 in the 
bovine liver.  
4.10.2 SULT1E1 in bovine liver 
 17β-estradiol is known to be a good probe substrate for SULT1E1 since it is 
highly specific for 17β-estradiol in the nanomolar concentration range found in 
physiological conditions (Kester et al., 1999b; Song and Melner, 2000). Other 
SULT isoforms such as SULT1A1 and SULT1B1 also metabolise 17β-estradiol but 
do so in the micromolar range (Kester et al., 1999b) . SULT1E1 is expressed in the 
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endometrium in humans where it is known to regulate estrogen action during the 
menstrual cycle, possibly under the influence of progesterone (Rubin et al., 1999). 
Hormones and other factors such as environmental pollutants like 
polychlorinated biphenyls which inhibit SULT1E1 activity (Kester MHA, 2000) 
and bring about endocrine disrupting effects (Safe, 1994)  might be responsible 
for the variation seen in its expression in female liver. Clear sex related 
differences were noted in the expression and activity of SULT1E1 in bovine liver. 
However, like other SULTs it was not possible to analyse the western blots for 
band density using QuantiScan. Although highly variable, female liver had a 
higher overall expression of SULT1E1 compared to the males. This is opposite to 
what has been observed in rat and mice where SULT1E1 expression is also 
sexually dimorphic but more prominent in sexually mature and competent males 
(Demyan WF, 1992; Song W-C, 1997). In humans, SULT1E1 expression is the 
greatest in fetal development and decreases with age. The expression was also 
found to be highest in foetuses of the male gender (Duanmu et al., 2006) . It is 
quite possible that high levels of SULT1E1 in immature males are responsible for 
the inactivation of estrogens, thereby increasing androgen intensity during 
gonadal organogenesis and a  lack of SULT1E1 expression in the mature bovine 
male liver is matter of age (Duanmu et al., 2006)  
4.10.3 SULT2A1 in bovine liver 
Expression of SULT2A1 was detected in both male as well as female bovine liver 
using anti human SULT2A1 antibody. However, activity towards DHEA, its probe 
substrate was not detected in the bovine liver. Structural studies on human 
SULT2A1 proposed that Met137 was responsible for the regulation of binding 
orientation of DHEA (Lu-Yi Lu, 2007). In bovine SULT2A1, Met137 is replaced by 
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alanine (chapter 3). It is quite possible that the substitution might affect DHEA 
binding in cattle SULT2A1. SULT2A1 also turns over pregnenolone (Fuda et al., 
2002). This was used to assess SULT2A1 activity in the bovine liver. Expression of 
SULT2A1 in bovine male liver was twice as much as the female liver. However, no 
major difference in activity was noted. Sex related differences in SULT2A1 
expression have also been observed in rat liver where females had higher 
expression levels than males (Rajkowski et al., 1997). SULT2A1 expression in rats 
is also age dependent being very high during fetal development where the liver is 
more androgen insensitive The expression levels drop in mature rats as the liver 
becomes more androgen sensitive (Roy, 1992a). The kinetics of sulfation of 
pregnenolone found in the bovine male liver was distinct from that in the female 
liver. Strong substrate inhibition was seen in the female liver but not in the male 
liver indicating that different enzymes or set of enzymes is involved in 
pregnenolone metabolism in bovine liver. Pregnenolone in the human liver is also 
metabolised by SULT2B1 (Fuda et al., 2002). The gene encoding bovine SULT2B1 
is present in cattle liver (Zimin et al., 2009) but the presence of bovine SULT2B1 
in the bovine liver has not yet been established, however a possibility of its 
existence remains. 
4.10.4 Conclusion 
Although human SULT antibodies used in this study cross reacted with the bovine 
SULT proteins, they do not bind as specifically and strongly as they would to 
human SULT proteins. Hence expression and activity of bovine SULTs should be 
compared with caution. In some cases where expression was not seen activity 
was still detected. For example expression of bSULT2A1 was not detected in F1 
and F3 however activity was still found. Except for 17β-estradiol which is highly 
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specific for SULT1E1 in the nanomolar range, most of the substrates used in this 
study were not exclusively metabolised by their respective isoforms. In humans 
and rat pregnenolone is extensively metabolised by SULT2B1 (Fuda et al., 2002) 
and 4-nitrophenol is turned over by several different members of the SULT1 
family (Tabrett and Coughtrie, 2003) and hence the two are not ideal substrates 
for studying SULT2A1 and SULT1B1 metabolism in bovine liver. Pregnenolone 
was used because DHEA, the human probe substrate for SULT2A1, is not 
metabolised by the liver or recombinant bovine SULT2A1. SULT1B1 metabolises 
the majority of the substrates turned over by SULT1A1. To date no known probe 
substrate that is exclusively turned over by SULT1B1 has been discovered. In the 
future to study drug metabolism brought about in the liver or any other drug 
metabolising tissue by SULTs it would be advantageous to have anti bovine SULT 
antibodies and probe substrates that would be exclusively turned over by their 
respective SULT isoforms (Roy, 1992a).  
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5 Conjugative metabolism of 
estradiol in vitro  
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5.1 Introduction 
Estrogens influence the growth, differentiation and functioning of target tissues 
such as the breast, ovaries, testis and prostate. They are produced in both male 
and female reproductive organs from where they rapidly diffuse in and out of the 
cells. They are retained in target cells by binding with high affinity to intracellular 
estrogen receptors (ER). Binding of estrogen causes the ER to undergo a 
conformational change which then binds to the chromatin to modulate 
transcription of target genes (Raftogianis et al., 2000). 17β-estradiol is the 
biologically active form of estrogen found endogenously. It is also a very potent 
stimulator of the ER. 17β-estradiol has been used clinically in the treatment of 
hormonal disorders in women especially in hormone replacement therapy 
(Raftogianis et al., 2000). In livestock it is used for growth promotion, improving 
feed efficiency and also in estrus synchronisation. 17β-estradiol is usually 
administered as a pro drug; estradiol benzoate. Studies have shown that estradiol 
benzoate is rapidly converted to 17β-estradiol at the site of injection or in blood. 
In ruminants, 17β-estradiol is converted to estrone and then to 17α-estradiol in a 
series of oxidation reduction reactions. The 17α-estradiol is then subsequently 
conjugated (Dunn, 1977). Subcutaneous implants at the rear side of the ear are 
the preferred route of application of steroid hormones since dose delivered over a 
period of time can be controlled by altering the implant matrix properties. 
Desired anabolic results can be achieved and at the same time accumulation of 
high amounts of unwanted residues in edible tissues can be avoided by using this 
route of administration. Estrogen is a requirement to elicit growth response 
hence all steroid compounds such as testosterone and androsterone used 
commercially are usually given with an estrogenic compound (Maume et al., 
2001). Due to the carcinogenic potential of these steroid hormones including 
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estradiol, their use as growth promoting agents is banned in the EU. However, 
their use is still legal in some nations like the USA, Australia and New Zealand. 
However, this is subject to strict regulation on the amount of these residues 
present in edible tissues such that residues of estradiol are permitted only in the 
parts per trillion range (Wayne, 1986) . A considerable amount of information is 
available on estrogen metabolites in reproductive tissues but very little on edible 
tissues in animals (Mellin and Erb, 1965; Velle, 1963). In order to ensure human 
food safety of animal derived food products, it is necessary for the pharmaceutical 
industry to obtain information on the metabolism of estradiol. In order to do so it 
must develop in vitro model systems that can reliably predict in vivo metabolism 
in target species. The aims of the following series of experiments were to evaluate 
microsomes, cytosol and cryopreserved bovine hepatocytes as in vitro models for 
studying the phase 2 metabolism of 17β/α-estradiol and compare results to 
existing data available on in vivo metabolism of estradiol.  
5.2 Strategy adopted 
Conjugative metabolism of 17β-estradiol and 17α-estradiol brought about by 
glucuronidation and sulfation were studied in the above mentioned model 
systems using Ultra Performance Liquid Chromatography coupled to tandem 
mass spectrometry (UPLC-MS/MS). Chromatographic conditions were optimized 
for internal standards (figure 57) and standard metabolites used (Figure 58). 
17β/α-estradiol was incubated with microsome, cytosol and hepatocyte 
preparations at 37°C with the appropriate reagents and the samples were 
subsequently run on a UPLC-MS/MS platform along with the standard 
metabolites and internal standards. Identification of metabolites generated in the 
test samples was done based on similar retention times with the available 
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standards. After time and protein concentration optimization, kinetics was 
performed wherever possible, on the detected metabolites.  
 
 
 
 
 
 
Figure 57: Chemical structures and molecular weight of internal standards 
used  
 
5.3 Use of an Internal Standard 
An internal standard is a compound that is added in equal quantities to the blank, 
calibration standards and the sample. This is essential for the normalization of 
analyte signal to the internal standard signal. Plotting the ratio of analyte signal to 
the internal standard signal as a function of analyte concentration in the 
standards allows for quantification of the analyte in the standard. Use of an 
appropriate internal standard controls for variability in extraction, HPLC injection 
and ionization between samples and allows for differentiation of two standard 
points at the lower end of the curve that would have generated a nearly identical 
signal.  
An ideal internal standard is a compound that closely resembles the chemical 
species to be quantified in a sample such that the effects of sample preparation 
and analysis should be the same for the internal standard as well as the analyte of 
7- hydroxycoumarin-sulfate  
(7OHCS) MW; 242.21 
7-hydroxycoumarin-glucuronide 
 (7OHCG) MW; 338.27                   
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interest. However, the internal standard should have a retention time that is 
sufficiently different to be distinguished by the instrument used.  
7-hydroxycoumarin-sulfate for sulfation reactions and 7-hydroxycoumarin-
glucuronide were used as internal standards in this study. They were chosen 
because they ionized in negative mode as the analyte and had a retention time 
that was distinguishable from the analyte of interest.  
5.4 Choice of metabolite standards 
The standards were chosen such that they represent the metabolites expected to 
be formed in vitro. At positions 3 and 17 the carbon atoms in 17β/α-estradiol are 
bonded to hydroxyl group (OH). It is easier to deprotonate the hydroxyl group 
than it is to remove hydrogen from the hydrocarbon backbone of estradiol to 
allow for conjugation. This is in agreement with the literature where most of the 
conjugative metabolites of estradiol in various species and tissues were 
sulfated/glucuronidated at 3 and/or 17 position (Dunn, 1977; Maume et al., 
2001). The standard metabolites would be subjected to the same 
chromatographic conditions as the test sample and hence would have a 
chromatographic profile that is similar to the metabolites in the test samples. 
These metabolite standards would then be used for quantifying unknown 
metabolites in the test samples based on similarity of retention time (RT).  
The only difference between 17β-estradiol and 17α-estradiol is in the orientation 
of the 17 OH group. It was assumed that this difference was too minor to affect 
the chromatographic properties of the diastereoisomers and hence will not affect 
the RT time of its resultant metabolites It is for this reason that 17β-estradiol 
metabolite standards were used for studying 17α-estradiol metabolism.  
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Figure 58: Conversion of 17β-estradiol to form 17α-estradiol and its 
conjugates.  
17β-estradiol can also be directly conjugated to sulfate and or glucuronic acid 
groups. Shown in this diagram are the chemical structures of 17β-estradiol-3-
sulfate, 17β-estradiol-3-glucuronide and 17β-estradiol-17-glucuronide used as 
metabolite standards for the identification and quantification of 17β/α-estradiol  
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5.5 Optimization of chromatographic conditions for the detection of 
metabolites of estradiol 
 
 Metabolite standards of 17β-estradiol-3-glucuronide (E3G), 17β-estradiol-17-
glucuronide (E17G), and 17β-estradiol-3-sulfate  (E3S) were spiked in phosphate 
buffer and loaded onto an appropriately chosen UPLC column. Conditions that 
resulted in the formation of clear distinct peaks of E3G, E17G, E3S and allowed 
the separation of metabolite standards from each other and their internal 
standard were chosen. E3G and E17G were separated on an acquity UPLC HSS T3; 
1.8µm column using a 0.1% formic acid: acetonitrile (10 to 70%) gradient. E3G 
eluted before E17G at retention time of 2.56 and 2.75 respectively (figure 59). For 
17β-estradiol reactions a single peak corresponding to the formation of E3G was 
seen at a retention time of 2.56 min. For 17α-estradiol reactions a single peak 
corresponding to 17α-estradiol-17-glucuronide was detected at a retention time 
of 2.72 min. For sulfation reactions, the metabolites in samples had a very low 
signal intensity and poor chromatography. After stopping the reaction with 
acetonitrile, the samples were centrifuged at a high speed in order to pellet the 
cytosol that could clog the column and interfere with the results. The supernatant 
containing acetonitrile was dried in a nitrogen dryer and resuspended in 0.1% 
aqueous formic acid before injecting it on to an Acquity UPLC BEH shield RP18; 
1.7µm column. The internal standard 7-hydroxycoumarin sulfate elutes before 
the only metabolite E3S detected at a retention time of 2.01 min. The signal 
intensity observed is much lower than what was seen for glucuronidation 
reactions.  (figure 60).    
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Figure 59: Chromatogram showing the separation of metabolite standards 
of 17β-estradiol. 
 17β-estradiol-3-glucuronide and 17β-estradiol-17-glucuronide at retention times  
(RT) 2.56 and 2.75 respectively.  
 
 
 
 
 
 
 
 
 
 
Figure 60: Chromatogram showing the detection of sulfate metabolites of 
17β-estradiol and 7-hydroxycoumarin.  
 17β-estradiol-3-sulfate had a retention time of 2.01 min in bovine liver cytosol 
incubated with 17β-estradiol. The internal standard 7-hydroxycoumarin-sulfate 
elutes at 1min.  
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5.6 Rate of formation of 17β-estradiol-3-glucuronide in bovine liver 
microsomes 
 
17β-estradiol was solubilized in 100% DMSO and serially diluted such that the 
final concentration of DMSO in the assay was at 5%. A study carried out by Dehal 
et al showed no significant change in activity of major UGT isoforms at 5% DMSO.  
(http://www.bdj.co.jp/gentest/articles/hkdqj2000001c8mr-att/Poster5-
3_UGT_org_sol.pdf )  A sample prepared by pooling 8 male liver microsomes (BD 
Gentest, 20mg/ml) was used for detection of 17β-estradiol metabolites followed 
by optimization of assay conditions. Assay conditions were optimized for 
incubation time and protein concentration prior to carrying out kinetic reactions 
for the metabolites formed. For these optimization reactions, formation of the 
metabolite was plotted against incubation time and protein concentration and 
only values that fell within the linear part of the curve were chosen. For protein 
optimization assays, protein concentration that consumed less than 10 % of the 
overall substrate present was used. All this was done to avoid performing kinetic 
reactions at saturating conditions. Standards contained a mixture of 17β-
estradiol-3-glucuronide and 17β-estradiol-17-glucuronide at known 
concentrations. All incubations were carried out at 37°C in a 96 well plate. 
Reactions were started by the addition of UDPGA. UDPGA was not added to 
control wells. The metabolite production in the control sample was subtracted 
from metabolite production in the test samples. This was done to correct for any 
glucuronidation occurring due to the presence of some inherent UDPGA in bovine 
liver microsomes.  
The Vmax and the Km (figure 61) were calculated by fitting the curve to Michaelis-
Menten equation using GraphPad Prizm software. The Michaelis-Menten model of 
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single substrate reaction is based on the knowledge that enzyme catalysed 
reactions are saturable. The initial rate of reaction measured over a range of 
substrate concentration increases with increasing substrate concentration. 
However, as the active sites on the enzyme become saturated with the substrate, 
the rate of reaction becomes steady as it reaches a maximum called Vmax.  UGTs 
that catalyse glucuronidation reactions are high capacity enzymes. This explains 
the high velocity and Vmax value seen.  A low Km value for the reaction indicates 
that the UGTs responsible for the formation of 17β-estradiol-3-glucuronide are 
indeed very efficient. On one hand, the formation of 17β-estradiol-3-glucuronide 
was noted to be a very efficient process that reached saturation levels very 
quickly, whereas on the other hand formation of 17β-estradiol-17-glucuronide 
was almost negligible.  
 
 
 
 
 
 
 
Figure 61: Kinetics of formation of 17β-estradiol-glucuronide in bovine 
male liver microsomes.  
Rate of formation of 17β-estradiol-3 glucuronide as a function of 17β-estradiol 
activity in a pool of 8 male bovine liver microsomes at 0.05mg/ml-pH 7.4. The rate 
of reaction had a Vmax of 3118 ± 159 pmol/min/mg and a Km of 2.4 ± 0.7µM. Each 
assay was carried out in triplicate in a 96 well plate. Data points are average values 
of each assay that was carried out in triplicates ± standard error.  
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5.7 Rate of formation of 17α-estradiol-17-glucuronide in bovine liver 
microsomes.  
 
Microsome incubations were carried out in a similar manner as 17β-estradiol 
incubations using 17β-estradiol-3-glucuronide and 17β-estradiol-17-glucuronide 
as standards. As opposed to glucuronidation of 17β-estradiol that produces 17β-
estradiol-3-glucuronide, glucuronidation of 17α-estradiol produces the 17α-
estradiol-17-glucuronide. Formation of the 3-glucuronide was not detected. 
Kinetics on the formation of 17α-estradiol-17-glucuronide was carried out in a 
substrate concentration range of 0-100 µM (figure 62). To get an accurate 
estimation of Vmax and Km, kinetic experiments are generally performed in a 
substrate range that encompasses the linear part of the curve where substrate 
concentration is directly proportional to the rate of metabolite formation and the 
part of the curve where increase in substrate concentration does not result in 
increase or causes inhibition of enzyme activity i.e. where saturation /inhibition 
occurs. It was not possible to achieve that in this case because of the solubility 
issues. 17α-estradiol was harder to solubilize compared to its β counterpart. It 
was used at a final concentration of 5% DMSO in the assay. Going above the 
substrate concentration of 100µM would mean using a higher percentage of 
DMSO to get 17α-estradiol completely in solution. It was thought that using a 
higher percentage of DMSO could have unforeseeable adverse effects on the 
activity of UGTs responsible for estradiol glucuronidation. The rate of formation 
of 17α-estradiol-17-glucuronide had a very high Km and a low Vmax meaning that 
it was less efficient compared to its 17β-estradiol counterpart.  
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Figure 62: Kinetics of formation of 17α-estradiol-glucuronide in bovine 
male liver microsomes. 
Rate of formation of 17α-estradiol-17glucuronide as a function of 17α-estradiol 
activity in a pool of 8 male bovine liver microsomes at 0.05mg/ml-pH 7.4. The rate 
of reaction had a Vmax of 79 ± 17 pmol/min/mg and a Km of 252 ± 71µM. Each assay 
was carried out in triplicate in a 96 well plate. Data points are average values of 
each assay that was carried out in triplicates ± standard error.  
 
5.8 Rate of formation of 17β-estradiol-3-sulfate in female bovine 
liver S9 
Negligible amount of sulfation was observed in the male bovine liver cytosol. The 
level of metabolite formation was too low for carrying out kinetics. S9 fraction 
from bovine female liver was found to produce 17β-estradiol-3-sulfate at levels 
that allowed quantitation. Hence it was decided to use bovine female liver S9 for 
kinetics. The S9 fraction is a supernatant fraction obtained by centrifuging an 
organ (usually liver) homogenate in a suitable medium at 9000g for 20 min. This 
fraction contains an entire set of drug metabolizing enzymes in the cytosol  
(Sulfotransferses) and microsomal  (Cytochrome P450 and UGTs) components. 
No sulfate metabolites of 17α-estradiol were detected.  
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The formation of 17β-estradiol-3-sulfate has a Vmax of 1.9 pmol/min/mg, a Km of 
22.5nM and a inhibition constant, Ki of 246nM. These were calculated by fitting 
the values to a partial substrate inhibition curve since substrate inhibition was 
observed at concentrations above 0.1µM (figure 63). A low Km is indicative of the 
high affinity that SULTs have towards their substrates. Low Km (nM range) values 
for 17β-estradiol sulfation in liver cytosol has been observed in humans (Kester 
et al., 1999b; Song and Melner, 2000) 
 
 
 
 
 
 
 
 
 
Figure 63: Kinetics of formation of 17β-estradiol-sulfate in bovine female 
liver S9.   
Rate of formation of 17β-estradiol-3-sulfate as a function of 17β-estradiol activity in 
bovine female liver S9. The rate of reaction had a Vmax of 1.9 ± 0.1 pmol/min/mg 
and a Km of 0.02 ± 0.003 µM. Ki was 0.25 ± 0.03 Each assay was carried out in 
triplicate in a 96 well plate. Data points are average values of each assay that was 
carried out in triplicates ± standard error.   
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 Table 36: Summary of rate of formation of Estradiol metabolites in bovine 
liver in vitro.  
Kinetics was carried out on a pool of 8 bovine male liver microsomes for 
glucuronidation reactions and on bovine female liver S9 for sulfation reactions. 
Each assay was carried out in triplicate in a 96 well plate. Values obtained are 
average of the triplicates ± standard error. 
 
5.9 Species and sex differences in the sulfation of 17β-estradiol from 
liver cytosol and S9 fraction. 
In order to see how sulfation of 17β-estradiol in other species related to that in 
cattle, it was decided to perform a qualitative analysis on cytosol and S9 obtained 
from the liver of different species and sex  (where possible). Assays were carried 
out using 5, 50 and 500nM concentrations of 17β-estradiol (figure 64 and 65). 
These concentrations were chosen based on a literature search which revealed 
that humans sulfate 17β-estradiol  in the nanomolar range (Kester et al., 1999b). 
Overall, sulfation in S9 had lower velocity values compared to that in cytosol. S9 
fraction contains a diluted pool of sulfotransferases as opposed to cytosol, hence 
the difference. Cat liver extensively sulfated 17β-estradiol as seen in cytosol and 
S9. It is known that due to the absence of certain UGT enzymes such as UGT1A6, 
the cat family cannot perform certain glucuronidation reactions (Court MH, 
2000). It is quite possible that they heavily depend on sulfation for metabolism of 
Metabolite Source 
Vmax  
(pmol/min/mg) 
Km  
(µM) Ki (µM) 
17β-estradiol-
3-glucuronide 
Bovine male 
liver microsmes  
(pool) 3118 ± 159 2.4 ± 0.7 N/A 
17α-estradiol-
17-glucuronide 
Bovine male 
liver microsmes  
(pool) 79 ± 17 252 ± 71 N/A 
17β-estradiol-
3-sulfate 
Bovine female 
liver S9 1.9 ± 0.1 
0.02 ± 
0.003 
0.25 ± 
0.03 
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xenobiotic compounds. However this assumption is entirely speculative. Minor 
differences were noted in the cytosolic sulfation of 17β-estradiol in male and 
female cats. No significant sulfation was observed in dog liver and male bovine 
liver in both cytosol and S9. Sex related differences were seen in rat liver cytosol 
and bovine liver S9. Expression of estrogen sulfotransferase in rats is known to be 
regulated in an age and sex specific manner where young male rats have a higher 
expression of the enzyme compared to the female rats (Demyan WF, 1992; Song 
W-C, 1997). This is in agreement with what has been observed here where the 
activity in the male rat liver cytosol is much higher than the female rat liver 
cytosol due to higher expression levels of estrogen sulfotransferase in the male 
rat. Substrate inhibition at increased 17β-estradiol concentration was observed 
only with the bovine female liver S9 and the bovine male liver cytosol. Substrate 
inhibition of estrogen sulfotransferase  has also been reported in the male rat 
liver with  concentration of 17β-estradiol above 1µm (Falany et al., 1995c)  
 
 Figure 64: 17β-estradiol sulfation in liver cytosol across different species 
and sex  
Formation of 17β-estradiol-3- sulfate as a function of 17β-estradiol activity at 5, 50 
and 500nM in liver cytosol from different species and sex. 
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Figure 65: 17β-estradiol sulfation in liver S9 across different species  
Formation of 17β-estradiol-3-sulfate as a function of 17β-estradiol activity at 5, 50 
and 500nM in S9 fraction from liver of different species. 
 
5.10  Assessing cell viability of cryopreserved bovine hepatocytes over 
a period of time 
 
Upon removal from liquid nitrogen, cell viability of cryopreserved hepatocytes 
was assessed using trypan blue exclusion method. The cells were counted on an 
automated BIO RAD cell counter and had a viability of 86%. In order to assess 
viability over a period of time the cells were incubated with 5% DMSO as in the 
test incubation and left at 37°C. Aliquots were withdrawn at 0, 3 min, 2.5 and 4 
hour upon incubation and cells counted on the cell counter. It was found that after 
3 minutes, there was no difference in the cell viability compared to the start. 
Owing to the large production of glucuronide conjugates seen in a short period of 
time with hepatocytes and microsomes, an incubation time of 3 minutes was 
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applied to all kinetic reactions here. After 2.5 hours, the cells had only 33% 
viability which further dropped to 18% after 4 hours (figure 66). 
 
 
Figure 66: Cell viability of cryopreserved hepatocytes assessed over a 
period of time using trypan blue exclusion methods. 
Cryopreserved hepatocytes upon removal (5.10a) have a very high viability of 86%. 
No significant difference was seen in cell viability after a 3 minute incubation; 5.10b. 
After 2.5 hours the cell viability drops to 33%; 5.10c followed by a further drop to 
18% after 4 hours; 5.10d after removal from cryo conditions. The cells were 
incubated with 5% DMSO to mimic incubation conditions. Green circles indicate 
viable cells and red ones are the dead cells. 
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5.11 Identification of 17β-estradiol metabolites upon incubation of 
17β-estradiol with cryopreserved bovine hepatocytes.  
 
In order to check for the presence and if possible identify any metabolites formed, 
some preliminary incubation with 17β-estradiol was carried out. 3 major peaks 
were detected at retention time of 2.56, 2.72 and 2.81 of which the peak at 2.56 
and 2.72 corresponded to 17β estradiol-3-glucuronide and 17β-estradiol-17-
glucuronide respectively. A neutral loss scan confirmed their identity. The 
identity of the metabolite giving rise to the 2.81 peak was unknown (figure 67).  
 
Figure 67: Chromatogram showing metabolites of 17β-estradiol detected in 
cryopreserved bovine hepatocyte incubations.  
17β-estradiol-3-glucuronide was the one to elute first at 2.56 min followed by 17β-
estradiol-17-glucuronide at 2.72 min. The identity of the metabolite eluting at 2.81 
min was unknown. Formation of 17β-estradiol-3-sulfate was not detected.  
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5.12 Rate of formation of 17β-estradiol-3-glucuronide as a function of 
17β-estradiol in bovine hepatocytes 
 
Hepatocytes at a final concentration of 1 x106 cells/ml in Hepatocyte Maintenance 
Media (HMM) buffer were used in the assay. Kinetics was carried out on the 
formation of 17β-estradiol-3-glucuronide in a similar manner to the one done in 
microsomes. Velocity of the reaction was measured in pmol/min/106 cells. A Km 
of 1.2 µM (figure 68) was seen which is not very different from the Km of 2.36 µM 
seen in microsomes. This suggests that probably the same sets of UGT enzymes 
are responsible for the metabolism of 17β-estradiol in microsomes and 
hepatocytes. It also implies that concentration of 17β-estradiol achieved in 
hepatocytes is equivalent to levels of 17β-estradiol available to UGTs in 
microsomes. This is given the fact that drug transporters are not present in 
microsomes. An interesting phenomenon observed was that as the production of 
17β-estradiol-3-glucuronide rose the formation of 17β-estradiol-17-glucuronide 
fell (figure 69). Microsomes contain UGTs as do hepatocytes but they do not 
contain drug transporters that are present in hepatocytes. Drug transporters are 
vital since they can affect drug metabolism by altering accessibility of the drug to 
drug metabolizing enzymes. Inhibitors of these transporters can also affect drug 
concentrations reached in vivo. A possible hypothesis for the observed 
phenomenon is that 17β-estradiol-3-glucuronide formation inhibits the uptake of 
further 17β-estradiol thus affecting the formation of 17β-estradiol-17-
glucuronide by certain UGTs. A complex interplay between drug metabolizing 
enzymes and transporters is probably at work here.  
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Figure 68: Kinetics of formation of 17β-estradiol-glucuronide in 
cryopreserved bovine hepatocytes 
 Rate of formation of 17β-estradiol-3-glucuronide as a function of 17β-estradiol in 
bovine hepatocytes. The rate of reaction had a Vmax of 23 ± 0.7 pmol/min/106 and a 
Km of 1.2 ± 0.2 µM. Each assay was carried out in triplicate in a 96 well plate. Data 
points are average values of each assay that was carried out in triplicates ± 
standard error.  
Figure 69: Formation of 17β-estradiol glucuronides in cryopreserved 
bovine hepatocytes 
 Relative formation of 17β-estardiol-3-glucuronide and 17β-estradiol-17-
glucuronide at increasing concentration of 17β-estradiol in bovine hepatocytes. 
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5.13 Discussion 
5.13.1 17α Vs. 17β-estradiol 
The majority of ruminants including cattle undergo oxidoreduction that converts 
17β-estradiol to estrone and estrone to 17α-estradiol. The 17α-estradiol that is 
formed is preferentially glucuronidated. Knowing this it was interesting to 
compare the metabolite formation and the rate of glucuronidation of the two 
diastereoisomers. We found that 17β-estradiol was mainly glucuronidated at the 
3-OH position whereas 17α-estradiol was preferentially glucuronidated at the 17-
OH position. The glucuronidation of 17β-estradiol was a more efficient reaction 
with a lower Km and high reaction rate than the glucuronidation of 17α-estradiol.  
This could in part be explained by the fact that it is easier to conjugate glucuronic 
acid on to the hydroxyl group that is part of an aromatic hydrocarbon (3-OH) than 
it is to do so with a hydroxyl group that is a part of an aliphatic ring (17-OH). 
Several different UGT enzymes catalyse the glucuronidation of estradiol but vary 
significantly in their kinetics, stereoselectivity and regioselectivity (Itaaho et al., 
2008). The majority of the members of the UGT1A family conjugated one or both 
the diastereoisomers at the 3-OH position with the exception of UGT1A4 whose 
activity was low and uniquely directed towards the 17-OH of both aglycones. The 
UGT2B family usually conjugated both estradiols at the 17-OH position with 
varying stereoselectivities. For example UGT2B4 is specific for epiestradiol 
whereas UGT2B7 can glucuronidate both the stereoisomers whilst UGT2B17 
specifically glucuronidated 17β-estradiol (Itaaho et al., 2008). Expression of these 
enzymes can be tissue age and sex specific. They can also vary between species. 
Rabbit, pig, bovine and elk liver microsomes preferentially glucuronidate both 
distereoisomers at the 3-OH position whereas 17α-estradiol-17-glucuronide and 
17β-estradiol-17-glucuronide were the major metabolites in human and rat liver 
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microsomes respectively (Itaaho et al., 2008). 17β-estradiol-3-glucuronide was 
the major metabolite detected in our study, however contrary to the results 
obtained in this study we did not detect the presence of 17α-estradiol-3-
glucuronide. Differences in kinetics of the two diastereoisomers depend on the 
expression profile of specific UGTs for the tissue age sex and species tested.  
5.13.2 Hepatocytes as a model for studying drug metabolism 
 
Hepatocytes contain both phase 1 and phase 2 drug metabolizing enzymes along 
with the necessary cofactors in concentrations that are representative of in vivo 
conditions. In addition to this they also contain drug transporters and hence able 
to achieve in vivo like drug concentration in cells. These properties make 
hepatocytes a good in vitro model for in vivo drug metabolism. In comparison to  
microsomes, hepatocytes are known to predict metabolic clearance more 
accurately (Brown et al., 2007; Lam and Benet, 2004). Freshly isolated 
hepatocytes are considered as the best in vitro model for studying drug 
metabolism in the liver because of their ability to closely mimic liver cells. 
However, there are several limitations to their successful usage. A major 
hindrance is the loss of expression and/or activity of the major drug metabolizing 
enzymes such as cytochrome P450s  (CYPs), UGTs and SULTs (Li et al., 1999a). A 
study carried out by Liu et al, 1996 on primary rat hepatocyte cultures showed 
significant decline in the expression of major SULT isoforms such as SULT1A1, 
SULT1C1, SULT1E1 and SULT2A1 within first 24 hours of hepatocyte isolation 
(Liu et al., 1996). This makes it very difficult to arrange logistics and plan 
experiments in a short period of time after hepatocyte isolation. Hence 
cryopreservation of hepatocytes has evolved as a lucrative means of preserving 
hepatocytes for long term usage. Some initial studies have shown that viability 
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and yield of cryopreserved hepatocytes from several different species was only 
slightly reduced after cryopreservation (Li et al., 1999b). No significant difference 
was observed in the drug metabolizing enzyme activities between freshly isolated 
and cryopreserved hepatocytes for the major drug metabolizing pathways. We 
detected the presence of 17β-estradiol-3-glucuronide in both microsomes and 
hepatocytes. No 17β-estradiol-17-glucuronide was detected in either of the two. 
Kinetics of the formation of 17β-estradiol-3-glucuronide was similar in both the 
model systems. Similar Km values indicated that probably the same sets of UGTs 
were metabolizing 17β-estradiol in microsomes and hepatocytes. Drug transport 
activity too seemed to be maintained in hepatocytes. Velocity of the 
glucuronidation reaction was not comparable since in microsomes velocity was 
measured in pmol/min/mg of total protein whereas in hepatocytes, velocity was 
measured in pmol/min/1x106cells. Similarly 17α-estradiol-17-glucuronide was 
produced in both microsomes as well as hepatocytes. Kinetics was not performed 
on the formation of 17α-estradiol-17-glucuronide since increase in this 
metabolite over time was not observed in hepatocytes. One possible explanation 
for this could be that some fraction of 17α-estradiol-17-glucuronide generated 
was being deglucuronidated by glucuronidases present in the lysosome. Low 
amount of 17β-estradiol-3-sulfate was produced from 17β-estradiol in bovine 
female liver S9, however no 17β-estradiol-3-sulfate was detected in female liver 
hepatocytes. Limited information is available to evaluate the effects of 
cryopreservation on gene expression and responsiveness to hormones. It has 
been noted that cryopreservation affects CYPs that bring about metabolism of the 
steroid androst-4-ene-3,17-dione in dog hepatocytes. Similarly, cryopreserved 
dog hepatocytes also lose their ability to respond to α1 and β2 adrenergic 
receptors indicating possible damage to receptors and/or their transduction 
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system (Skett et al., 1999) Expression of the estradiol metabolizing SULT1E1 is 
also tightly regulated by hormonal activity in humans. (Rubin et al., 1999). Hence 
any damage during cryopreservation affecting the regulation of SULT1E1 can 
result in its loss of expression and activity in bovine hepatocytes.  
5.13.3 Glucuronidation versus sulfation in bovine liver 
Clearly, glucuronidation seems to be the most important pathway responsible for 
the metabolism of estradiol in bovine liver. The `results here are in agreement 
with observations noted in vivo where majority of estradiol metabolites detected 
have been glucuronide conjugates (Maume et al., 2001). No sulfate conjugates 
have been detected in vivo in the bovine liver (Maume et al., 2001). It is quite 
possible that sulfate conjugation might play a role in extra hepatic metabolism of 
estradiol especially in hormone responsive tissues such as the endometrium 
where it might be responsible for mediating important biological functions 
(Rubin et al., 1999).  
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6. Concluding Remarks 
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6.1 Summary 
Significant advances have been made in sulfotransferase research in the recent 
years with respect to understanding the structural features that govern activity 
and specificity. Since sulfotransferases are recognised as a major xenobiotic drug 
and steroid metabolising pathway, profiling the quantity and activity of SULTs in 
major drug metabolising tissues has allowed better prediction of drug toxicity. 
However, most of the research has predominantly being carried out in humans.  
Administration of veterinary drugs and other xenobiotics to cattle can often result 
in the accumulation of toxic metabolic residues in edible tissues that can 
potentially affect humans through the food chain. An understanding of drug 
metabolism in this species is therefore vital to ensure safe use of drugs in cattle 
and eventually the provision of safer animal food products to man. Despite this 
very little research has been done on drug metabolising enzymes in cattle.  This 
study has produced useful tools such as recombinant enzymes for studying some 
of the major drug metabolising isoforms of SULTs in cattle. Valuable insights have 
been generated into the sulfation of steroids and xenobiotics in the bovine liver. 
In addition to this, conjugative metabolism of the steroid hormone 17β-estradiol 
and its diastereoisomer 17α-estradiol was investigated in cattle using different 
model systems such as cytosol, microsomes and hepatocytes.   
6.2 Major findings 
Like human SULT1B1, bovine SULT1B1 also had overlapping substrate 
specificities with SULT1A1. Substrate specificity profiling carried out with equal 
amount of bovine SULT1A1/SULT1B1 revealed that bovine SULT1B1 was more 
efficient in the sulfation of small phenolic compounds compared to bovine 
SULT1A1. This is in contrast to humans where sulfation brought about by 
SULT1A1 is several orders of magnitude higher than SULT1B1. Bovine SULT1A1 
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also demonstrated substrate inhibition with 4-nitrophenol like human SULT1A1. 
However, it was less intense   (Ki is 24µM) than human SULT1A1  (Ki is 34µM ) 
(Riches et al., 2007). In male and female bovine livers, the expression of SULT1B1 
was found to be higher than SULT1A1. Whilst the male livers displayed Michaelis-
Menten kinetics with 4-nitrophenol, the female livers demonstrated substrate 
inhibition. 4-nitrophenol is sulfated by many members of the SULT1 family with 
overlapping substrate specificities. The difference in kinetics of 4-nitrophenol 
between male and female bovine liver suggests that different members of the 
SULT1 family are involved in 4-nitrophenol sulfation. 
In humans, SULT1E1 has a very high affinity for the endogenous compound 17β-
estradiol and is known to metabolise it in the low nanomolar range (Kester et al., 
1999b). However, it was not found to be true for bovine SULT1E1 which had a 
higher Km and metabolised 17β-estradiol in the micromolar range. Comparison of 
primary amino acid sequences of human and bovine SULT1E1 revealed major 
substitutions in the enzymes active site which could possibly account for some of 
the differences above. Furthermore, huge variation was seen in SULT1E1 
expression in the bovine liver. The variation in expression observed was 
consistent with the activity detected with 17β-estradiol. An overall, low level of 
activity was observed with 17β-estradiol in bovine liver. Evaluation of 
microsomes, cytosol and hepatocytes for the conjugative metabolites of 17β-
estradiol revealed that glucuronidation was probably the major pathway for 17β-
estradiol metabolism in cow as most of the metabolites detected were 
glucuronide conjugates as opposed to the almost negligible amount of sulfate 
conjugates seen. Livers from cows treated with an exogenous progestin on 
average showed three fold increases in activity as compared to the untreated 
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ones. However, this finding cannot be attributed to the effect of the exogenous 
progestin because of the small sample size of 4 livers and the huge amount of 
variation seen in the expression and activity of SULT1E1 in between those treated 
livers.  
Our untagged recombinant bSULT2A1 was insoluble; however soluble expression 
was achieved upon tagging the protein with maltose binding protein (MBP) but 
no activity against DHEA, androsterone or pregnenolone (SULT2A1 substrates) 
was detected.  SULT2A1 was detected in bovine liver using anti human SULT 2A1 
antibody however, no activity towards its probe substrate DHEA was detected. 
Activity was detected in the bovine liver with pregnenolone which is known to be 
metabolised by both SULT2A1 and SULT2B1 in humans (Strott, 2002). 
6.3 Does DHEA have a greater role than DHEA sulfate in cattle?  
The steroid, DHEA and its sulfo conjugate DHEA sulfate (DHEAS) are secreted by 
the adrenal cortex. DHEA and DHEAS are the most abundant circulatory steroids 
in humans and usually are precursors to the production of androgens and 
estrogens (Labrie et al., 2005). They are associated with numerous biological 
actions such as stress response, lipid metabolism, immune system activation and 
pathological phenomena such as behavioural and neurodegenerative disorders in 
humans (Hansen et al., 1997; Labrie et al., 2005). SULT2A1 is the major enzyme 
responsible for the sulfoconjugation of DHEA to DHEAS. It was unable to express 
recombinant bSULT2A1 in solution. Recombinant bSULT2A1 was expressed in 
solution as a fusion with MBP. However, no activity was detected against known 
SULT2A1 substrates.  SULT2A1 was detected in bovine liver using anti-human 
SULT2A1 antibody, however no activity with DHEA was recorded. Comparison of 
the primary amino acid sequence of bovine and human SULT2A1 revealed major 
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substitutions in the active site region of bovine SULT2A1 which could possibly 
affect the secondary structure and function of the enzyme significantly. In female 
bovine, the mammary gland utilises DHEA to make androstene-3β, 17β-diol 
(Belvedere et al., 1996), a metabolite with immunoenhancing activity (Loria et al., 
1996). Recently, it was also shown that cows with inflammatory foot lesions 
showed a 23% decrease in serum DHEA concentrations suggesting the 
importance of DHEA in the inflammation process in cattle (Almeida et al., 2008). 
However, in cows circulating DHEAS was found to be significantly lower than 
DHEA (Feher et al., 1977; Marinelli et al., 2007). Indeed, it is quite a possibility 
that DHEA as compared to DHEAS might have a bigger biological function in cows. 
This is reflected by the inability of SULT2A1 to sulfate DHEA in bovine which 
restricts the creation of large reservoirs of DHEAS.  
6.4 17β-estradiol metabolism in the bovine liver 
 17β-estradiol is routinely used by the animal industry for growth promotion in 
cattle. Several studies have been carried out to detect the metabolites of 17β-
estradiol in vivo. Results reveal that very few metabolites detected were sulfate 
conjugates and the majority of them were glucuronide conjugates (Ivie et al., 
1986; Maume et al., 2001). This suggests a strong role for glucuronidation in the 
elimination of 17β-estradiol. Indeed, 17β-estradiol-3-glucuronide was the major 
metabolite formed in bovine liver microsomes and hepatocytes when detected 
using UPLC-MS. A large amount of variation was observed in the expression of 
SULT1E1 in the bovine especially in the female liver. In humans, expression of 
SULT1E1 in the endometrium is exquisitely regulated during the menstrual cycle 
under the influence of progesterone (Falany and Falany, 1996b). Since all the 
female livers were of the same breed and age, it is quite possible that the 
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variation seen was due the heifers being at different points in their menstrual 
cycle at the time of slaughter.  
6.5 Is SULT1B1 the major xenobiotic metabolising enzyme in the bovine 
liver? 
Recombinant bSULT1A1 was not very efficient in sulfation as compared to human 
SULT1A1. It sulfated phenolic compounds at a rate which was 10 times lower 
compared to human SULT1A1. The Km for recombinant (non purified) bovine 
SULT1A1 sulfation of 4-nitrophenol was 33 µM as opposed to that of 4µM for 
human SULT1A1 (purified) (Riches et al., 2007). Lesser substrate inhibition with 
4-nitrophenol was observed for bovine SULT1A1. A Possible explanation for these 
observations lie in the structural differences of the active site of human and 
bovine SULT1A1 that bind the second molecule of 4-nitrophenol. On the other 
hand, recombinant bovine SULT1B1 was found to be better at sulfating phenolic 
compounds than bovine SULT1A1 and had huge overlapping substrate specificity 
with bovine SULT1A1. SULT1B1 was detected in bovine liver whereas SULT1A1 
was not. 4-nitrophenol sulfation by recombinant bovine SULT1B1 followed the 
Michaelis-Menten kinetics with no inhibition whereas that of recombinant bovine 
SULT1A1 followed Michaelis-Menten with partial substrate inhibition. No 
substrate inhibition was seen for 4-nitrophenol sulfation in bovine male liver as it 
followed Michaelis-Menten kinetics similar to that of recombinant bovine 
SULT1B1. These findings point towards the possibility that SULT1B1 rather than 
SULT1A1, might be the major xenobiotic metabolising enzyme in the bovine liver. 
Further evidence is needed to back up this hypothesis. Availability of a SULT1B1 
specific probe substrate that is exclusively metabolised by SULT1B1 would 
certainly be of a great advantage.  
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6.6 Future work 
6.6.1 Validation of structure function relationship 
Our study has generated important tools in the form of recombinant SULTs for 
the study of conjugative drug metabolism in cattle. Comparison of primary and 
tertiary structure of bovine and human sulfotransferases threw light on 
prominent structural features that could possibly govern some of the functional 
differences observed in SULT activity between the human and bovine. Site 
directed mutagenesis of critical residues in the structure of bovine SULTs to 
resemble that of human SULTs will be required to establish whether the residues 
identified are responsible for making significant changes to SULT activity in cows. 
This information would certainly be useful to the pharmaceutical/animal health 
industry who would be able to better predict the fate of drugs metabolised by 
SULTs in cattle.  
6.6.2 The need for a SULT1B1 probe substrate 
Currently the research in the field of sulfotransferases is seriously limited by the 
availability of exclusive probe substrates to assess activity of individual isoforms 
in a tissue where more than 1 isoform of SULT is present. For example, 4-
nitrophenol is metabolised by a range of members of the SULT1 family and was 
used in this study as a substrate to assay the activity of SULT1A1/1B1. We 
presented evidence which might suggest that SULT1B1 is more active in sulfation 
in the bovine liver as opposed to SULT1A1, which is known to be a major 
xenobiotic metabolising enzyme in human liver. However, in order to confirm this 
hypothesis we need a SULT1B1 probe substrate which to date has not been 
discovered due to the reason that SULT1B1 has a high overlapping substrate 
specificity with SULT1A1. 
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